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Abstract 
 
Population ageing is a major concern for developed countries in terms of public 
expenditure required to pay for health care (HC). The broad aim of this thesis is to 
contribute to and expand the debate on the independent effects that population ageing 
and the time immediately before death (TTD) have on HC expenditure in Scotland. This 
study analyses, for the first time in Scotland, how HC expenditure projections are 
influenced through the application of two approaches; the first only accounting for an 
increasing proportion of the elderly population, and the second also implementing a TTD 
component.  
Several issues that are under-researched or have not been addressed in TTD studies 
previously, are explored and alternative approaches are presented. Utilising two large 
linked datasets this thesis addresses important methodological issues. Alternative 
methods to cost inpatient hospital stays are examined as this has pivotal implications for 
any analysis undertaken to estimate the independent effect of TTD and age on HC 
expenditure. Explanatory variables that have previously not been considered, such as 
health risk and health status measures at baseline, are included in these analyses. The 
issue of sample selection, arising through the inclusion/exclusion of survivors in a TTD 
study is investigated and the impact of individuals’ socio-economic status on costs is 
examined.   
The analysis of alternative costing methods clearly showed that any inference that can 
be made from econometric modelling of costs, where the marginal effect of explanatory 
variables is assessed, is substantially influenced by the chosen costing method. The 
application of a Healthcare Resource Group (HRG) costing method was recommended. 
This study found that TTD, age and the interactions between these two factors were 
significant predictors for HC expenditure. The analysis further identified some of the 
health status and health risk measures to be important predictors of future HC 
   vi  
expenditure. An examination of how sample selection impacts on estimated costs at the 
end of life showed that if survivors were excluded from the analysis, costs might be 
overestimated.  
Drawing on a representative sample of the Scottish population, the investigation of the 
association that the socio-economic status had with HC costs suggested that less is 
spent on individuals from more deprived areas. This might partly be explained through 
the decreased probability of accessing hospital services for individuals from more 
deprived areas. Furthermore, results showed that projected HC expenditure for acute 
inpatient care for the year 2028 was overestimated by ~7% when an approach that only 
accounts for the higher proportion of elderly people in a population in the future is being 
used as compared to an approach that also accounts for the effect that remaining TTD 
has on costs.  
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1 INTRODUCTION 
1.1 Introduction 
Population ageing is a major concern for developed countries in terms of public 
expenditure that will be required in the next decades to pay for pensions, health care 
(HC) and other social services or benefits. With a very large population cohort, i.e. the 
‘baby boomers’, approaching the age of 65 the issue of population ageing and its 
possible impacts on public expenditure requirements is a very immediate and topical 
one. In recent years there has been an increasing interest from policy makers and 
academics in analysing the main driving forces of demand for HC services and 
associated expenditure, in addition to changes in the demographic pattern.  
There is an ever growing literature on the various factors to explain, estimate and project 
HC spending. In one of the first contributions, Fuchs found that cross-sectional 
differences in HC expenditures by age overestimated the changes that would result from 
an ageing population (Fuchs, 1984). After Fuchs’s initial research that showed how 
determinants other than population ageing might influence HC expenditure, many 
studies followed. There is now a large body of evidence that the time immediately before 
death (time to death, TTD) seems to be a period that is characterised by a very high 
demand for HC and subsequently high costs, in addition to age. However, there does 
not seem to be a consensus on the degree of the relative importance of TTD in 
explaining increasing HC costs as individuals get older. Some research has found that 
patient age becomes an insignificant predictor for HC expenditure once TTD is included 
(Zweifel et al., 1999). Less strong findings merely support the argument that age alone 
is not solely responsible for increased HC spending and that TTD is also an important 
predictor (Seshamani and Gray 2004b).
Chapter 1  2  
   
 
A multitude of methods, sample populations and HC settings have been used to explain 
the relationship between ageing, TTD and HC expenditure, making it difficult to draw 
consistent conclusions. Analyses have been undertaken in many countries, all showing 
very different characteristics of how HC is being funded, delivered and the precision with 
which HC utilisation is being measured. So far, however, there has been no 
comprehensive and robust analysis of the impact of population ageing and TTD on HC 
expenditure in Scotland.  
This thesis is the first empirical study to estimate the relationship between TTD, age and 
HC expenditure in Scotland utilising two large linked datasets of acute inpatient care 
records and survey data. This is guided by an extensive review of existing methods in 
the research area on an international level. Outlining gaps in existing studies and 
introducing approaches to improve current methods, this thesis seeks to contribute to 
the discussion around the role that TTD has to play in determining future HC 
expenditure in Scotland.  
 
1.2 Objectives of this thesis 
The overall aim of this thesis is to contribute to the debate on the independent effects 
that population ageing and the time immediately before death have on HC expenditure 
in Scotland, thereby investigating issues that remain under-researched or have not been 
adequately addressed. As life expectancy in the Scottish population increases, it is 
important to understand whether additional years of life gained would be spent in ill 
health, thereby placing financial pressure on HC service provision, or whether these 
additional years are healthy, meaning less pressure on existing HC budgets. It is also 
vital to ascertain whether the demand for HC is concentrated in specific population 
groups, categorised for instance by their socio-economic status.
Chapter 1  3  
   
 
Scotland has the advantage of having good quality and extensive, longitudinal data on 
HC resource use which can be linked to survey data. These data will be exploited in this 
thesis to answer the following research questions: 
1. What is the independent effect of TTD and age on expenditure for acute inpatient 
care in Scotland? 
2. How are HC expenditure projections influenced when using a model accounting for 
TTD versus a model that only accounts for the increasing proportion of elderly 
individuals? 
3. How do previously unconsidered explanatory variables, such as health risks and 
health status measures impact on HC expenditure as the population ages and 
approaches death? 
4. How does sample selection, in particular the inclusion/exclusion of surviving sample 
members due to right censoring, impact estimated costs? 
5. What is the association between socio-economic status and HC expenditure at the 
end of life? 
6. How do different methods to cost inpatient hospital stays affect cost estimates and 
what marginal effect do various explanatory variables have?  
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1.2.1 Objective 1: Effect of TTD and age on HC expenditure in 
Scotland 
This thesis estimates the independent effects that TTD and age have on HC expenditure 
in an acute inpatient care setting in Scotland.  
1.2.2 Objective 2: HC expenditure projections 
This analysis addresses the issue of a possible overestimation of future HC costs if 
remaining TTD is not accounted for. Results are to inform policy makers when faced 
with HC budgeting decisions. The importance of drawing on a representative sample of 
the Scottish population is discussed, as reliability of results needs to be ensured. 
1.2.3 Objective 3: Impact of health measures on HC expenditure 
A longitudinal dataset (Renfrew/Paisley study) covering a period of 35 years is utilised, 
including baseline survey data linked to subsequent hospital admissions and death 
records. The breadth of the Scottish data mean that explanatory variables that have 
previously not been considered can be included, such as health risk and health status 
measures at baseline, thus allowing an examination of the importance of these factors 
and their impact on future HC expenditure.  
1.2.4 Objective 4: Right censoring of survivors 
This objective seeks to address the relationship between TTD, age and HC expenditure 
in Scotland over the last three years of life; in doing so an approach is introduced to 
include surviving sample members with an unknown TTD at censoring. Differences in 
estimated costs are compared under different sampling scenarios, highlighting the 
importance of the choice that is made in terms of the sample. 
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1.2.5 Objective 5: Effect of socio-economic status on HC expenditure 
This part of the thesis uses the Scottish Longitudinal Study (SLS), linked to hospital 
admissions. The SLS is an anonymised 5.3% representative sample of the Scottish 
population (~270,000), drawn from the Scottish Census and started in 1991. It is 
important to ascertain whether the patterns of ageing and TTD in terms of HC costs are 
the same for different socio-economic groups. This is especially relevant in Scotland, 
which is characterised by a high proportion of people living in deprived areas, which is 
usually argued to translate into health inequalities.             
1.2.6 Objective 6: Alternative methods to cost acute inpatient stays 
This thesis will review health economic costing methodologies in order to distinguish 
between costs per event (episode), per diem or per Continuous Inpatient Stay (CIS) and 
any additional costs that are incurred through “expensive” interventions. This will take 
account of the fact that patients with the same diagnosis may receive different 
treatments and therefore incur different costs. In the absence of a ‘gold standard’ to 
estimate the economic burden of disease, a decision about the most appropriate costing 
method is required. Researchers have employed various methods to cost hospital stays, 
including per diem or Diagnosis Related Group (DRG) based costs. Alternative methods 
differ in data collection and costing methodology. Using data from Scotland as an 
illustrative example, costing methods are compared, highlighting the wider implications 
for other countries with a publicly financed health care system. 
In order to address the main objectives 1 and 2 in this thesis, the methodological issues 
that have been presented as objectives 3 to 6 need to be addressed. Three empirical 
chapters (4, 5 and 6) are presented and the overall structure of this thesis that is to 
support investigation of the research questions is presented below. 
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1.3 Structure of the thesis 
Chapter 2 outlines how population ageing is expected to affect demographics in 
Scotland. An overview of HC costs and resource allocation in Scotland is given, 
emphasizing the role that population characteristics play when assessing need.  
In Chapter 3 a review and critical assessment of all relevant literature that analysed HC 
expenditure in relation to population ageing is presented, concentrating on the area of 
the literature that examined remaining TTD in addition to age and its association with 
HC costs. Important methodological issues and gaps are highlighted informing and 
motivating the empirical analyses in subsequent chapters. 
Chapter 4 examines alternative costing methods for acute inpatient care episodes, 
addressing research objective 6. Results from this analysis are fundamental as they 
provide guidance for the costing undertaken in the subsequent empirical chapters of this 
thesis (Chapters 5 and 6).  
Chapter 5 uses an empirical example (Renfrew/Paisley study) to estimate the effect that 
previously unconsidered covariates have on HC expenditure towards the end of life. 
These are health status and health risk measures at baseline and their impact and 
importance to predict future hospital costs is assessed. In addition, the implications that 
the inclusion/exclusion of surviving sample members in a TTD study has on estimated 
costs are analysed. Chapter 5 focuses on employing a method to correct for limitations 
arising in other studies that have faced the challenge of how to include surviving sample 
members with an unknown TTD. In order to provide results regarding the magnitude of 
the over- or under-estimation of costs at the end of life, costs will be estimated for 
different sample scenarios. This chapter addresses research objectives 1, 3 and 4. 
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Investigating objectives 1, 2 and 5, Chapter 6 utilises a representative sample of the 
Scottish population, the SLS. It builds on the analyses and conclusions derived from the 
two subsequent empirical chapters and utilises an appropriate costing method as well as 
a method to account for right censoring of survivors in the sample. In addition the 
analysis tests the impact that the socio-economic status has on HC expenditure for 
acute inpatient care, an issue that is of special interest and importance in Scotland. 
Exploiting the fact that the SLS is representative of the Scottish population, this chapter 
finally presents the methods and results for projecting future HC expenditure as outlined 
in objective 2. This is carried out by comparing two methods, thereby assessing the 
importance of including TTD in any such predictions. 
Chapter 7 summarises and discusses the main findings of the analyses in the empirical 
chapters and highlights the wider implications these results may have. It also presents 
the conclusions derived from this work. Limitations of the thesis are discussed and the 
scope for future research is presented.  
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2 POPULATION AGEING AND HC EXPENDITURE 
IN SCOTLAND 
2.1 Introduction 
This chapter describes and defines in detail, how the two main factors that are analysed 
in this thesis, population ageing and HC expenditure, are measured in Scotland. It 
provides the foundations for the subsequent analyses and discussion in this thesis. 
First, a summary is provided of the main assumptions when talking about population 
ageing in Section 2.2. An assessment of how population numbers, and particularly the 
elderly proportion of the population, are expected to change in Scotland over the next 
decades is provided in Section 2.3. Section 2.4 outlines the main components of HC 
expenditure in Scotland and introduces the allocation formula for HC resources within 
the hospital sector. This section also introduces the current thinking on TTD in resource 
allocation. In Section 2.5 a short overview of the organisation and cost for LTC is 
presented. A description of how HC resource utilisation can be measured in Scotland is 
provided in Section 2.6. 
 
2.2 Population ageing 
Population ageing will occur in virtually every country over the next decades although 
with a varying pace and at different levels. It is the process through which the proportion 
of older people in a population becomes larger. Population ageing is usually described 
as an increase in the proportion of people over the age of 65 in a population (Payne et 
al., 2007). It can also be expressed as an increase in median age. Population 
projections suggest that the median age of the world population will increase from 27
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years (in year 2000) to 36 years by 2050. This would mean that half of the world’s 
population will be older than 36 years (UN, 2002).  
In general, population ageing is caused by a decline in the number of births, decreasing 
mortality, and to a lesser degree by migration. Declining births rates have been identified 
as one important reason for population ageing, with fertility being well below the 
replacement level in nearly all industrialised nations (UN, 2002), i.e. the birth rates are 
smaller than the death rates. 
The main cause for population ageing alongside decreasing births rates is decreasing 
mortality rates, leading to longer life expectancy on average (at any age) (Howse and 
Harper, 2008). On a global level, life expectancy at birth has increased by about 20 
years over the last five decades (UN, 2002). This increasing life expectancy can be 
observed to a greater extent in developed countries, whereas in less developed 
countries a huge variation in life expectancy exists (UN, 2002). As mortality is being 
shifted towards older ages, the survival curve follows a more and more rectangular 
shape. This rectangularisation of the survival curve is mainly due to an increased life 
expectancy through disease control and the elimination of premature death.  
The curve becomes almost square with a probability of survival close to 1 which then 
suddenly drops to 0 (Manton, 1982). One example, of the rectangularisation of the 
survival curve, using data from Sweden is presented below in Figure 2.1 (Yashin et al., 
2002).  
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Figure 2-1 Example of rectangularisation of the survival curve. Reprinted from (Yashin et 
al, 2002) with permission  
 
Population ageing will have effects in many areas of public life. For instance, it will 
impact on labour market participation and the share of the population in receipt of 
transfer payments, i.e. pensions. This could potentially cause an accelerated financing 
problem: a higher share of older individuals, whose demand for transfer payments 
increases, especially for HC (as has been argued in the literature), and a decreasing 
share of the population funding these payments through taxes or compulsory insurance 
contributions. Another layer that population ageing may add to this overall workforce 
problem is a possible decline in the NHS workforce, i.e. the staff that delivers HC 
(Wiener and Tilly, 2002, Segal and Bolton, 2009). Two scenarios could unfold alongside 
each other: a) a decrease in services provided and/or b) an increased financial incentive 
to either retain existing staff or to attract new staff into the HC sector.  
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The main challenge for policy makers in the future will therefore be to allocate available 
scarce resources so that the populations’ demand is met. The challenge policy makers 
are faced with is to accurately quantify this future demand. An increasing demand for 
HC services has been identified as the main contributor for increasing costs. This 
assumption is based on the general perception that health deteriorates with increasing 
age and therefore more older people will mean more use of HC services, and an 
increasing proportion of older people will necessarily lead to a higher demand for HC 
and consequently higher HC expenditure (Payne et al., 2007).  
 
2.3 Population ageing in Scotland 
2.3.1 Population numbers 
As outlined earlier, several factors contribute to an ageing population, including the 
number of births and the number of deaths. Figure 2.2 shows the actual and predicted 
number of births and deaths in Scotland between 1951 and 2033. Since the 1960s there 
has been first a sharp decline in the total number of births (1965 until 1978) followed by 
a less severe decline from 1979 onwards. The total number of deaths in Scotland has 
fluctuated around 60,000 per year with a slight decline from the year 2000 onwards. 
Deaths are expected to reach 60,000 again by 2033. 
Until about 2026 the number of births is projected to exceed the number of deaths. After 
2026 however the number of deaths is expected to outweigh the number of births, which 
will lead to fertility falling below the replacement level. 
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Figure 2-2 Births and deaths, actual and projected, Scotland, 1951-2033 (GROS, 2010) 
 
Population numbers are also, to a lesser degree, influenced by migration. Net migration 
is calculated by subtracting the number of people leaving a country (emigrants) from the 
number of people entering a country (immigrants). Figure 2.3 shows the net migration 
for Scotland, which was negative until the 1990s but with an increasing trend until 2008, 
after which time net migration is projected to decrease slightly to remain at a constant 
positive level from about 2013 onwards, with about 12,000 more people coming into 
Scotland annually than leaving the country. 
Together, the natural change (births minus deaths) and migration act to increase 
population numbers until 2026. Beyond 2026, the number of deaths is projected to 
exceed the number of births with a constant positive net migration rate (GROS, 2009). 
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Figure 2-3 Estimated and projected net migration, Scotland, 1951-2033 (GROS, 2010) 
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Figure 2-4 Estimated population of Scotland, actual and projected, 1953-2083 (GROS, 
2010) 
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Compared to the rest of the UK, population ageing in Scotland will be even more 
pronounced due to differences in the demographic pattern. The first element to take into 
consideration when analysing the age structure, is the total size of the population. The 
following projections from the then General Register Office for Scotland (GROS)3 are 
based on 2008 population estimates. According to these, the Scottish population is 
expected to rise from 5.17 million in 2008 to 5.36 million in 2018 and after that to 5.54 
million in 2033 (GROS, 2009). After 2033 though, Scotland’s population numbers are 
expected to decline slowly, but to remain above current figures (Figure 2.4). 
2.3.2 Age composition 
More important than total population numbers when analysing aspects and implications 
of population ageing is the age composition of the population.  
The population pyramids in Figures 2.5 and 2.6 below show the changing age structure 
of Scotland’s population and compare the most recent structure with the projected 
structure in 2031. Historically, a pyramid shaped diagram showed a very high number of 
young people at the bottom of the scale and a decreasing number of people as age 
increased. Figure 2.5 shows the population structure for 2011, where a pyramid shape is 
no longer present, indicating an increasing number of people at the top end of the scale 
(older people)  and a decreasing number of people at the bottom end (younger people). 
These differences are even more pronounced for the projected composition of 
Scotland’s population in 2031 (Figure 2.6).  
 
 
                                               
3 From the 1st April 2011 the General Register Office for Scotland has merged with the National 
Archives of Scotland to become the National Records of Scotland (NRS). 
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Figure 2-5 Population pyramid 2011, (GROS, 2011) 
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Figure 2-6 Population pyramid 2031, (GROS 2011) 
 
Chapter 2  16 
Between 2008 and 2018, the number of children under the age of 16 is expected to 
increase from 0.91 million to 0.92 million (1% increase). This is followed by a decrease 
and expected to reach 0.90 million by 2033 (1.5% decline compared to 2008 figures) 
(GROS, 2009). Over the same period the number of people aged 75 and older is 
projected to increase from 0.39 million to 0.48 million, an increase of 23% (2008-2018). 
Thereafter, this number is projected to continue increasing until it has reached 0.72 
million, in 2033. This translates into an increase of 84% from 2008 figures (Figure 2.7) 
(GROS, 2009). 
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Figure 2-7 Projected percentage change in Scotland’s population by age group, 2008-2033, 
(GROS, 2010) 
 
In light of these developments, it has previously been anticipated that the costs of HC 
(along with other public expenditure costs, like social security and social care) will 
increase (Dang et al., 2001); an assumption that is discussed in detail in Chapter 3. 
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2.4 Health care costs in Scotland 
2.4.1 ‘Costs Book’ 
NHS Scotland is divided into 14 health boards, which provide HC services to the 
population in their area. Each of the 14 health board’s annual accounts, which includes 
their net operating costs, provide the basis for the ‘Scottish Health Service Costs’, also 
known as the ‘Costs Book’ (ISD, 2011). The Costs Book is the only source that has 
published detailed cost information for the NHS Scotland. Cost information is mainly 
derived from health boards’ financial returns data. About 94% (~£9.7 billion) of all 
operating costs of the NHS Scotland are contained within the Costs Book. Costs include 
all hospital services, community services and family health services (ISD, 2011). In 
addition to cost information, information on patient demographics is also published in the 
Costs Book. 
Costs for hospital services encompass a variety of services, including surgery provided 
by consultants at large urban hospitals (inpatient services) as well as outpatient clinics 
at rural community hospitals. Total costs of £5.5billion were incurred in the hospital 
sector in the financial year 2009/2010. Community services include services provided by 
district nurses, health visitors, prevention services, screening programmes and health 
promotion; in 2009/10 £1.4billion was allocated to this HC setting. Family health services 
are all Primary Medical Services provided by GPs, opticians, dentists and pharmacists, 
totalling about £2.3billion in 2009/2010 (ISD, 2011).  
Figure 2.8 shows the share of costs for each of the different sectors covered in the 
Costs Book for the financial year 2009/2010. With a share of close to 60%, costs for 
hospital care are the main contributor to total HC costs in Scotland. 
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Figure 2-8 Overall health care costs in Scotland in 2009/10 by health care sector (ISD, 
2011) 
 
Costs of NHS Scotland are produced through a top-down approach, so that these are 
mainly based on the annual HC budget for Scotland, which is determined by Ministers 
during the Spending review process. The annual budget for hospital and community 
health services and GP prescribing is allocated to each of the 14 health boards based 
on a formula that adjusts for relative need of the population in each of the health boards. 
This allocation formula is discussed below. The Costs Book reflects how the annual 
budget is distributed over different HC services, with acute inpatient care comprising the 
largest sector. It also provides information on how, within each service, costs are 
cascaded down to specialty specific costs in the case of hospital care.  
2.4.2 Resource allocation 
The Arbuthnott formula, which was introduced in 2000, was in place until 2008, when it 
was replaced by the National Resource Allocation Committee (NRAC) formula after an 
extensive review between 2005 and 2007. NRAC carried out the review and its 
recommendation on updates for the resource allocation formula were implemented from 
2009 onwards (ISD, 2011). In general, resource allocation takes place after the total 
amount of money to be allocated has been determined through the Spending review 
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process, so that a given amount of money needs to be distributed. Resource allocation 
of the entire HC budget comprises the basis for HC costs that are later reported in the 
Costs Book, i.e. that part of the budget that was allocated to hospital services by health 
board and cascaded down to specialties and other services.  
Arbuthnott Formula 
From its introduction in 2000, the Arbuthnott formula allocated about 70% of the total HC 
budget to health boards (Fair Shares for All, 2000). The current NRAC formula updated, 
refined and improved the elements of the Arbuthnott formula, but fundamentally 
maintained its structure.  
The Arbuthnott formula is a weighted capitation formula. It is used to calculate shares of 
the budget to be allocated to health boards rather than money (NRAC, 2007). Initial 
shares of the HC budget are calculated using information on the size of the population. 
The formula then seeks to adjust for relative need in a health board area to capture the 
composition and characteristics of a population beyond size. It also adjusts for any 
additional costs of delivering HC services in that area compared to the rest of Scotland. 
The main elements to capture relative need have been identified as: population size, the 
relative number of males and females in different age groups, an adjustment to take 
account of the additional costs of delivering HC services in remote and rural areas 
compared to the national average and, a measure of deprivation, the so called morbidity 
and life circumstances (MLC), which are based on the four indicators detailed below 
(Fair Shares for All, 2000).  
Adjustment for age accounts for the fact that a Health Board with a higher proportion of 
elderly people will have a greater need for HC services. Adjustment for gender, for 
example, takes into account that a Health Board with a higher proportion of women in 
childbearing age will face a greater demand for HC services related to child birth (Fair 
Shares for All, 2000).  
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The resource allocation formula takes account of MLC in each Health Board. This is also 
known as the Arbuthnott Index, which is calculated using a combination of the following 
key components, which are closely linked to HC need:  
• the mortality rate for people under the age of 65,  
• the area’s unemployment rate,  
• the percentage of elderly people living on income support and  
• the number of households with two or more measures of deprivation from the 1991 
census (NHS Scotland Resource Allocation Committee (NRAC), 2007).  
The choice of these indicators is based on the assumption that people in more deprived 
areas have a higher exposure to factors that have a negative impact on health, so that 
people in these areas tend to have a greater need for HC (Fair Shares for All, 2000). It is 
important to note that the ‘Arbuthnott Index’ is a measure of population characteristics 
that influence need; it is not a direct measure of need (Fair Shares for All, 2000). The 
‘Arbuthnott Index’ is also responsive to changes in need over time. This is ensured by 
updating three of the four key components, i.e. the mortality rate for people under the 
age of 65, the area’s unemployment rate, and the percentage of elderly people living on 
income support in each Health Board. Health Boards, for instance, with an index of less 
than zero (the index ranges from -4 to 4) have levels of deprivation and morbidity that 
are below the national average (Fair Shares for All, 2000).  
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Relative need of a population is estimated based on the assumption that service use 
reflects need and the Arbuthnott formula accounts for need in the following HC settings:  
• acute inpatient care 
• maternity care 
• mental health 
• geriatric care 
• learning disabilities 
• community services and  
• General Practitioner (GP) prescribing.  
In order to assess population need in each of these settings, the four elements, which 
have been described above are taken into account.  
NRAC formula 
NRAC reviewed each element of the Arbuthnott formula between 2005 and 2007 and 
proposed the following main updates to the existing formula:  
• an updated method to measure population size 
• a refinement of age bands that are used for age and gender adjustment from 8 to 20 
categories, to obtain more precise indications for costs incurred by elderly people 
• in terms of the MLC adjustment, the suggestion was to replace the Arbuthnott index 
with three separate indices to capture differences in costs by HC services and to factor 
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in ‘unmet’ need due to under-utilisation of acute services for circulatory diseases, as 
evidence showed that despite an increased need in deprived areas, these services were 
not used accordingly 
• in terms of the unavoidable excess costs of delivering HC services in remote areas, it 
was recommended that for hospital services, an adjustment should be made based on 
the difference between local and national average costs by rural- urban category.   
2.4.3 Resource allocation and TTD 
The ‘Fair Shares for All’ report stated that mortality differences between Health Boards 
could be a proxy for need beyond the differences that had already been taken into 
account in terms of population size and population characteristics. The report also 
acknowledged evidence for an increase in resource utilisation as people approach 
death. Some first analyses undertaken showed that Health Boards with a higher 
mortality rate also had higher HC resource utilisation. Although TTD had been identified 
as a useful element of the resource allocation formula, it was decided not to include it as 
research in Scotland that provided evidence that TTD is an important predictor for HC 
expenditure alongside age, was at an early stage. Some disadvantages of including 
TTD in resource allocation had also been outlined, such as accounting for issues arising 
from utilisation of ‘mental health’ services, where TTD might not be as strong a predictor 
as in other HC settings (Fair Shares for All, 2000).  
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Following on from the ‘Fair Shares for All’ report, NRAC reviewed the components of the 
Arbuthnott Formula and specifically, how TTD is currently taken into account in resource 
allocation in Scotland. One focus of the review undertaken by NRAC was to assess 
whether the existing utilisation approach should be replaced with an epidemiological 
approach4 or a TTD approach. Different methods were explored and NRAC argued that 
although the age-gender adjustment of the allocation formula does not account for 
remaining TTD, the MLC component would adjust for any deprivation-related effects and 
would so adjust for differences in life expectancy that are due to socio-economic 
components (Bishop et al., 2006).  
NRAC’s conclusion was that TTD was the least re-distributive of all alternative methods 
compared and therefore likely to underestimate variations in costs among Health 
Boards. For the TTD approach, NRAC found obstacles, especially in determining how 
close to death residents in each health board area were. The review concluded that 
these results were due to the omission of additional explanatory variables such as 
deprivation to explain differences in costs at different times before death. The review 
found that the current MLC adjustment (after age-gender adjustment) was highly 
correlated with life expectancy and in turn with TTD. NRAC concluded that through the 
current Arbuthnott index, which can be used as a proxy for HC need, a large proportion 
of the variation between health boards due to TTD is reflected. NRAC recommended 
that further research into HC needs that are related to TTD, age and resource allocation 
was required as TTD studies were at an early stage and recommended more empirical 
applications. 
 
                                               
4
 An epidemiological approach would require detailed data on the morbidity of the entire 
population. This would also require linkage of morbidity data to subsequent utilisation of HC 
services at a patient level. After available data was reviewed by NRAC, it was concluded that 
implementing a formula based on a comprehensive epidemiological approach was not 
something that could be achieved within the time scale of the Committee’s work (Bishop et al, 
2006). 
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It has to be noted here that the studies NRAC based their recommendations and 
conclusions on are mostly preliminary studies (Graham and Normand, 2001, Lowe, 
2005) that show scope for an improvement in methods, relating to both the sample used 
and also the econometric modelling techniques employed. Further ‘room for 
improvement’ is also found in the costing methods these studies have used. A detailed 
review of both studies is provided in Chapter 3.  
 
2.5 Costs for long-term care 
Apart from costs for acute inpatient care, which had been shown to be the main 
contributing sector to the entire costs for the NHS and other NHS costs, the LTC sector 
is another sector that would be expected to be heavily affected by a shift towards a 
higher proportion of elderly people.  
The provision of LTC in Scotland does not fall within the remit of the NHS but is mainly 
the responsibility of Scottish local authorities (Councils). Costs for LTC are therefore not 
part of the Costs Book. Unlike hospital care, LTC can be provided in a variety of 
settings. Care can either be provided in care homes or in peoples’ own homes. A wide 
range of financial sources provide payments to fund LTC. Local authorities receive 
funding through grants from the Scottish and the UK Government. Council tax and user 
charges also contribute towards financing LTC (Scottish Executive, 2006)  
In care homes, user charges amount to 37% of total care home fees. In 2002, the 
Scottish Parliament introduced Free Personal and Nursing Care (FPNC), following 
recommendations from the Royal Commission on long-term care for people over the 
age of 65 either living in care homes or in their own homes (Bell and Bowes, 2006). 
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However, this does not include subsidies for hotel and accommodation charges, hence 
the rather substantial contribution that comes from user charges. 
Care for people living in their own homes is also funded by a number of sources. Again, 
a proportion of care provided is funded privately. Estimates on private spending for 
home care are very difficult to obtain and subject to great uncertainty, according to the 
‘Review of Free Personal and Nursing Care in Scotland’ (Scottish Government, 2008). A 
further share comes from local authorities and the main financial contribution comes 
from the Department for Work and Pensions (DWP). An additional component of LTC 
that is supported by local authorities is Housing Support (Scottish Government, 2008).  
As pointed out earlier, spending on LTC is not published in the NHS Costs Book. Rough 
estimates can only be obtained at an aggregate level by summarising costs of each of 
the services that are most likely involved in providing LTC. This means that cost data for 
LTC is not available at an individual level. It will therefore be very difficult to relate costs 
to personal characteristics, such as gender, age and health status measures etc. This is 
further complicated by the fact that no patient level data are available, which would 
provide information on length of stay in care homes or the duration during which care 
was provided in peoples’ homes, the level of care received etc. As a consequence, any 
cost estimates obtained using aggregate data are unlikely to be reliable. Without reliable 
data, it will however be very difficult to assess the impact that population ageing might 
have on the demand for LTC in Scotland. 
LTC and its organisation differ substantially from HC. Ideally, primary care services, 
hospital care and LTC would all be considered in a study looking at population ageing 
and related social costs, especially as a shift between hospital care and LTC might be 
observed.  
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Given these data constraints, this thesis concentrates on the most expensive HC sector, 
namely hospital care. Limitations arising from not including other HC sectors, especially 
LTC are discussed in Chapter 7 of this thesis. 
 
2.6 Measuring resource utilisation in Scotland 
Information on resource use, which will serve as the basis to measure HC expenditure, 
needs to be available over a sufficiently long observational period during which death for 
a substantial part of the sample can be observed. Ideally data would be in a panel 
format, which means unobserved heterogeneity between patients can be controlled for, 
so that multiple observations per individual can be treated as dependent observations.  
Scotland has the advantage of maintaining very comprehensive hospital episode 
statistics to measure resource use of acute inpatient and day care. These are known as 
the Scottish Morbidity Records 01 (SMR01) data and are held by the Information 
Services Division (ISD) of NHS Scotland. SMR01 records exist in computerised format 
since 1968 with approximately 1 million records generated per year (Scottish Public 
Health Observatory, 2010). Care episodes that are excluded from SMR01 are obstetric 
and psychiatric specialties. Geriatric long stay episodes were part of SMR01 until 1997. 
Since LTC does not fall within the remit of the NHS anymore, as outlined in Section 2.5, 
these records were excluded from SMR01. 
2.6.1 Record linkage 
Scotland also has the advantage of having a very good data linkage system, allowing 
SMR01 records to be linked to survey data. Linkage of medical records in Scotland goes 
back to the late 1960s and is undertaken by ISD using probability matching 
(Fischbacher et al., 2007). Probability matching allows for imperfections of the data 
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compared to an exact matching approach, which could miss up to 15% of true links. 
Linkage is usually undertaken on a number of core items: surname, initial, year, month 
and day of birth with a discrepancy rate of up to 3% in pairs of records belonging to the 
same individual. Probability matching is done by assigning probability weights (every 
time an item of identification is the same in two records, the probability that these two 
records belong to the same person is increased and vice versa) (Kendrick and Clarke, 
1993).  
2.6.2 Survey data 
The inclusion of that part of the population, which is not observed in resource use data, 
e.g. that part of the population without any hospitalisations, can only be achieved 
through the utilisation of survey based data. The SMR01 datasets have been routinely 
linked to death records from the GROS. This link provides information on hospital 
episodes (positive costs) for individuals with a death record. However, it does not 
provide information on individuals with a death record, who never utilised hospital 
services. SMR01-GROS linked data also gives information on individuals without a 
death record, who incurred costs. It does not however provide any information on 
individual characteristics for those without a death record, who did not incur any costs. 
Linkage to a survey based dataset can provide information on individual characteristics 
for these people. 
Therefore, administrative data does not seem to be sufficient to capture all subgroups of 
a population that are to be included in a TTD study. A population based approach that 
also includes individuals without positive HC expenditure requires a separate survey 
based dataset, where individuals can be observed regardless of incurring HC costs or 
having a death record. Exploiting the fact that SMR01 can also be linked to a number of 
other data sets this thesis makes use of two survey based datasets, the Renfrew/Paisley 
study (as one of the Midspan studies) (Hart et al., 2005) and the Scottish Longitudinal 
Study (SLS) (Hattersley and Boyle, 2007), which represents a 5.3% sample of the 
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Scottish Census. These two datasets are introduced and described in more detail in 
Chapters 5 and 6.  
A further advantage of having longitudinal survey based data is that a number of 
explanatory variables can be exploited, some of which have not previously been 
included in an analysis of the association between TTD, population ageing and HC 
expenditure. These are health status measures, health behaviour and health risk 
variables. They constitute important individual characteristics, which are not routinely 
collected in resource use data. The ability to capture time trends and possible 
improvements in medical technology that could have influenced costs is also supported 
by the analysis of a comprehensive longitudinal linked dataset. 
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3 LITERATURE REVIEW 
3.1 Introduction 
This chapter summarises and critiques the seminal contributions to the literature in 
terms of population ageing and its effect on HC expenditure, thereby providing a) the 
motivation for this thesis and b) the justification for methods employed in this thesis. 
Early contributions to the research field are also reviewed. A review of the literature was 
carried out in MEDLINE after developing a search strategy (Appendix I). In addition, 
reference lists of studies that were identified from the search were scanned and the 
‘Web of Knowledge’ database was used for citation searching. Language restrictions 
were imposed to include English studies only and the database was searched for 
studies published between 1950 and 2009. 
This chapter outlines the underlying assumptions of why an ageing population is 
expected to cause a steep rise in HC costs. Following on from this, recent contributions 
to the literature are presented that also take into account other factors than population 
ageing that might impact on HC expenditures, namely the time immediately before an 
individuals’ death, which tends to be characterised by aggressive and expensive 
treatments/therapies. 
The review of the literature focuses on these TTD studies and specifically on the 
methods that have been employed to analyse the relationship between population 
ageing, TTD and HC expenditure, which are shown to vary widely. Issues of particular 
interest are the distinction between a macroeconomic and a microeconomic approach, 
the sample that is analysed and its representativeness (survivors versus decedents and 
individuals with and without zero cost observations), the HC sector (primary care, 
hospital care, LTC) and the different costing methods that have been used.  
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Furthermore, recurring methodological issues such as the appropriate econometric 
modelling framework, the problem of endogeneity of TTD and the inclusion of surviving 
sample members with an unknown TTD are discussed. Different methods that were 
employed in the literature to calculate the amount of future HC expenditure under 
different modelling scenarios are explained in order to inform HC expenditure projection 
for Scotland in Chapter 6. The review concludes with a detailed summary of the status 
quo of TTD studies in Scotland and an outline of how TTD is currently acknowledged in 
policy. Finally, data requirements and data availability to undertake a TTD study in 
Scotland are described.  
Focussing on research that used micro-econometric analysis this chapter proceeds with 
outlining and critically assessing these studies in terms of their methodological 
differences which can lead to varying and sometimes conflicting results. Special 
attention is paid to differences in 
• the econometric modelling framework and sample selection 
• the HC sector that has been used in the analysis and its associated costs, the costing 
method and the choice of an appropriate estimator for HC expenditure, 
• the inclusion of survivors in TTD studies   
Sections 3.4 to 3.7 review and summarise the literature under these aspects and 
present the main contributions. Gaps in some of these methods are highlighted. These 
deserve further methodological investigation and have motivated the empirical analyses 
undertaken in this thesis, which are presented in Chapters 4, 5 and 6. 
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3.1.1 Pioneering research from the 1950’s 
Generally, as age increases, health deteriorates. Chronic diseases develop and require 
medical attention and the number of contacts with HC services usually increases, 
therefore HC spending varies with age. 
The first research to investigate the relationship between population ageing and HC 
expenditure was undertaken by Abel-Smith and Titmuss in 1956. When forecasting 
future expenditure needs the authors assumed that demographic change would be the 
only factor influencing the cost of the National Health Service (NHS) and that other 
factors, such as incidence and type of disease and type and quality of treatment would 
remain unchanged. The authors estimated future HC expenditure combining population 
projections from the Registrar-General with Census data on the proportion of the 
population in hospital by sex and age (Abel-Smith and Titmuss, 1956).  
This research presents very early work to quantify the impact that demographic change 
is expected to have on HC expenditure. The data included to answer their question are 
limited in a sense that it is aggregated data on only two variables which are expected to 
solve a rather comprehensive problem. This early research also shows its limitations in 
econometric techniques, which were less developed in the 1950s compared with more 
recent research. The assumptions Abel-Smith and Titmuss (1956) made about the 
unchanged incidence, the character of diseases, and the quality and quantity of 
treatments would also need to be reconsidered.  
However this has been an important contribution and certainly pioneering work in this 
field which provoked and encouraged a growing research area in decades to come. 
Since the 1950s a wide range of studies was undertaken and published that employed 
new and improved methods to try and explain the impact that an ageing population has 
on HC expenditure. The following sections provide a comprehensive and critical review 
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of these studies and summarise improvements that were made in terms of methodology 
and econometric modelling techniques. 
 
3.2 Morbidity scenarios 
Research that was undertaken in order to explain the impact that population ageing 
might have on HC expenditure is usually motivated by one of the three 
different/conflicting assumptions (see Sections 3.2.1 to 3.2.3 below) about how morbidity 
as the main driver of HC demand and expenditure will develop in the future. Given that 
life expectancy is improving in general in most countries, the central question is that of 
quality of life (health status) in which these additional years of life will be spent. In 
contrast to Abel-Smith and Titmus (1956), this is based on the assumption that the type 
and incidence of disease would change over time. Changing disease pattern cause 
changes in the demographic composition of a population and due to increased longevity 
a higher proportion of elderly people will be present. This is mainly caused by a 
reduction in, for instance, cardio-vascular disease, so that people live longer but might 
be at risk of developing other morbidities, such as cancer.   
However, evidence that a higher proportion of the elderly population causes an 
inevitable increase in HC expenditure is not as clear cut. The central question is whether 
any additional years of life will be spent in good or bad health, i.e. will an 80 year old 
person in 20 years time be more or less healthy than an 80 year old person now? In 
other words, how many of the additional years of life will be spent in good health and 
how many in bad health? If people, due to medical advances, experience shorter and/or 
less severe spells of illness towards the end of life this will have an impact on the 
amount of HC resources required to treat them. A measure commonly used to describe 
this relationship is healthy life expectancy, i.e. the number of years a person can expect 
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to live in good health. The difference between life expectancy and healthy life 
expectancy gives the number of years a person can expect to live in poor health. The 
three main concepts that had been put forward in order to describe the pattern of how 
life expectancy and healthy life expectancy could develop are 1) the expansion of 
morbidity concept, 2) the compression of morbidity concept and 3) a concept assuming 
a dynamic equilibrium. A detailed presentation of each of these scenarios is provided 
below. 
3.2.1 The expansion of morbidity hypothesis 
The expansion of morbidity concept was put forward by Gruenberg (1977) who assumed 
that additional years of life gained would be spent in poor health. Gruenberg (1977) 
argued that an increase in life expectancy was mainly achieved through improved 
medical technology, which serves to extend the lives of individuals with disabilities and 
diseases, but the underlying epidemiology of degenerative diseases would remain 
unchanged (Gruenberg, 1977). His failure of success hypothesis claims that individuals 
surviving to older ages would have increased levels of diseases and disabilities. With life 
expectancy increasing faster than healthy life expectancy, individuals would 
consequently spend more time in a state of ill health. 
A similar assumption has also been put forward by Olshansky and colleagues (1991). 
Although the authors agreed generally with Fries’ argument of a natural limit to 
longevity, they argue that even minor improvements in mortality for the elderly would still 
lead to increased morbidity due to people surviving longer with non-fatal chronic 
diseases (Olshansky et al, 1991). 
3.2.2 The compression of morbidity hypothesis 
A contrasting concept is that of the compression of morbidity which has been described 
by Fries (1980) and assumes both an absolute increase in life expectancy and also an 
increase in the number of years that are spent free of illness and disease. The age at 
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which illnesses occur (age at onset) and the progression of diseases are delayed 
through changes in lifestyle that modify risk factors for mortality. Increases in life 
expectancy are mainly achieved through improvements in the underlying epidemiology 
of diseases. Healthy life expectancy increases faster than life expectancy and the 
absolute number of years spent in ill-health decreases. Another assumption Fries made 
was that any increases in life expectancy must slow down over time as human longevity 
approaches a natural limit (Fries, 1980).  
3.2.3 The dynamic equilibrium hypothesis 
A third concept, the dynamic equilibrium, puts forward a ‘midway solution’ between the 
compression and expansion of morbidity hypotheses. It assumes a delay in the 
progression from less severe states of illnesses to more severe states. The number of 
years lived with an illness and the number of years lived with less severe illnesses would 
increase simultaneously and so result in an average increase in the number of years 
spent in a state of moderate illness. However, the level of care required during this 
period may decrease (Manton, 1982). An increase in life expectancy would therefore 
lead to an increase in disease prevalence, but this would mainly be caused by an 
increase in prevalence of less severe or less disabling diseases.  
These three concepts can only be mutually exclusive in theory. In practice it seems 
more likely that factors such as delayed onset, delayed progression and increasing 
survival with severe illnesses that support either of these concepts would act together.   
3.2.4 Evidence for morbidity scenarios 
Which scenario will unfold over the next decades remains an issue that has not been 
resolved entirely and may also vary between countries (Williams, 2005). More recent 
research that has reviewed studies from different developed countries that have 
assessed how their demographics have changed over time suggested that although it is 
still not established, evidence seems to point in the direction of people living longer than 
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they had previously with less disabling diseases or functional limitations (Christensen et 
al., 2009). Further evidence that supports the ‘compression of morbidity’ concept as the 
scenario that might unfold in the future has been summarised by Payne and colleagues 
(2007).  
3.2.5 Evidence for morbidity scenarios in Scotland 
Findings from Christensen et al (2009) suggested that countries where the disparity in 
lifespan between population sub-groups is low are those that tend to have the longest 
life expectancies. Evidence from Scotland, published by the Healthy Life Expectancy 
Measurement in Scotland Steering Group showed that although increases in healthy life 
expectancy at age 65 had been similar to increases in life expectancy in absolute terms 
and larger in relative terms, there were significant differences between socio-economic 
groups (Clark et al, 2004).  
On average this research found that remaining life expectancy for a 65 year old man 
was 14.8 years, of which on average 11.5 years will be spent in good or fairly good 
health. For a 65 year old woman mean life expectancy was 17.9 years, 13.4 of which will 
be spent in good or fairly good health. The report concluded that for people aged 65 and 
older healthy life expectancy is increasing at the same rate as life expectancy, so that 
the proportion of years spent in ill health has remained the same over the last 20 years. 
The report also showed that healthy life expectancy at birth in the most affluent areas 
was almost identical to average life expectancy (0.3 years less), whereas in the most 
deprived quintile healthy life expectancy at birth was up to 17.7 years less than average 
life expectancy. Differences in healthy life expectancy by socio-economic status were 
also more pronounced in areas that experienced lower life expectancies and also having 
a higher level of morbidity whilst people were alive (Clark et al, 2004).  
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3.3 The cost of dying –TTD as predictor for HC expenditure 
Based on the assumption of a compression of morbidity, there is a growing body of 
literature that takes into account factors other than population ageing to explain and 
estimate future HC spending. Accounting for changing disease pattern over time, these 
studies have tried to disentangle the effects that other factors than demographic 
changes might have on future HC expenditure. Among the most researched factors is 
remaining TTD. This is based on the experience that individuals near death might 
receive very expensive and aggressive treatments in order to prevent death. This 
implies that older people are more expensive not because they are older but because 
they tend to be closer to death compared to younger people. One study suggested that 
decedents, who made up 6% of the analysed sample accounted for 28% of total 
Medicare expenditure and that the intensity of HC utilisation increased as people 
approached death (Lubitz and Prihoda, 1984). 
Accounting for remaining TTD will change the predicted effects of purely demographic 
changes, i.e. population ageing. If population ageing was the result of increased life 
expectancy, then the expectation would be that the age profiles of HC expenditure move 
downwards for those age groups for which mortality is improving. This would imply that 
HC expenditures could even decline (in theory). 
In the 1980s, Fuchs (1984) established that cross-sectional differences in HC 
expenditures by age overestimated the changes that would result from an ageing 
population. Using Medicare data he found that HC spending is more a function of TTD 
than it is of age and that the reason why expenditure increased with age in cross-
sectional data was the increasing proportion of people near death. Grouping people as 
survivors or decedents Fuchs showed that after adjusting for age and sex differences in 
the survivor group, most of the age-related increase in expenditure could be eliminated. 
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This study was one of the first to show that TTD may be a better predictor for HC 
expenditure than age (Fuchs, 1984). 
A number of more recent studies followed that considered TTD in addition to age and 
how this affects HC expenditure employing an array of methods. The most influential 
work that provided evidence against the relatively simplistic methods of relating 
population ageing to HC expenditure was undertaken by Zweifel and colleagues (1999). 
In their seminal study the authors argued that population ageing could not be made 
responsible for increasing HC costs, an argument that has since entered the literature 
as the ‘red herring’ argument (Zweifel et al., 1999). The authors claimed that accounting 
for remaining TTD will significantly change the effect that demographic changes of the 
population will have on HC expenditure and if there was a significant association 
between TTD and HC expenditure, population ageing per se could not be the main cost 
driver. Zweifel et al (1999) found that the positive relationship between age and HC 
expenditure can be completely attributed to the fact that mortality increases with 
increasing age. The association between age and HC costs therefore seems to reflect a 
possibly stronger relationship between remaining TTD and HC expenditure, which 
Zweifel and colleagues found to be a much better predictor of acute HC costs than 
population ageing per se.  
As more elderly people are at their end of life it has previously been assumed that age is 
driving HC expenditure. But if age alone would be made responsible for HC spending 
other aspects, such as treatment intensity at the end of life, age-related rationing and 
advances in medical technology over time would be ignored.  
The conclusion reached by Zweifel and colleagues (1999) is a very strong one as it 
implies that demographic changes do not matter in terms of their contribution to HC 
expenditure. This research motivated a number of other national studies, some of which 
came to the conclusion that age is still an important factor associated with HC 
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expenditure, but accounting for TTD reduces the magnitude of the effect age had on HC 
costs (Seshamani and Gray, 2004a, Seshamani and Gray, 2004b, Moorin and Holman, 
2008, McGrail et al., 2000). In addition to initiating further research in this area, Zweifel 
et al (1999) also provoked criticism among researchers (Salas and Raftery, 2001, 
Seshamani and Gray, 2004b) some of which is discussed in detail in the following 
sections.  
This thesis highlights that the methods that have been used to analyse the relationship 
between population ageing, death and HC expenditure in different national studies vary 
greatly, which may hinder our ability to draw definite conclusions. The aim of the 
following sections is to provide a comprehensive description of these methods, 
concentrating on the following distinctions: a) studies that used descriptive analyses to 
explain the relationship between population ageing, HC expenditure and TTD, b) studies 
that used more advanced econometric techniques to explain this association.  
An additional level at which a distinction between methods can be made is whether 
researchers have chosen a macroeconomic approach, using aggregate country level 
data or whether a microeconomic approach, using individual level data was employed.  
Concentrating on research that used econometric techniques to analyse individual level 
data, this thesis will then proceed to outline further distinctions in methods that have 
been used within a microeconomic framework. 
3.3.1 Descriptive analyses of the cost of dying and the cost of ageing 
There are a number of studies which have undertaken descriptive analyses of the cost 
of dying and the cost of ageing, some of which have used a sample consisting of 
decedents only and have split these into different age groups. Costs for each age group 
were then plotted against TTD and HC expenditure was compared for a given TTD (last 
year of life) across different age groups (Batljan and Lagergren, 2004). Other methods 
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included the calculation of days spent in hospital by age group during the last year of life 
(Henderson et al., 1990). 
Other descriptive studies have also included surviving sample members and generally 
compare HC costs incurred by a group of decedents over a particular time period 
(calendar year) with those costs incurred by a group of surviving sample members of the 
same age group. Results are then presented as, so-called decedents/survivor ratios. For 
instance, Roos et al (1987) split their sample into survivors and decedents for their 
projection period and made expenditure projections for each of the sub-samples. 
Combining the two separate projections, the authors concluded that hospital utilisation 
would increase by 64% between 1976-2000 compared to an increase of 73% if the 
standard method of cost projection was to be used (Roos et al., 1987). The standard 
method employed by the authors was based on the projected growth in the number of 
the elderly population by the year 2000, whereas the alternative projecting method, 
which produced a lower growth rate for HC utilisation, was based on the projected 
number of decedents and survivors in the year 2000. The authors estimated age-
specific death rates and utilisation rates were obtained for survivors and decedents. The 
authors then applied utilisation rates without a decedent/survivor distinction to the 
projected number of the population in 2000 (standard method) and with a 
decedent/survivor distinction (alternative method) (Roos et al., 1987).   
Another study undertaken in British Columbia, Canada by McGrail and colleagues 
(2000) also compared expenditures for survivors with expenditures for decedents. Costs 
for nursing and social care as well as acute medical care were analysed utilising data 
from the British Columbia Linked Health Data (McGrail et al., 2000). The authors 
calculated costs for hospital care for the last 6 months of life using per diem costs and 
multiply these by length of stay (LOS). Their comparison group consisted of survivors in 
the same age range over a 6 month period (McGrail et al., 2000). This research found 
costs for acute care to rise with increasing age, but concluded that TTD was a stronger 
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predictor for HC costs and additional costs of dying would fall with age. Contrasting 
results were found for the use of LTC, where costs increased with increasing age, but 
the additional costs of dying also increased with age (McGrail et al., 2000). The authors 
highlighted implications of these different findings for different HC settings. 
Further research that has employed a descriptive analysis used a cohort study from 
Germany, which represented ten percent (stratified by age and gender) of all individuals 
insured by a German sickness fund (Busse et al., 2002). Instead of estimating HC 
expenditure, the authors compared the number of days that survivors and decedents 
spent in hospital, stratified by age and sex. For decedents they analysed the last three 
years of life and survivors were only included if they were observed to be at least three 
years away from death. For individuals in their last year of life the average number of 
days spent in hospital was found to be highest for ages between 55 and 64 years. 
Beyond this age the mean number of hospital days was found to decrease, whereas for 
the survivor group a steady increase in the mean number of hospital days was observed 
(Busse et al., 2002). The highest ratio of hospital days was found to be between 
decedents in their last year of life and survivors at age 44. The authors therefore 
concluded that the most costly patients were people who died young. This conclusion 
requires, however, that LOS is linearly related to costs, a concept that might not prove 
entirely correct given that a hospital stay is characterised by a fixed and a variable cost 
component. 
The age groups studied by Busse and colleagues were more encompassing than the 
age ranges that have been used in other analyses, which may make direct comparison 
with studies that mostly include individuals aged 65 and older difficult. Findings from 
Busse et al (2002) are however in line with findings from other research, confirming the 
‘red herring’ argument. 
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3.3.2 Macro-level analysis 
Yet another distinction that can be made in terms of the methodology used to explain 
how the changing age structure might impact on HC expenditure is that between using 
aggregate country level data and using individual micro-level data. Macroeconomic data 
can be used to make comparisons across different countries. Many studies that have 
utilised a macro-economic approach have not included TTD, but have rather analysed 
the effect of the age structure of the population on HC spending. 
Utilising cross-sectional data from 19 member countries of the Organisation for 
Economic Co-operation and Development (OECD) in 1987, Gerdtham et al (1992) 
analysed the effect that the age structure in addition to other factors, such as the Gross 
Domestic Product (GDP) had on HC expenditure (Gerdtham et al., 1992). The authors 
found no significant effect of age on HC spending and identified the GDP to be the 
biggest influencing factor (Gerdtham et al., 1992).  
In a study by O’Connell (1996), country specific age variables were used to analyse the 
effects that ageing had on HC expenditure in a number of OECD countries (O'Connell, 
1996). This study used data from 21 OECD countries for the period 1975 to 1990 and 
found the effect that the age structure had on HC spending to vary between countries. 
The age structure influenced HC spending significantly in a number of countries with a 
varying magnitude. The author acknowledged that less aggregated data would 
contribute to a better understanding of how exactly age influences HC expenditure 
(O'Connell, 1996). This is however difficult to achieve with country-level data as 
opposed to individual level data. It is also difficult to determine with this analysis 
approach, how unobserved country-specific effects impact on HC expenditure and the 
share of the Gross Domestic Product (GDP) devoted to HC expenditure.  
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Another study that analysed data on population ageing in OECD and UN countries is 
that of Anderson and Hussey (2000). They examine the correlation between the 
proportion of GDP spent on HC for people aged 65 and over and the proportion of the 
population in that age group (Anderson and Hussey, 2000). Their estimated correlation 
coefficient suggested very little correlation between these two variables and the authors 
proceeded to conclude that factors other than ageing might be far better predictors for 
HC expenditure (Anderson and Hussey, 2000). 
Issues arising from using aggregate country level data are that these data might not be 
comparable between countries. It could also be argued that there might be a weak 
theoretical basis for using aggregate data to explain which factors exactly determine HC 
expenditure. Individual population characteristics can not be modelled using a macro-
economic approach which makes it difficult to draw conclusions on the association 
between HC expenditure and population characteristics. As most macro-economic 
studies conclude, the age structure seems to have a negligible impact on HC 
expenditure. These studies also suggest that ‘other’ factors might be more important in 
explaining HC spending. However, using aggregate country-level data it is not possible 
to determine what these ‘other’ factors are.  Another limitation of employing a macro-
economic approach, using aggregate data is that these are averages over extreme 
values, and do not provide results for these extreme observations. In addition the quality 
of the data would be expected to vary greatly between countries. 
Including TTD as well as age, Colombier and Weber (2011) did not compare different 
countries but used Switzerland as an empirical example and analysed aggregate 
country-level data to prove that when using individual-level data in regression analyses, 
the effect that TTD has on HC costs towards the end of life might be overestimated. The 
authors argued that applying econometric regression techniques would suffer from bias, 
firstly because population ageing in the past has not been as pronounced as it is 
expected to be over the next decades. The authors further argued that econometric 
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estimations might suffer from ‘expectation bias’. This could be caused since cost 
estimates for the end of life are based on ex post data. Colombier and Weber (2011) 
claimed that decedents should only be treated differently from survivors if physicians 
expect them to die, which is unknown until individuals are very close to death 
(Colombier and Weber, 2011). According to the authors, rather than using the number of 
deceased people as a proxy for an estimate of the cost of dying, it would therefore be 
more appropriate to use the number of people, who are terminally ill. Colombier and 
Weber (2011) concluded that mortality only plays a minor role when it comes to future 
developments of HC expenditure and pointed out limitations of the ‘red herring’ 
argument. 
Despite the criticism that was raised by Colombier and Weber (2011), a microeconomic 
approach allows estimation of costs on an individual level which has the advantage of 
being able to capture differences in characteristics on an individual level rather than an 
aggregate level and so to account for individual characteristics. Individual level analysis 
also offers means to include explanatory factors that were measured on an individual 
level such as health status and health behaviour. Data availability could be perceived to 
be an issue here, however many countries now have administrative data available that 
facilitate a micro-level analysis. Scotland in particular has the advantage of having 
available excellent data linkage systems which provide a rich source of survey and 
administrative data, combing health data and additional baseline individual 
characteristics. 
Focussing on research that used micro-econometric analyses this chapter proceeds with 
outlining and critically assessing these studies in terms of their methodological 
differences which can lead to varying and sometimes conflicting results. Special 
attention is paid to the following issues: 
• the choice of an appropriate estimator for HC expenditure (Section 3.4) 
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• the econometric modelling framework (Section 3.5) 
• the HC sector that has been analysed and costing methods employed (Section 3.6) 
• the inclusion of survivors in TTD studies (Section 3.7) 
• the approach employed in order to project future HC expenditure (Section 3.8) 
• methods that have been employed to model the association between TTD, age and 
HC expenditure using Scottish data (Section 3.9). 
Methodological issues arising from the literature have motivated the empirical analyses 
undertaken in this thesis, which are presented in Chapters 4, 5 and 6. 
 
3.4 Estimators for HC expenditure  
Knowledge about the characteristics of HC expenditure data and appropriate estimators 
informs any subsequent discussion on how to estimate HC costs accounting for TTD, 
age and other explanatory variables. In a recent paper Basu and Manning (2009) 
concluded that there was no universally optimal estimator for HC expenditure data and 
outlined important methodological limitations that alternative estimators had (Basu and 
Manning, 2009). However, the following paragraphs provide a summary of available 
methods, discussing their advantages and limitations. 
Typical characteristics of HC expenditure data are: a mass point at zero, a non-normal 
distribution with long, heavy right hand tails and excess kurtosis (Deb et al., 2006). This 
distribution is typically observed because very few patients are usually responsible for a 
high proportion of costs, whereas the majority of patients tend to incur costs at the lower 
end of the scale. Mean HC costs are typically larger than median costs. Cost data are 
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further characterised by being non-negative and heteroscedastic5, i.e. having a non-
constant variance. And finally, the relationship between costs as the dependent variable 
and a set of regressors may not be linear. The choice of an appropriate estimator for HC 
expenditure is frequently discussed in the literature (Manning and Mullahy, 2001, Briggs 
et al., 2005, Hill and Miller, 2009). Discussion mainly revolves around the transformation 
of cost data versus the importance of being able to derive the arithmetic mean of cost 
estimates on the original monetary scale. 
A number of approaches exist to model cost data. First, cost data can be estimated 
using Ordinary Least Squares (OLS). OLS offers the advantage of being easy to 
implement and cost estimates are obtained on the original monetary scale. OLS has 
however disadvantages as it can produce negative predictions, which would be 
meaningless when dealing with cost data. It also assumes a linear relationship between 
the cost variable and the regressors; unless fractional polynomials or cubic splines were 
used in the analysis, where a curvi-linear relationship would be assumed. Due to the 
presence of heteroscedasticity, the classical assumptions for OLS are violated. The 
resulting coefficients will be unbiased, but estimates will be inefficient, i.e. OLS can not 
be the best linear unbiased estimator (BLUE) when heteroscedasticity is present. The 
standard errors are usually underestimated and t-statistics are made too large. This is a 
problem in particular, when the dataset is small and in case of extreme observations.  
Another approach would be to log transform the dependent cost variable and apply 
OLS. This transformation achieves a more normal distribution, increases robustness and 
improves precision. While log-transformation can solve the issue of skewness and 
reduce problems of heteroscedasticity and kurtosis, estimates can no longer be 
obtained on the original monetary scale and cumbersome re-transformation involving a 
smearing factor needs to be applied. Simple exponentiation of obtained estimates does 
                                               
5
 Heteroscedasticity indicates that error terms do not come from the same probability distribution. 
It often occurs in cross-sectional data, where there are large differences in size between 
observations (Halcoussis, 2005) 
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not provide the arithmetic mean of costs but the geometric mean of costs. Log OLS 
models the arithmetic mean of log costs, which is the geometric mean. It has been 
shown that the log of the mean does not equal the mean of log (Glick et al., 2007). 
Another issue of using log OLS would be that the log of zero costs is not defined and an 
offset would need to be added. Any decision about what the offset should be would be 
arbitrary.  
A third approach to estimate expenditure data is that of employing a Generalised Linear 
Model (GLM). GLMs are an extension of OLS and have the advantage of being able to 
specify a link function, which allows transformation of the mean of regressors rather than 
the mean of the cost variable, and a distributional family. For instance, GLM with a log 
link does not model the log of arithmetic mean costs, but the arithmetic mean of log 
costs. GLMs also allow for heteroscedasticity through a variance structure, which is 
defined through the distributional family and relates the variance to the mean (Glick et 
al., 2007).  
An additional characteristic of HC expenditure data is the fact that there are usually a 
high number of observations in any one period without any HC utilisation. These are 
called ‘zero cost observations’. Single regression models including these zero costs will 
likely lead to problems in obtaining regression estimates. To overcome these problems, 
a two-part model can be employed (Mullahy, 1998). The first part estimates the 
probability of accessing HC (usually employing a probit or logistic model) in any given 
period and the following second part (cost estimation) predicts costs, conditional on 
having incurred positive costs. The second part can be estimated employing GLMs, as 
described above. Predictions from the first and the second part are then multiplied to 
obtain the expected costs for subgroups of patients (Glick et al., 2007).  
Employing a two-part model has the advantage that the effects of individual 
characteristics on the probability of utilising HC services can be assessed in a first step. 
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This can be of special importance, when analysing multivariate models to explain the 
effects that age, TTD and also other factors, such as the socio-economic status, have 
on HC utilisation. Two-part models can unravel two things: what influences access and, 
given positive utilisation, what influences costs. Where there is no sample selection 
issue, a two-part model is preferred over a Heckman sample selection model. Given that 
all zero costs (times without hospitalisation) can be observed in the analyses of this 
thesis, the empirical analyses in Chapters 5 and 6 will utilise a two-part model.   
Further, comprehensive reviews of statistical methods to analyse HC expenditure data 
are available here (Dodd et al., 2006, Mihaylova et al., 2011). 
 
3.5 Micro-econometric models  
Compared to purely descriptive analysis as described in Section 3.3.1, studies 
employing micro-econometric regression, some of which have already been introduced 
briefly, (Zweifel et al., 1999, Zweifel et al., 2004, Seshamani and Gray, 2004a, 
Seshamani and Gray, 2004b) take into account that the age profiles for HC expenditure 
are not constant over time. Especially over the last decade, a number of studies have 
developed empirical models employing individual level data to explain the relationship 
between TTD and HC expenditure when controlling for age and other explanatory 
factors. These more advanced models go beyond comparing costs for decedents and 
survivors. In particular the application of cross-sectional time-series models allows 
estimation of how HC expenditure develops and changes as individuals approach death. 
Table 3.1 provides evidence on the main literature that is discussed throughout this 
chapter. 
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Table 3-1 Evidence from the literature 
 
 
Author/ 
Country 
Year(s) and Data Age groups/ 
sample 
HC sector Dependent 
Variable 
Method Main Findings 
Felder et al 
(2000) 
 
Switzerland 
1985-1992 
 
 
Deceased 
members of 
Swiss Sickness 
Fund 
 
 
415 deceased 
individuals 
over 8 
quarters 
 
N=3,300 
All HC costs covered 
by sickness fund 
HC 
expenditure 
for HC 
covered by 
insurance 
OLS and log OLS 
of HC expenditure 
HC expenditure increases with 
TTD, for retired individuals; HC 
expenditure decreases with 
age, low income individuals, as 
compared to high income 
individuals incur lower HC 
expenditure in the last months 
of life 
 
McGrail et 
al (2000) 
 
Canada 
(British 
Columbia) 
1987-1988 and 
1994-1995 
 
British Columbia 
Linked Health 
Data 
65 years and 
older 
 
 
Matched 
sample of 
survivors and 
decedents 
 
 
 
Medical care sector 
and social care 
sector 
Costs of 
hospital care 
(service use 
multiplied by 
per diem 
rates)   
 
 
 
Descriptive 
method 
Costs for medical care rise with 
age for survivors and fall with 
age for decedents, Additional 
cost of dying falls with age, 
even when social care costs 
are included 
 
 
 
 
Busse et al 
(2002) 
 
Germany 
1989-1995  
 
German sickness 
fund 
N~70,000 
(10% sample 
of sickness 
fund) 
 
Survivors and 
decedents 
 
 
 
 
Acute inpatient care 
 
 
n/a Descriptive study 
of total number of 
hospital days 
Hospital use for people, who 
die at 50 or later is directly 
proportional to number of years 
lived, no exponential rise in 
costs as longevity increases 
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Author/ 
Country 
Year(s) and Data Age groups/ 
sample 
HC sector Dependent 
Variable 
Method Main Findings 
Serup-
Hansen et 
al (2002) 
 
Denmark 
1995 
 
Prevention 
Register at 
Statistics 
Denmark 
All ages 
 
Random 
sample of 
1,011,000 
individuals  
 
Survivors and 
decedents 
Hospital use and 
primary care 
services 
n/a Descriptive study; 
Cohort component 
technique to 
project 
demographic 
changes  
Age still has considerable 
impact on future HC 
expenditure; traditional 
projection method suggested 
18.5% increase in costs 
between 1995 and 2020 and 
improved method suggested a 
15.1% increase. 
Lowe 
(2004) 
 
Scotland 
1981-2004 
 
SMR01 data 
linked with death 
records 
65+ 
 
Sub sample 
for Ayrshire 
and Arran 
Health Board 
Region 
 
Decedents 
 
Acute inpatient care 
 
Per diem 
costs 
(aggregated 
to annual 
costs per 
patient)  
Replication of 
Seshamani and 
Gray (2004b, 
2004c) model 
 
Two part model 
TTD in the last year of life has 
highly significant association 
with costs 
 
Age is a highly significant 
predictor for costs (age squared 
is highly significant and 
negative) 
Seshamani 
and Gray 
(2004b, 
2004c) 
 
England, 
Oxford 
Region 
1970-1999 
 
Oxford Record 
Linkage Study 
(ORLS) 
65+ 
 
106,000 in 
Oxfordshire 
 
Decedents, 
followed over 
30 years 
Acute inpatient care Specialty 
specific costs  
Two part model  
 
Heckman sample 
selection model as 
comparator 
Heckman model: neither age 
nor TTD are significant 
predictors for hospital costs 
Two part model: age and TTD 
have a significant effect on 
quarterly costs as far as 15 
years before death 
Tenfold increase in costs from 
5 years to death until 1 year 
before death; 30% increase in 
costs from age 65 to age 85 
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Author/ 
Country 
Year(s) and Data Age groups/ 
sample 
HC sector Dependent 
Variable 
Method Main Findings 
Stearns and 
Norton 
(2004) 
 
U.S. 
1992-1998 
 
Medicare Current 
Beneficiary 
Survey  
66-99 years 
 
N=22,100  
 
Decedents 
and survivors 
 
 
 
 
 
 
 
HC expenditure as 
obtained from claims 
data 
HC 
expenditure 
(inflated to 
1998 $) 
Two part model 
 
1st part: logit 
2nd part: OLS 
 
 
TTD negatively correlated with 
HC expenditure and age, 
omitting TTD leads to 
overestimation of HC 
expenditure by 9% (for current 
population) to 15% (for 
projected population in 2020) 
 
 
 
 
Breyer and 
Felder 
(2006) 
 
Germany 
 
 
 
 
 
 
Swiss insurance 
claims data 
(1999) and 
population 
estimates from 
the German 
Statistical Office 
up until 2050 
 
 
Ages 30-95 
years 
 
N=91,327 
 
4% 
decedents, 
96% survivors 
1999 by at 
least 42 
months 
 
 
All HC costs covered 
by sickness fund 
HC 
expenditure 
for HC 
covered by 
insurance 
Two part model of 
individual HC 
expenditure  
 
Impact of medical progress is 
much larger than the impact of 
ageing; 
 
Overestimation of future HC 
expenditure when using a naïve 
model found to be small 
compared to other research 
(~4%) 
Polder et al 
(2006) 
 
Netherlands 
1998-1999 
 
Health insurance 
data linked to 
data on home 
care and nursing 
home use and 
cause of death 
N~2.1 million 
 
Survivors and 
decedents 
(~16,000) 
All medical care 
costs including 
hospitals care, 
pharmaceutical, 
nursing home care 
and home care 
n/a Descriptive study  Costs for decedents were 
higher than for survivors; costs 
for people dying young were 
higher than for older decedents; 
costs highest for deaths from 
cancer; projection showed 10% 
decline in growth rate of future 
HC expenditure compared to 
conventional methods 
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Author/ 
Country 
Year(s) and Data Age groups/ 
sample 
HC sector Dependent 
Variable 
Method Main Findings 
Werblow  et 
al (2007) 
 
Switzerland 
1999 insurance 
claims data 
(Swiss Sickness 
Fund) 
30-95 years 
N= 62,120 
57000 alive, 
5000 
deceased 
 
Decedents 
and survivors 
HC expenditure by 
components: 
ambulatory care, 
nursing home care, 
home care, hospital 
inpatient care, 
hospital outpatient 
care, prescription 
drugs, other services 
 
 
HC 
expenditure 
for HC 
covered by 
insurance 
Two part model 
 
2nd part GLM 
Age effect on total HC 
expenditure negligible for 
survivors and deceased,  
 
TTD positively related to HC 
expenditure, same effect for 
LTC users, apart from acute 
care provided to LTC users, 
which is driven by age 
 
 
 
 
Hakkinen et 
al (2008) 
 
Finland 
1998 
 
Individual level 
linked data from 
various sources 
(cause of death 
statistics, social 
insurance 
institution, 
hospital 
discharge 
register) 
 
40% sample 
of Finnish 
population 
aged 65+ in 
1997 
(N=285,317), 
follow-up for 
death until 
2002 
 
Survivors and 
decedents 
Decomposition of 
health care 
expenditure into 
long-term care and 
non long-term care 
components 
 
 
Costs 
deflated from 
2000 to 1998 
prices 
8 models, first: 
likelihood of being 
LTC patient, 
remaining models 
estimated 
separately for LTC 
and non-LTC 
 
Two-part model 
(logit/probit+ OLS) 
 
Projection of HC expenditure is 
overestimated by 13% if a 
naïve model, excluding 
remaining TTD was used. 
 
 
 
Moorin and 
Holman 
(2008) 
1997-2000; 
Death records for 
Western Australia 
linked to hospital 
records 
N= 13,783  
 
Decedents 
only (up to 3 
years prior to 
death) 
Acute hospital 
inpatient care in the 
last 3 years before 
death 
Inpatient 
hospital 
costs based 
on Australian 
DRGs  
Comparison 
stratified by cause 
of death, Lorenz 
curves to detect 
variation in costs 
within strata 
 
 
 
Increase in costs associated 
with TTD, but magnitude of 
increase inversely related to 
age; irrespective of age costs 
increase in last 5 months of life  
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Author/ 
Country 
Year(s) and Data Age groups/ 
sample 
HC sector Dependent 
Variable 
Method Main Findings 
Shang and 
Goldman 
(2008) 
 
U.S. 
1992-1999  
 
Medicare Current 
beneficiary 
Survey  
N= 83,412 
 
Ages: 65+ 
 
Survivors and 
decedents 
All HC costs in 
claims data 
Total HC 
expenditure 
(include 
programme 
spending 
and out-of-
pocket 
spending) 
Proportional 
hazard model to 
predict life 
expectancy, 
comparison of 
predictive power 
of age and life 
expectancy in 
explaining HC 
expenditure, HC 
expenditure 
lagged by one 
year to mitigate 
endogeneity  
 
 
 
Age has little predictive power 
for HC expenditure after 
controlling for life expectancy, 
introducing life expectancy in 
addition to age results in lower 
projections of future HC 
expenditure 
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3.5.1 Econometric modelling framework 
The ‘Red Herring’ 
Zweifel et al (1999) were the first to apply advanced regression modelling to analyse 
individual level costs for the last two years before death. In this study the authors 
employed a Heckman sample selection model (Zweifel et al., 1999), estimating a 
decedent’s probability to utilise HC services in the first modelling part using probit 
regression. From the first modelling part the inverse Mills ratio λ6 was calculated. The 
second part of the model estimated positive HC expenditures (log transformed to 
mitigate skewness of the data) using OLS regression. The second part included the 
same set of regressors as the first together with the inverse Mills ratio λ.  
The modelling framework used by Zweifel and colleagues (ZFM model) had provoked 
some criticism, the first being raised by Salas and Raftery (2001), who showed 
weaknesses in the ZFM model. Their main criticism was concerned with the possible 
multicollinearity with the inverse Mills ratio in the second part of the model estimation 
(Salas and Raftery, 2001). The same point of criticism had later been raised by 
Seshamani and Gray (2004a, 2004b). The authors established that if a Heckman 
sample selection model was used in the first step of the model estimation, the second 
modelling part would only be identified if the inverse Mills ratio showed a non-linear 
relationship with the remaining regressors, i.e. the modelling needs an ‘exclusion 
restriction’ with an explanatory variable that is significant in the selection part, but not in 
the cost estimation part of the modelling (Seshamani and Gray, 2004b). 
For their analyses Seshamani and Gray (2004a, 2004b and 2004c) used data from the 
Oxford Record Linkage Study (ORLS), which is a longitudinal dataset for hospital 
                                               
6
 The inverse Mills ratio denotes the ratio between the probability density function and the 
cumulative distribution function. It is applied in regression analyses were there is selection 
bias as first suggested by Heckman in 1976 who suggested application of a two-part model to 
account for selection bias, estimating the inverse Mills ratio in the first part (probit) and using 
the estimated result in the second modelling part (Heckman, 1976). 
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episodes in Oxfordshire, England.  The dataset included people who were aged 65 and 
over in 1970 and died during the follow-up period until 1999. In order to highlight issues 
of model selection, the first part of this study replicated the ZFM model as closely as 
possible, but with differences in the cost variable. Seshamani and Gray (2004b) 
analysed hospital costs for acute and inpatient care (weighted average per diem costs, 
specific to each specialty), whereas Zweifel et al (1999) had used HC costs that are 
covered by the sickness fund and consequently included additional costs from other HC 
sectors. Another difference in the regression model was the absence of an indicator 
variable for individuals’ insurance status, which is very specific to the Swiss HC system, 
but is not relevant for the UK’s National Health Service. 
A replication of the ZFM model (Heckman sample selection model) with ORLS data 
revealed that neither age nor TTD had a significant effect on hospital costs, although an 
increase in the value of coefficients for TTD could be observed as individuals 
approached the end of life (Seshamani and Gray, 2004b). Overall, the size of the effect 
of TTD on costs was similar in both studies with differences found in quarters one and 
two before death. This might, however, be attributable to different numbers of quarters 
being analysed in the ZFM model (eight) and by Seshamani and Gray (2004b) (20). 
Furthermore, differences in findings in terms of the significance of TTD could be 
attributed partly to the different HC sectors analysed, although it seems surprising that 
hospital costs should not be strongly related to TTD and that other HC sectors, such as 
primary care or pharmaceutical prescriptions should be more closely associated with 
TTD. 
In the second part of their study, Seshamani and Gray (2004b) employed an extended 
two-part model introducing additional measures (cause of death and social class) for the 
first modelling part. These variables however proved to be significant in both parts of the 
econometric model and could therefore not serve as an exclusion criterion. The authors 
subsequently posed the question of the appropriateness of a sample selection model as 
Chapter 3  55 
 
zero costs were treated as missing values in the ZFM model, where in actual fact these 
were observed rather than unobserved. They argued that truncating the data in this way 
may misinform actual budgeting for HC expenditure (Seshamani and Gray, 2004b). 
Further criticism of the ZFM was related to the fact that quarterly cost observations were 
treated as independent from each other, not allowing for correlation between 
observations coming from the same patient. Seshamani and Gray (2004b) therefore 
proposed clustering by patient to derive more accurate standard errors. Results of their 
updated model, employing a two-part model rather than a Heckman sample selection 
model, including zero cost observations for decedents and accounting for correlation 
between observations coming from the same individual did show that age as well as 
TTD had a significant effect on hospital costs, emphasising the importance of correct 
model selection and highlighting methodological issues that can severely affect results. 
If correlations between observations are not accounted for, this would usually under-
estimate standard errors and could lead to invalid tests for statistical significance. 
Accounting for correlations though effectively decreases the sample size and reduces 
power, however, it provides a correct measure of the standard errors. Seshamani and 
Gray (2004b) concluded therefore that results obtained in the ZFM model could not be 
generalised when using alternative datasets. 
Seshamani and Gray (2004a) later extended their analysis and applied a panel data 
framework to the ORLS, rather than a cross-sectional framework, so as to adequately 
account for prior hospitalisations. This study confirmed results from their previous 
analysis and also revealed that the effect of TTD overshadowed the effect that age has 
on costs (Seshamani and Gray, 2004a, Seshamani and Gray, 2004b).  
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The ‘red herring’ updated 
In subsequent research, Zweifel et al (2004) updated their analysis to address the 
criticism that had been raised regarding their econometric modelling approach. The 
authors agreed that the second part of a Heckman selection model is only identified 
when λ can be specified as a non-linear function of the regressors, which was not the 
case in their first analysis in 1999. Fundamentally however the updated ZFM model 
confirmed the ‘red herring’ argument (Zweifel et al., 2004). This confirmation was 
reinforced by further research using the Swiss data (Werblow et al., 2007, Felder et al., 
2010).  
The research undertaken by Seshamani and Gray and Zweifel and colleagues can be 
regarded as the most influential in this area, however other national studies have been 
undertaken that also used econometric regression methods to test the impact that TTD 
had on HC expenditure towards the end of life and whether age per se remained a 
significant predictor. In a U.S. study, Stearns and Norton (2004) also focused on the 
justification of including TTD into a model of HC expenditure predictions. They argued 
that longevity was increasing, which in turn led to HC expenditure at the end of life being 
postponed into the future, i.e. to older ages. The authors therefore concluded that if TTD 
were omitted from a model estimating HC expenditure, biased estimates would be 
obtained for future HC expenditure (Stearns and Norton, 2004). Using data from the US 
Medicare Current Beneficiary Survey (MCBS) on survivors and decedents aged 66 to 99 
for the period from 1992-1998, costs were estimated for the last eight quarters of life. 
The modelling framework used in this study also employed a two-part model, as done by 
Seshamani and Gray (2004a and 2004b). For their second modelling part, (the cost 
estimation), the authors used OLS regression, arguing that they were interested in 
predictions on a monetary scale rather than a log scale. However, using OLS regression 
neglects the skewed distribution and the other characteristic of HC expenditure data as 
outlined in Section 3.4. 
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A recent study from Finland used individual level linked data representing a 40% sample 
of the Finnish population aged 65 and over in 1997, followed up until 2002 (Hakkinen et 
al., 2008). The authors had linked data available from a number of sources, which 
included survivors as well as decedents. To prevent multicollinearity and endogeneity, 
costs were studied in one year and TTD was measured from the end of that year as a 
single explanatory variable (lagged). This also allowed inclusion of patients that survived 
until the end of the follow-up period. The authors decomposed costs into several 
components: LTC and non-LTC and estimated eight different models with the first one 
estimating the likelihood of being an LTC user. Estimating separate models they found 
that total expenditure for both LTC and HC rises with age, although the association is 
weaker when controlling for TTD (Hakkinen et al., 2008).  
It could be argued here that by estimating separate models Hakkinen et al (2008) might 
be ignoring any substitutional or complementary pattern of HC resource use. This could 
potentially lead to an overestimation of the separately modelled effects and a systems 
approach such as ‘Seemingly Unrelated Regression’ (SUR) might have been a better 
estimator to capture potential simultaneous effects. The separate equations might be 
related through correlation in their error terms, i.e. decisions about accessing different 
HC services are not made independently from each other. 
Very recent research has been carried out in the Netherlands which tests whether the 
‘red herring’ argument holds for disease specific expenditures in the same way as it 
does for overall inpatient care costs or a variety of HC costs (Wong et al., 2011). 
Separate two-part models were run for different diseases (94 in total), and the results 
showed that the effect of TTD remained for most diseases and was strongest for 
patients with cancer. There were however varying degrees of influence of TTD and age 
on HC expenditure. Wong et al analysed separate datasets for different diseases, which 
means that patients, who were admitted for different diseases appear in different 
datasets with their respective costs allocated. The authors then estimated separate 
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Generalised Equation Estimation (GEE) models (Wong et al., 2011) to account for 
correlated observations, coming from the same patient.  
One point of criticism that needs to be raised is that Wong and colleagues (2011) used 
different datasets for different morbidities. This would not take into account admissions 
for patients that suffer from multiple chronic conditions and whose hospital episodes 
would consequently appear in different datasets, ignoring that these observations are 
related as they come from the same patient. The impact and rise of multiple morbidities 
and their related costs is a very topical issue (Caughey et al., 2008, Aspin et al., 2010) 
and not controlling for it possibly underestimates the impact that co-morbidities might 
have on costs incurred. It could therefore be argued that any analysis should avoid 
splitting the data by disease area, something that will be taken into account in the 
empirical part of this thesis. 
3.5.2 Sample selection 
The selection of a sample to be analysed appears to be mainly driven by the availability 
of data to examine the effect that age and TTD have on HC expenditure. Table 3.2 
shows four groups in any population/sample for any given period. It includes those who 
use HC services, those who do not utilise (or at least are not observed to utilise) HC 
services, and those who die and those who survive. 
Most studies, because of the nature of their data, only consider a selection of the 
quadrants and not all four groups. 
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Table 3-2 Population groups 
 
HC utilisation No HC utilisation 
Decedents Decedents who utilised 
HC services 
Decedents who did not 
utilise HC services 
Survivors Survivors who utilised 
HC services 
Survivors who did not 
utilise HC services 
 
For example, in the initial ZFM model, only decedents’ costs were analysed for periods 
with positive HC utilisation, excluding periods in which no utilisation could be observed. 
Zweifel et al (1999) acknowledged that the exclusion of deceased individuals, who did 
not incur costs in their last two years of life, may bias results: sick individuals, who are 
likely to incur higher costs, may be over-represented. They argued however that this 
bias would only be relevant if the inverse Mills ratio λ (which had been included to 
account for potential selection bias, which may have been caused by excluding zero 
cost observations), turned out to be significant in the second part of the model. If the 
sample selection test is non-significant though, Zweifel et al suggested that the 
exclusion of zero cost observations for decedents would not cause bias. Even if there 
was bias, the authors argued this would be corrected by including λ in the second part of 
the estimation.  
Salas and Raftery (2001) on the other hand argued that selection bias could have been 
caused due to the exclusion of decedents with zero cost observations. To correctly 
inform budgeting procedures and resource allocation it appears important to include 
zero-cost observations and so to prevent selection bias. If the sample selection process 
is observed rather than unobserved, excluding zero costs results in missing data rather 
than a reflection of the underlying selection process. Seshamani and Gray (2004a, 
2004b) later reinforced this criticism and proposed an updated model, which also 
included zero cost observations for decedents. 
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The exclusion of zero cost observations is a two-fold issue, which has not been made 
entirely clear in the above studies: Individuals will have periods in which they do not 
incur HC costs. Depending on the observational unit for TTD (years, quarters or months) 
these periods will need to be assigned zero costs. Another layer to this is that there will 
be individuals, who do not appear in resource use data at all, since they never accessed 
HC services (over their entire life, or over the observational period the administrative 
dataset spans). If these individuals are to be included in an estimation of costs incurred 
before death survey data is required to obtain demographic data. These are two 
different issues and both are informative and need to be taken into account. This thesis 
addresses this by using survey based datasets, which provide baseline characteristics 
for individuals who do not appear in resource use data, thus facilitating estimation of 
costs on a population level and avoiding sample selection and possible bias.  
 
3.6 Health care sectors 
Another factor that separates TTD studies in terms of their methodology is the HC sector 
that has been analysed in order to draw conclusions about the relationship between 
TTD, population ageing and costs. A much higher proportion of zero costs would be 
expected to be observed for acute inpatient care than for primary care, which is usually 
provided by General Practitioners (GP) who, in the case of the UK, control a large part 
of the access to hospital care. Huge variations would also be expected for the impact 
that age might have on expenditure for LTC and the impact it might have on 
expenditures for other HC services. Also the organisation of the provision, especially 
LTC, may influence any inference that can be made in terms of costs. For instance in 
Scotland, where LTC provision does not lie within the remit of the NHS, but is organised 
and provided by regional councils, costs are not borne by the NHS. This may only be a 
‘spreadsheet exercise’ as costs have to be paid through public funds nevertheless, but it 
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is important to be aware of these distinctions when analysing expenditures for an ageing 
population in different institutional HC settings and different countries. Further 
differences in results might be attributed to the inherent differences between an 
insurance based HC system, as found in the U.S., where HC facilities are largely owned 
by the private sector and a publicly provided HC system funded through taxation, as 
found in the UK. Both systems create very different incentives for HC providers, which 
will impact on both, delivery and costs of HC.   
Referral schemes in different HC systems will also have an impact on resource 
utilisation. The UK’s GP gate-keeping system serves as a ‘barrier’ to accessing 
secondary care, a fact that will in all likelihood have consequences on the first part of a 
two-part model, where the probability of accessing HC services is estimated. GP’s gate-
keeping function will affect different HC sectors differently. Notably, different national 
referral schemes can not have been taken into account by researchers who have 
analysed aggregate country level data, something that could have affected results. This 
provides another argument for the analysis of individual level data within a HC setting, 
i.e. country. It might even provide justification for TTD studies to be undertaken for each 
country separately and tailored to their specific HC settings and other observable or 
unobservable characteristics of a) individuals within a country/ethnicity etc. and b) the 
HC system. 
Zweifel et al (1999, 2004) utilised individual level data from Swiss sickness funds and 
therefore the included HC sectors and related costs were very comprehensive. The 
majority of other research however concentrates on the most expensive sector of HC 
provision; that of hospital care (Batljan and Lagergren, 2004, Busse et al., 2002, Culler 
et al., 1995, Graham and Normand, 2001, Henderson et al., 1990, Himsworth and 
Goldacre, 1999, Lowe, 2005, Moorin and Holman, 2008, Seshamani and Gray, 2004b, 
Wong et al., 2010, Wouterse et al., 2010, Wouterse et al., 2011, Wong et al., 2011).  
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A number of studies also analysed the effect that population ageing and TTD had on 
LTC (Riley and Lubitz, 2010, McGrail et al., 2000, Spillman and Lubitz, 2000, Schulz et 
al., 2004, Weaver et al., 2008, de Meijer et al., 2011). Results from studies analysing 
hospital care (see above) showed that TTD seemed to be an important predictor for HC 
costs and that the effect that age had on costs was reduced when TTD was accounted 
for. However this effect looked somewhat different for the LTC sector. McGrail et al 
(2000) reported costs for acute medical care to rise with increasing age for the survivor 
group, while costs seemed to decrease with increasing age for the deceased group. 
Costs for social and nursing care however were found to increase with age for both 
survivors and decedents. After adding the additional costs for social and nursing care to 
medical care costs, the authors still found decreasing total costs with age for decedents, 
but this decrease was much smaller than for acute medical costs alone (McGrail et al., 
2000). In general, the authors supported the finding that TTD is a much stronger factor 
in determining HC costs. 
O’Neill et al (2000) studied costs that were incurred in primary care (GP services) in a 
sample of nursing home residents and compared these to a sample living in the 
community, matched by age and sex. The authors found that among decedents, age 
was an insignificant predictor for GP costs, but TTD showed a significant association 
with costs. Although supporting conclusions drawn from Zweifel et al (1999) that TTD 
was a better predictor for HC expenditure than age (O'Neill et al., 2000), limitations of 
this study must be noted. The sample size was very small (N=52 for nursing home 
residents) and nine GP practices opted in to take part. It could be argued that this 
sample was not representative of the entire nursing home population in the UK and that 
sample selection bias might have been present. The small sample could also have had 
an effect on the power the statistical model possessed, rendering possible significant 
factors insignificant. 
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A number of studies that have analysed data from the U.S., i.e. the Medicare Current 
Beneficiary Survey (MCBS) have included total HC costs, which in this case 
encompassed costs for inpatient and outpatient care, costs for physicians, 
pharmaceuticals, home and hospice care. It also included – on top of the costs borne by 
the programme, cost that had to be paid out-of-pocket (Shang and Goldman, 2008, 
Hogan et al., 2001, Stearns and Norton, 2004). These studies have not necessarily 
undertaken separate analyses for these different cost components, but it should be 
noted that these are included in their overall costs that were estimated. 
3.6.1 Costing methods 
The choice of an appropriate costing method will mainly depend on the HC sector 
analysed. Costing methods differ between national studies, and the availability of 
alternative methods within a country makes this a very important methodological issue 
to consider.  
For acute inpatient care, Busse et al (2002) used LOS as a proxy for HC expenditure 
(Busse et al., 2002). This would only provide meaningful results if the costing method 
chosen is based on per diem costs, i.e. the cost increases proportionally with LOS. Per 
diem costing neglects the fact that treatment intensity will vary with LOS and a 
proportion of costs incurred will be fixed and another proportion will vary with LOS. 
The costing method used by Zweifel et al (1999 and 2004) was not explicitly explained, 
however as the authors used health insurance claims data, this will have been 
aggregated costs over a range of HC services including different methodologies of 
assigning a unit cost to a specific service (Zweifel et al., 1999, Zweifel et al., 2004). 
Hakkinen et al (2008) used the average cost per inpatient day specific to each DRG 
(NordDRG) (Hakkinen et al., 2008).  
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The analysis undertaken by Seshamani and Gray (2004a) employed expenditure data 
from the Department of Health, which were weighted average costs per inpatient day, 
specific to the specialty the patient was admitted to. These per diems were then 
aggregated to provide a yearly cost for each year before death. Per diem costs for 
inpatient care were also employed by Sato and Fushimi (2009), who analysed the 
impact of TTD, age, and LOS on HC expenditure (Sato and Fushimi, 2009). If per diem 
costs are employed and fixed and variable components of a hospital stay are not taken 
into account, it is likely that costs might be overestimated due to the assumption that the 
first day in hospital is as expensive as any subsequent day, which may not prove 
correct.  
Generally, each costing approach will have advantages and disadvantages. Per diem 
costing doesn’t account for the fixed and variable components of a hospital stay. In 
contrast a DRG or HRG costing approach is usually insensitive to small variations in 
LOS that do not exceed a trim point value.  
The choice of an appropriate costing method therefore adds an important 
methodological angle to this research field. Varying results between national studies 
might be partially explained by varying costing methods. This thesis further highlights 
these issues in Chapter 4, by testing alternative methods of costing hospital episodes 
statistics, which uses the same HC sector and the same sample and still shows 
important differences. Operating across a variety of HC settings in different countries 
and costing methods as done in the literature presented above is very likely causing 
issues of results not being comparable between studies, something that should not be 
surprising.  
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3.7 Survivors in TTD studies 
Another recurring issue in TTD studies is how to account for censoring and the resulting 
surviving part of the sample population. If the analysis of the relationship between 
ageing, TTD and HC expenditure is to aid resource planning and resource allocation at 
a population level, the sample ought to be representative of the population in question. 
The exclusion of survivors may lead to an overestimation of costs. If in any given year 
(or any other period) only costs for those individuals that will die during this period are 
considered, and costs for people who survive that period are neglected, estimated HC 
expenditure may not be a reflection of costs actually incurred by a population. If 
estimates based on decedents only were then to be used to project HC expenditure for 
future periods in order to obtain estimates of future HC demand, these projections may 
also be incorrect. The sample therefore ought to represent survivors as well as 
decedents in any given period. 
As raised by Hakkinen et al (2008), the effect of age on HC expenditure may be different 
for survivors and decedents (Hakkinen et al, 2008, pg.170). It could be argued that there 
would be selection bias if only decedents were included. In addition, the inclusion of 
survivors increases the sample size and therefore the power for any econometric model. 
If there was HC rationing, depending on the survival prospect of individuals, this would 
result in a difference between survivors and decedents and should be accounted for in 
any analyses. One further reason that might distinguish survivors from decedents is the 
difference in treatments they will receive, which arises from advances in medical 
technology over time. Survivors live to experience medical care later than decedents, 
hence the chance for survivors to utilise more advanced therapies, pharmaceuticals and 
clinical knowledge. 
In a longitudinal TTD study with an official study end, where death of participants can be 
observed, participants without an observed date of death (survivors) during the 
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observational period are typically right censored. Consequently, any HC costs that are 
observed at the end of the study are not necessarily HC costs at the end of life. The 
remaining TTD of survivors and therefore any HC expenditure incurred between the 
official end of the study and their death are unobserved (right censored). The length of 
time between entry into the study and in this case, death is unknown. Given entry at 
time 0 and observation at time t, all that is known is that the completed time in the study 
is of length T > t. 
3.7.1 Addressing censoring of survivors 
The issue of survivors’ unknown TTD has been addressed by a variety of methods. A 
number of studies that have looked at the relationship between TTD, age and HC 
expenditure have done so by excluding survivors from their analysis (Zweifel et al., 
1999, Felder et al., 2000, Moorin and Holman, 2008). It could be argued here that these 
studies have avoided the issue of survivors’ censored TTD rather than addressed it 
adequately. Some studies that have included survivors have done so mainly for 
descriptive analysis, comparing decedents’ with survivors’ HC expenditure (Polder et al., 
2006, McGrail et al., 2000, Busse et al., 2002).  
For the analysis carried out using the ORLS, survivors were excluded due to the fact 
that there were very few individuals without a death record at the end of the 
observational period, most of which had migrated (Seshamani and Gray, 2004a; 2004b; 
2004c). 
Hakkinen et al (2008) estimated the relationship between TTD, age and HC expenditure 
for two groups of individuals: LTC and non-LTC individuals. Notably Hakkinen et al 
raised the issue that the effect of age on HC expenditure may be different for survivors 
and decedents. They note that their approach “is extended to include patients who 
survive to the end of the follow-up period, since concern has also been that the effect of 
age may be different for the survivors than it is for the deceased” (Hakkinen et al, 
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pg.170). Therefore survivors had been included by means of studying HC expenditure in 
an initial year (1998) and measuring TTD from the end of that year until 2002, observing 
decedent and survivor status until 2002. However, survivors were still censored at the 
end of follow-up and their TTD remained unknown. 
An exploratory study undertaken in Scotland by Graham and Normand (2001) used 
Scottish Morbidity Records (SMR01) linked to death records from the GROS. Their data 
were split into separate datasets for decedents and for survivors. Further stratification of 
the cost data by age and sex facilitated comparison of effects that a changing age 
structure had on costs. Their results showed that acute HC costs for survivors increased 
with increasing age, whereas costs for decedents decreased with increasing age. This 
seems to confirm the concerns raised by Hakkinen et al (2008) above.  
Stearns and Norton (2004) include dummies for quarters until censoring for survivors 
instead of quarters until death and analysed survivors alongside decedents. These 
quarter dummies were also interacted with age, analogous to interacting TTD with age. 
TTD and age interaction terms take account of the fact that TTD affects HC expenditure 
differently for different age groups. In their analysis the authors used MCBS data and 
specifically the ‘Cost and Use’ files for the years 1992 to 1998. Respondents aged 
between 66 and 99 years were included and costs observed at a quarter-person level.  
Breyer and Felder (2006) assumed a constant TTD for all survivors in their study that 
analysed the impact on HC expenditure that population ageing could have in Germany. 
To do this they used a Swiss data set to obtain HC expenditure profiles stratified by 
gender and survival status, i.e. survivors vs. individuals in their last 4 years of life. In 
order to impute a TTD for survivors the authors set TTD as being one month greater 
than the entire observational period (Breyer and Felder, 2006). The authors compared a 
model with age as predictor for HC expenditure, a model also including TTD and a 
model accounting for a technology driven increase of costs (1% annually) and found 
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small differences between the ‘age’ and ‘TTD’ model, but a rather large impact that 
advances in medical technology would have.  
Lastly, Wong et al. (2011) modelled decedents and survivors separately in order to deal 
with different age patterns between these groups. Although they included survivors in 
their sample, they excluded their TTD and only included a dummy variable for the year 
of admission to hospital. The authors then generate ‘deceased/survivor’ ratios for every 
specific disease they investigate for different age groups and found that TTD was a 
significant predictor for HC expenditure for most diseases and strongest for cancer 
(Wong et al., 2011).  
Other studies that have included survivors have used a variety of methods, from simple 
descriptive analysis to interactions and separate regression analyses. This makes it 
difficult to draw comparative conclusions.7 
In summary, various approaches have been employed to deal with the unknown TTD of 
survivors in a sample. Excluding them from the analysis could lead to an overestimation 
of costs, since at any given age, HC expenditure was found to be higher for decedents 
than it was for survivors (Graham and Normand, 2001, Hakkinen et al., 2008). 
Employing a constant TTD (acknowledging survivor status but adding a constant period 
beyond the censoring date) neglects individual characteristics of survivors. The 
approach of treating them as if they were deceased (using their censoring date as date 
of death, but accounting for survivor status) also carries the risk of not correctly 
estimating costs, since any observed costs for survivors can not be attributed to a 
particular period before death. This limited consistency and generalisability makes 
comparisons across the studies very difficult. It seems that an approach that could 
predict survivors remaining life time would add to solving this methodological issue. 
                                               
7
 This is further complicated by those studies which despite obviously including survivors do not 
explicitly state how the unknown TTD for survivors is handled, see for example Pavlokova (2009) 
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Shang and Goldman (2008) realised these shortcomings and investigated a method that 
might rectify weaknesses from previous research. The authors investigated whether age 
or life expectancy drives HC expenditure and argued that for any HC expenditure 
forecasting exercise a prospective method should be employed based on a cohort that 
is alive at the time the research is undertaken. Based on data from the 1992-1999 
MCBS the authors estimated hazard models to predict remaining life time and then used 
regression analysis to test the predictive power that life expectancy and/or age had on 
HC expenditure. Predicted life expectancy was based on demographic characteristics as 
well as health status simulating a survival curve for each individual. Simulation was 
repeated until the mortality rate was close to one and life expectancy was calculated as 
the area under the curve.  
TTD for each individual was predicted using a random draw to determine an individual’s 
death in the next period. If predicted mortality from the previous step was greater than 
the random draw that individual was predicted to die in the next period. The random 
draw process was repeated until every individual in the sample died. TTD was then 
calculated as the difference in years between entering the study, i.e. the interview date 
and the year of death. The authors found that predicted TTD had a much larger variance 
than predicted life expectancy. Actual TTD may contain information on unobserved 
characteristics, which could not be controlled for in estimations. The authors therefore 
judged predicted life expectancy to be a better predictor for HC expenditure. Shang and 
Goldman (2008) also compared the distribution of predicted TTD obtained from hazard 
models with the distribution of TTD obtained from life tables and found these to be very 
close. The distribution of predicted life expectancy obtained from hazard models 
however was found to be very different from the distribution of TTD.  
Shang and Goldman’s (2008) approach is extended in this thesis insofar that a 
comparison of the magnitude at which estimated costs differ, when employing 
alternative methods of correcting for survivors’ unknown TTD is made. Results are also 
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expected to reveal differences in the association between costs and covariates and so 
reveal to what extent cost estimates are influenced by sample selection.  
3.7.2 Endogeneity between HC expenditure and TTD 
One frequently identified issue with TTD studies is the possible endogeneity between 
HC expenditure and TTD. Salas and Raftery (2001) were the first to raise this and based 
their discussion on results shown in Zweifel et al (1999), who had argued that age per 
se did not influence HC costs once TTD is controlled for. The authors argued that these 
results would hinge on the assumption that TTD was exogenous, i.e. HC expenditure 
had no effect on remaining life expectancy. This assumption may not hold and the 
reverse may seem more likely. Individuals seek medical care and medical interventions 
are aimed at prolonging and saving individuals’ life. Therefore, Salas and Raftery (2001) 
argued that if HC was sought in any given period of observation, this must clearly affect 
an individual’s health status in that period and might therefore also determine their 
remaining life expectancy. TTD would thereby be influenced by current and previous HC 
expenditure. Estimates might consequently be biased and inconsistent and standard 
errors will be incorrect (Salas and Raftery, 2001).  
To rectify this econometric modelling weakness, the authors recommend that if TTD is 
not strongly exogenous, and lagged HC expenditure is uncorrelated with the error term, 
that lagged HC expenditure can ‘Granger-cause’8 TTD and may therefore be used as an 
instrumental variable (IV).  This would require the lagged dependent variable (HC 
expenditure) to be orthogonal to the error term. This assumption could not hold however 
if unobserved time-invariant individual characteristics (disease etc) are likely to influence 
HC expenditure (lagged and non-lagged) (Salas and Raftery, 2001). To reduce the 
                                               
8
 Granger causality is inferred when lagged values of a variable x have explanatory power in a 
regression of a variable y on lagged values of y and x. If lagged values of a variable x have no 
explanatory power for any of the variables in a system, then x would be viewed as weakly 
exogenous GREENE, W. (2008) Econometric Analysis, Pearson Prentice Hall. 
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problem of endogeneity, Zweifel et al (2004) adopted a quasi- instrumental variable (IV) 
approach that was suggested by Salas and Raftery (2001). 
Stearns and Norton (2004) in their study also acknowledged the problem of endogeneity 
and suggested the application of a fixed effects model. This approach was based on 
their reasoning that endogeneity bias was mainly caused by correlations in the error 
terms between simultaneous equations. A fixed effects model should control for 
unobserved time-invariant characteristics and reduce correlations in the error terms. The 
authors also acknowledged methods of using lagged values etc, but did not employ 
these for their specific analyses (Stearns and Norton, 2004). 
In an updated analysis, Felder et al. (2010) concentrated on the endogeneity problem 
and agreed with criticism that had been raised previously and rejected an exogeneity 
assumption of TTD and HC costs (Felder et al., 2010). Their most recent analysis of the 
‘red herring’ hypothesis concentrated on testing instrumental variables that could purge 
TTD off its endogeneity. The authors used an extended dataset, including 60,000 
individuals. Death was observed for some individuals (11%) from 2000-2006, and costs 
were observed from 1997 and 2006. Felder et al. (2010) used the first three years of 
observed HC expenditure (1997, 1998 and 1999) and TTD for the following three years 
(2000, 2001 and 2002) to calculate estimated TTD values for the years 2003-2006.  
These estimated values were then used to replace observed values for TTD to estimate 
HC expenditure for 2003, i.e. the authors used lagged (by three years) explanatory 
variables to explain more recent HC expenditure. They found that although the 
instrument failed the Hausman exogeneity test, TTD retained its explanatory power, 
leading the authors to conclude that even if it was not possible to entirely purge TTD of 
its endogeneity, the ‘red herring’ hypothesis could still be confirmed (Felder et al., 2010).  
Shang and Goldman include life expectancy instead of TTD in their analysis (Shang and 
Goldman, 2008). The authors argued that this would solve the problem of endogeneity 
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to some extent as the predicted life expectancy in year t was based on demographics 
and health status in year t and was not correlated with HC expenditure after year t. 
Actual observed TTD however would not solve this problem (Shang and Goldman, 
2008).  
None of the above studies reached an entirely satisfying conclusion on how to account 
for the possible endogeneity between TTD and HC expenditure. And although attempts 
have been made it did not seem possible to purge TTD of its endogeneity. This thesis 
therefore assumes exogeneity of TTD throughout the analyses. 
 
3.8 HC expenditure projections 
To complement this review of the main contributions to the research field, the following 
section discusses those studies that have analysed population ageing and the impact 
this might have on future HC expenditure using a simplified approach by assuming 
constant age profiles for HC expenditure and studies that have used remaining TTD in 
addition to demographic changes in order to project future HC costs.  
3.8.1 HC expenditure projections: constant age profiles  
This simplified method to calculate the effect that changing demographics may have on 
future HC expenditure decomposes current HC expenditure into expenditure by age or 
age groups. Earlier research mainly looked at how much spending for HC varied by age 
group and found that per capita spending increased steadily with age for most HC 
sectors (Fisher, 1980).  Fisher’s research on population ageing and HC expenditure 
showed that a disproportionate amount of money was spent on providing HC to the 
elderly (Fisher, 1980). Fisher analysed three factors that constitute total expenditure on 
HC: the number of contacts with HC providers (number of hospital episodes, LOS), the 
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intensity of the contact (number of treatments), and the price of the service provided. 
Analysing different HC sectors, he found that for the sector of hospital care, elderly 
people had longer stays than younger individuals, but that the intensity of care was less. 
Fisher (1980) therefore concluded that volume, i.e. number of episodes and LOS were 
the dominant factors that caused the observed differences in HC spending by age 
groups. These results have led the author to predict an increasing financial burden for 
HC policy and financing, especially with the share of elderly people increasing and the 
share of younger people, who incur less costs decreasing.   
Fisher’s findings have partly been confirmed by further research undertaken in Sweden 
in the 1970s and 1980s (Gerdtham, 1993). In the absence of exact measures of HC 
utilisation by different age groups, researchers have reverted back to using age-specific 
number of bed days per capita. But this could lead to an overestimation of costs for the 
older age groups as their expenditure per bed day is lower on average compared to 
younger age groups (Gerdtham, 1993). Fisher (1980) had already pointed out that the 
intensity of care is less in older ages. 
Other research involves the projection of HC expenditure in order to quantify the future 
demand of HC. Using the population numbers in each age group, expenditure was 
decomposed into expenditure per capita. To project HC expenditure into the future, 
current or historical HC expenditures are multiplied by the projected number of people in 
each age group. Current and projected HC expenditures can be compared and the 
difference is attributed to population ageing, i.e. the ageing effect. This method has been 
widely used (Dang et al., 2001, Jacobzone, 2000, Serup-Hansen et al., 2002). 
Dang et al (2001) undertook a very comprehensive study including a number of 
countries and analysing HC and LTC. According to the authors’ findings, expenditure on 
HC and LTC in a number of OECD countries are expected to increase from 6% of the 
GDP in 2000 to 9.3% of the GDP in 2050. Population ageing would be responsible for 
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55% of this increase (Dang et al., 2001). A slightly lower projection had been calculated 
in a study from the Economic Policy Committee in 2001, which analysed HC and LTC 
spending for European countries and predicted an increase from 6.6% in 2000 to 8.8% 
in 2050, which reflects an increase due to demographic changes of 33% (Economic 
Policy Committee, 2001). 
This purely demographic method of extrapolating HC expenditure possesses a 
weakness that was pointed out earlier in this chapter: it assumes that any given age 
group is expected to consume the same amount of HC in the future as they are currently 
consuming. Under the compression of morbidity assumption, however, a downward shift 
of the age profiles of HC expenditure would be observed, i.e. HC expenditure might be 
observed to decrease over time at any given age. At the same time, if morbidity levels 
are reduced, reduced mortality rates at any given age can be observed as mortality is 
shifted to older ages, so that the demographic method might not be projecting HC 
expenditure correctly, since the mortality component is ignored. If remaining TTD as an 
indicator of an individual’s health status is not accounted for, constant age-expenditure 
profiles are assumed.  
Many researchers have raised the issue of an overestimation of future HC costs if 
constant age-expenditure profiles are assumed and have highlighted advantages of 
being able to capture changes in morbidity over time when employing econometric 
techniques of analysing the association of costs, TTD and demographic indicators and 
also using longitudinal data to do so (see Payne et al’s (2007) review of the TTD 
literature). 
3.8.2 HC expenditure projections: accounting for TTD 
In their descriptive analysis of the cost of dying and subsequent projection of HC costs, 
Serup-Hansen et al (2002) found that age still played an important role when estimating 
future HC expenditure. Using a random sample of the Danish population (19%) the 
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authors first used the cohort-component technique to project demographic changes. 
These data are generally available from national statistics in varying precision in terms 
of either providing projections for age groups or single years of age. Serup-Hansen and 
colleagues (2002) then employed two methods to project HC expenditure. The first, 
traditional method assumed that costs were a function of age and sex, whereas a 
second, improved method assumed costs to be a function of TTD as well (Serup-
Hansen et al., 2002). Average costs per person, where calculated for each age and sex 
stratum, irrespective of TTD, i.e. irrespective of whether an individual had died. These 
costs were ultimately assigned to the projected population to obtain projected costs 
under the traditional approach. The improved method calculated costs in the same way, 
but separately for survivors and decedents and assigned obtained costs to projected 
population numbers in the future. The authors found HC expenditure to increase by 
18.5% (1995-2020) using the traditional method, whereas an approach accounting for 
remaining TTD revealed a 15.1% increase in future HC expenditure (Serup-Hansen et 
al., 2002).  
One further study that used extrapolation adjusting for TTD to calculate future costs was 
carried out in the Swedish region of Skane (Batljan and Lagergren, 2004). The authors 
argued that a simple demographic extrapolation to forecast future HC demand was 
based on the assumption that changes in the total number of individuals in a certain age 
group determined the extent of service need (Batljan and Lagergren, 2004). Their 
analysis was based on inpatient and outpatient care utilisation data and compared ratios 
for HC expenditure for different strata (age, sex, year before death). Results showed 
that less than 1% of their sample within their last year of life were responsible for about 
11% of the total annual HC expenditure for inpatient care. Projecting HC expenditure the 
authors compared a simple extrapolation with their mortality adjusted demographic 
extrapolation and found these to be markedly lower (Batljan and Lagergren, 2004).  
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Seshamani and Gray (2004c) used age-specific per capita HC expenditure from the 
Department of Health and population projections by single year of age from the 
Government Actuary’s Department, England (Seshamani and Gray, 2004c). These 
population numbers were stratified by age and sex group and also by remaining TTD. 
From their econometric model, the authors predicted yearly per capita HC expenditure 
for individuals aged 65 and older (their sample). They then multiplied these with 
projected population numbers in each sex, TTD and age groups and so obtained cost 
estimates for the years 2008-2026 under the TTD approach. Seshamani and Gray found 
that using this approach provided an annual growth rate of 0.40%, which was half the 
growth rate than that obtained from their comparison projection, which only analysed 
expenditure changes associated with increased life expectancy and did not account for 
TTD (Seshamani and Gray, 2004c). 
Stearns and Norton (2004) found that the exclusion of remaining TTD from a cost 
prediction model led to higher cost estimates compared to a model that included TTD. 
They also explored the magnitude at which HC expenditure may be overestimated if 
TTD is not controlled for. Estimating two models, one including TTD quarter dummies 
and one, excluding these measures they found predictions for HC costs to be 9% higher 
for a model that did not include TTD using current life tables and 15% higher for 
projected life tables in 2020 (Stearns and Norton, 2004).  
Breyer and Felder (2006) combined their utilisation data from Switzerland and 
population projections from Germany to estimate the demographic impact on HC 
expenditure until 2050. To do this, the model was calibrated to reflect German HC 
expenditures (Breyer and Felder, 2006). The authors projected costs under two 
assumptions, first a naïve method, where only the age structure changes and second, 
an extended method that takes account of higher costs in the last year of life. Breyer 
and Felder (2006) found that the first method projected a 23.9% increase in HC 
expenditure by 2050, whereas the second method only projected a 19.5% increase. 
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They found however that the increase in HC expenditure that would be due to advances 
in medical technology would outweigh the rather small effect that would be found when 
excluding the cost of dying (Breyer and Felder, 2006). 
Slightly different results in terms of the magnitude of overestimation of costs if TTD was 
excluded from expenditure projections were found in a more recent study undertaken by 
Hakkinen et al in Finland (Hakkinen et al., 2008). The authors estimated a 13% lower 
projection for total expenditure (HC and LTC) when including TTD, compared to a model 
that does not include TTD. These results are in line with projection results from other 
studies, which consistently range from a 9-15 percent lower expected expenditure when 
TTD is incorporated as compared to analyses, which do not account for remaining life 
expectancy (Payne et al., 2007).  
In general, HC expenditure projections that are based on the inclusion of TTD when HC 
estimates are obtained, are based on the assumption, that decedents and survivors are 
different and incur different costs in any period. It is also based on the fact that mortality 
rates change over time and fewer individuals are observed to die at any given age in the 
future. 
 
3.9 Scottish studies 
The research in Scotland that has investigated the relationship between population 
ageing, death and HC expenditure is limited and provides scope for a detailed analysis 
as undertaken in this thesis. 
The first research undertaken in the West of Scotland analysed the pattern of hospital 
utilisation for an ageing cohort employing data from the Renfrew/Paisley study as one of 
the Midspan studies (Hanlon et al., 1998). The authors analysed baseline risk and 
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combined these data with subsequent hospital admission data over a follow-up period of 
23 years. In their descriptive analysis they also examined acute hospital use before 
death and found that decedents had a higher number of hospital episodes. Hanlon et al 
(1998) detected an increasing demand for hospital services over time for the cohort 
analysed. 42% of all acute admissions for decedents were in the last 12 months of their 
life and 33% in the last six months (Hanlon et al., 1998).   
Graham and Normand (2001) conducted an exploratory study using Scottish Morbidity 
Records (SMR01) linked to death records from the General Register Office for Scotland 
to investigate the variation of utilisation of acute hospital services by age, TTD and other 
explanatory factors (Graham and Normand, 2001). Their data were split into separate 
datasets for decedents and for survivors. Further stratification of the cost data by age 
and sex facilitated comparison of effects that a changing age structure had on costs. 
The dataset for decedents had information on people, who had died in 1999 and their 
hospital admissions for the 12 months preceding their death. The dataset for survivors 
included people, who did not have a death record, but had at least one episode of acute 
hospital care in 1999 and information for the last six months of 1998. Graham and 
Normand (2001) assumed that the rest of the population did not utilise HC during that 
period.  
Analysing HC expenditure for decedents and survivors separately, Graham and 
Normand (2001) found that acute HC costs for survivors increased with increasing age, 
whereas costs for decedents decreased with increasing age. Graham and Normand 
(2001) also analysed variations in these patterns by different socio-economic groups 
and found significant differences in costs incurred by survivors or decedents between 
deprivation categories and by age group. Costs for hospital care were found to be 
significantly higher for decedents at younger ages that were living in the most affluent 
areas compared with decedents at younger ages from the most deprived areas. From 
the age of 75 however, people from more deprived areas became more expensive than 
Chapter 3  79 
 
people from more affluent areas. The analysis of differences between health boards 
revealed significant differences in costs as well. Results from this study have not been 
published in peer-reviewed journals, and can only be found in their final report to the 
Chief Scientist Office (CSO) (Graham and Normand, 2001).  
No detailed description of the statistical methods and/or econometric modelling used by 
Graham and Normand (2001) is provided in their CSO report, so no discussion about 
these methods can be made here. No information can be found on how zero cost 
observations have been dealt with. Although the report stated that decedents are less 
expensive than survivors it does not explicitly show how HC expenditure develops as 
people approach death. The costing method used, seems to be based on specialty 
specific costs, leaving scope for the introduction of more precise measures of costs that 
are based on disease classifications rather than the specialty patients were admitted to. 
Using specialty specific costs means that there is a set of costs for 50 specialities only. 
Compared to using costs that are disease and treatment specific this does not offer 
much variation. Although Graham and Normand (2001) provided some initial important 
results in this research field for Scotland, they also left scope for extensive future 
research in this area.  
Other unpublished research that utilised Scottish data was undertaken by Murray Lowe 
in 2005 for the purpose of a MSc dissertation (Lowe, 2005). The author used a similar 
dataset to the one analysed by Graham and Normand but for a later time period and 
only analysed data for one Health Board region in Scotland, Ayrshire and Arran. Linking 
SMR01 data to death records the association between TTD, ageing and HC expenditure 
was estimated following the methodology employed by Seshamani and Gray (2004b). 
The sample population consisted of people, who were aged 65 and over at the 
beginning of 1981 and who subsequently died during the follow up period until the end 
of March 2004. Consequently, the sample only includes decedents with hospital 
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episodes between 1981 and 2004. HC expenditure was measured on a yearly basis and 
the last five years before death were analysed.  
To account for differences in costs and utilisation by socio-economic status SIMD 
(Scottish Index of Multiple Deprivation) quintiles were used as one explanatory variable 
in regression modelling. The costing method employed to estimate HC expenditure was 
that of applying specialty specific per diem costs multiplied with individual episode LOS 
to derive a total cost per episode. These costs were then aggregated to obtain a yearly 
cost variable. The author acknowledged the potential problem of endogeneity of TTD but 
assumed exogeneity for the analysis. Including zero-cost observations for years without 
hospital utilisation, Lowe (2005) employed a two-part model to estimate HC expenditure, 
conditional on positive utilisation. 
Results showed a significant association of age and TTD with HC expenditure. The 
author found a steady increase in costs as individuals approached death with costs 
being 78% higher for someone in their last year of life compared to an individual five 
years away from death. Although age at death also was a significant predictor for costs, 
the effect was less pronounced than that of TTD, with one additional year leading to an 
increase in costs by 4.45% (Lowe, 2005). Lowe also found significant effects on costs by 
socio-economic status, the health board of residence and the principal diagnosis.  
Similar to Graham and Normand (2001), Lowe’s (2005) study also leaves scope for 
further analysis. Although econometric modelling techniques used here are more 
advanced than those (apparently) used in Graham and Normand (2001), the author did 
not include the surviving part of a population. The costing method employed by Lowe 
(2005) uses specialty specific per diems. Although having the advantage of being very 
sensitive to small variations in LOS, per diem costing does not account for the nature of 
a hospital stay as explained earlier. Alternative costing methods could be explored in 
order to account for the fixed and variable cost components of a hospital stay. In the 
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absence of a survey based dataset that could have been linked to hospital admission 
records, the author also misses the opportunity to account for individual baseline 
characteristics that could prove important in explaining future HC expenditure.   
3.9.1 Recognition of TTD in policy 
In its second report ‘The future care of older people in Scotland’, the Range and 
Capacity Review Group for the Scottish Executive (Scottish Executive, 2006) 
emphasized the predictive power of TTD for future HC expenditure, based on published 
work from Seshamani and Gray (2004b). The researchers argued that if the assumption 
of improved levels of age-specific health holds, the impact that an ageing population 
might have on the demand and consequently the cost of acute HC services could be 
weakened to some extent. The authors also claimed that this pattern may look very 
different when the effect of an ageing population on the demand for social or long-term 
care were analysed and that the above research findings could not easily be applied to 
the LTC sector. 
Based on published evidence from the UK and other countries, in his report for the HM 
Treasury in 2002, Derek Wanless acknowledged that the cost for acute care services is 
strongly related to TTD, regardless of age at death (HM and Treasury, 2002). This 
review took account of demographic changes in the UK by developing three different 
scenarios of population growth, life expectancy and morbidity. When modelling 
utilisation and costs of acute hospital care a split is made between people in their last 
year of life (decedents) and people not in their last year of life (survivors) in order to 
incorporate TTD. 
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3.10 Conclusion  
There seems to be a general agreement in the literature as well as amongst policy 
makers that age alone does not drive HC expenditure. The association between age 
and HC costs seems to reflect a possibly stronger relationship between TTD and HC 
expenditure, which in turn seems to be a much better predictor of acute HC costs than 
population ageing per se.   
Conflicting opinions exist on the extent to which future HC expenditure might be 
influenced by TTD, age and also other (supply side) determinants, such as technological 
advances in medical care. Most of these conflicting results seem to arise from applying 
different methods to estimate HC expenditure at the end of life.  This includes the choice 
of the sample (survivors and/or decedents) and whether this is representative of the 
population, the HC sector that is analysed, the costing method employed for assigning 
unit costs to HC resources used and the econometric modelling techniques employed to 
estimate HC expenditure. 
A conclusion that can be drawn from findings in the literature so far is that the inclusion 
of the additional factor TTD may provide a more accurate estimate for future HC 
expenditure. If remaining TTD is not accounted for, HC budgeting could be misinformed 
and as a consequence, future costs could be overestimated.   
This thesis will add to the existing research by picking up on a selection of these issues 
and introducing methods that could add clarification. A thorough investigation of the 
existing limitations will help our understanding of factors that should be considered in 
this research area.   
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4 COMPARISON OF ALTERNATIVE COSTING 
METHODS FOR ACUTE INPATIENT CARE9 
4.1 Introduction - valuing resource utilisation 
In publicly funded health care systems (through taxation or national health insurance) 
such as the NHS in the UK, which are characterised by the absence of prices, costs are 
used to value resource utilisation. The estimation of the economic burden of disease in 
the absence of a ‘gold standard’, and in the presence of a multitude of alternatives, 
requires a decision about the most appropriate costing method. First and foremost the 
costing method should be guided by the research context. However, data availability or 
alternative choices may also play a role in the decision process. The variety of costing 
methods is especially apparent for hospital inpatient care, which has been shown to be 
the main contributor to the total cost of health care provision in many countries (OECD, 
2010). For hospital inpatient care, costing can either be undertaken as per diem, per 
episode, per stay, or as case-mix costing. However, these alternative methods differ in 
data collection and costing methodology. 
The aim of this chapter is to outline and compare alternative costing methods for acute 
inpatient care episodes in Scotland, highlighting advantages and disadvantages of 
alternative approaches. Five different costing methods are compared. To facilitate 
comparison and to guide the choice of an appropriate costing method for Chapters 5 
and 6 that will analyse costs for acute inpatient care towards the end of life, regression 
analysis is employed to test differences between methods. The choice of the costing 
method may influence the inferences that can be made from the econometric modelling 
of costs. Assessing the marginal effect that explanatory variables have on estimated 
costs will provide valuable information beyond scale differences. Results from this 
                                               
9
 This chapter is based on a published paper: Geue C et al (2011). Spoilt for choice: Implications 
of using alternative methods of costing hospital episode statistics. Health Econ. DOI: 
10.1002/hec.1785 
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analysis of Scottish data will also highlight implications for other countries with a publicly 
funded health care system. 
4.1.1 Relevant costs  
Health care resource utilisation can be valued either from a societal perspective, 
including direct and indirect costs or from a payers’ or insurers’ perspective, including 
direct medical costs only. Direct costs represent resources that have been consumed by 
patients and can again be split into different categories. The first group of direct costs 
can be seen as costs that are incurred in order to provide the necessary services. These 
costs encompass all treatment costs and include costs for the hospital stay, diagnostic 
tests and pharmaceuticals, health care professionals’ time, hospital rent and overheads. 
These direct costs have also been described as organising and operating costs 
(Drummond et al, 1987). The second group of direct costs include those that are borne 
by the patient or their families and include out-of-pocket payments for medical services 
and travel expenses that are related to the treatment process. Indirect medical costs 
occur in the form of production losses due to time out of work for either the patient or 
their family that is related to the treatment process (Drummond et al, 1987). 
4.1.2 Bottom-up versus top-down costing 
The analysis in this chapter will consider direct medical costs from a payer’s (NHS) 
perspective which include costs that fall into the first category of direct costs described 
above. These costs can be measured using either bottom-up costing (micro-costing) or 
top-down costing. Bottom-up costing measures resource use at patient level after which 
a unit cost for each type of resource consumed can be calculated (Mugford et al., 1998). 
Top-down costing calculates a unit cost per patient by dividing total expenditure by a 
measure of volume (per diem, per episode or per case-mix). Top-down approaches 
usually emphasise national average costs, whereas bottom-up approaches are utilised 
to measure local variations in costs between different medical centres (Chapko et al., 
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2009). A bottom-up approach to costing is employed for instance by the US Department 
of Veterans Affairs’ Decision Support System. Although bottom-up or micro-costing 
usually provides greater precision in measuring costs it does have the disadvantage of 
being very complex and expensive to implement (Chapko et al., 2009). The decision 
whether to apply a top-down or bottom-up approach to costing will mainly be determined 
by the research question, the availability of data and financial resources. 
The analysis in this chapter is presented as follows: Section 4.2 reviews costing 
methods for hospitalisation data. Section 4.3 describes the dataset that has been 
employed and details the econometric modelling. Results are presented in Section 4.4, 
followed by a summary and discussion of main findings in Section 4.5. 
 
4.2 Review of costing methods  
All costing methods that are explored in this chapter use a top-down approach. Five 
methods of deriving costs for hospital inpatient care are analysed, which generally differ 
in the unit at which resource utilisation is measured. Regression analysis is employed to 
test whether the choice of costing method influences any inferences that can be made 
from econometric modelling of costs.  
The identified costing methods are based on three broad schemes, which differ in their 
underlying assumptions. A review of the literature on costing acute inpatient care, both 
in the UK and worldwide has identified Diagnosis Related Group (DRG) costing (or the 
respective national equivalent) (Lorgelly et al., 2010, Poole et al., 2010, Maheshwari et 
al., 2010, Anandan et al., 2009) and per diem costing, which is mainly used in economic 
evaluations, (Gray et al., 2001, Stewart et al., 2002, Ringborg et al., 2009, Harjola et al., 
2009, Christensen and Munro, 2008, Liu et al., 2002, Miller et al., 2009, Walker et al., 
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2003), as the two most commonly applied approaches. These can also be employed in 
combination, for example Hakkinen et al used the average cost per inpatient day 
specific to each DRG (NordDRG)  (Hakkinen et al., 2008). As mentioned by Reinhardt 
(2006) Medicaid and private insurance payments to hospitals are also dominated by 
either flat fees per DRG or per diems (Reinhardt, 2006). Given the predominance of per 
diem and DRG-type costing, special emphasis is given to comparing these two 
methods.  
Two further costing methods are introduced, which do not frequently feature in the 
literature, but for which costs are easily accessible in Scotland. The first, per episode 
costing, uses individual LOS and a variable/fixed cost split, assigning a fixed cost 
component per episode and a variable cost component per diem; while a final method 
explored here uses per episode costing based on national average LOS.  
4.2.1 HRG based costing 
Healthcare Resource Groups (HRGs) are similar to DRGs. DRGs were first developed 
in the U.S. in the early 1980’s for Medicare to be used as a prospective payment system 
for hospitals. Since the 1990s HRGs have routinely been used to cost hospital activities 
in England (Street and Dawson, 2002). HRGs are a measure of case mix, presenting 
standard groupings for clinically similar treatments, which consume a common set of 
health care resources (The Health and Social Care Information Centre, 2010a). Each 
case-mix group or HRG provides the cost for each category of hospital inpatient (cases). 
The precision of an HRG depends on the level of detail when specifying the cases. 
Based on procedure, diagnosis, LOS, complications, co-morbidity, discharge method, 
age and gender, each patient record can be grouped in an HRG and reflects one 
finished consultant episode (FCE) (Street and Dawson, 2002). Australia and many 
European countries have developed similar grouping systems, which are based on the 
Health Care Financing Administration (HCFA) system introduced in the U.S., but have 
been modified substantially to meet local requirements (Schreyogg et al., 2006).  
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Two methods that employ HRG costing are presented. The first (method 1) uses the 
English tariff to cost hospital episodes, while a second approach (method 2) utilises the 
national tariff for Scotland. This last approach provides a means to test the implications 
of one country ‘borrowing’ another country’s data/methods in the absence of its own. 
Although the NHS in the UK is funded centrally through taxation, the NHS in England, 
Scotland, Wales and Northern Ireland are managed separately, resulting in differences 
in the development of HRGs and the collection of financial data.   
HRGs based on the English Tariff (method 1) 
The English tariff provides cost data for elective and non-elective hospital episodes and 
an additional per diem cost for very long stays that exceed the so called ‘trim- point’, 
which marks the expected LOS for each HRG. Information on respective trim- point 
values is available for both, elective and non-elective admissions. Employing a top-down 
approach; a hospital’s annual financial returns data are cascaded down to treatment 
services, specialties and finally HRGs to derive a cost (Street et al., 2007). Compared to 
a bottom-up approach, which might be more preferable, this approach circumvents the 
issue of underestimating costs as it is more likely to cover all key input variables to care 
(Mugford et al., 1998). Estimated costs are reported as a national schedule of reference 
costs (The Health and Social Care Information Centre, 2010b) and are also aggregated 
by hospital to provide the reference cost index10 (Street and Dawson, 2002). 
HRGs based on the Scottish National Tariff (SNT) (method 2) 
In Scotland, HRG based tariffs have recently been developed for cross boundary flows 
between health boards for acute inpatient care and day cases, that is where patients 
reside in one health board area, but are treated in another (ISD, 2010). The Scottish 
National Tariff (SNT) has been designed to better reflect differences in case-mix 
                                               
10
 Equal to a weighted average of all HRG costs in each hospital relative to the national average. 
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complexity. To develop the SNT, the SNT project group had exploited English reference 
costs. Cost data from the Scottish Costs Book was used to derive a unit cost per HRG. 
The SNT is therefore a direct representation of national average costs, as published on 
the ‘Costs Book’, but distributed over hospital activity data. In Scotland, costs for 
inpatient hospital episodes are not available on an HRG level, only at specialty level. 
The SNT project group has therefore developed an algorithm that allows the estimation 
of costs at the more specific HRG level. This approach involved deriving relative cost 
weights utilising English costs, and applying those weights to the Scottish cost basis. 
This was done under the assumption that the resource differential between any two 
procedures was the same in Scotland and England (ISD, 2010). Calculated costs were 
converted into a tariff, adjusted for pay and price factors and published as the SNT. 
Notably the derived SNT does not provide information on extra daily costs if a hospital 
stay exceeds a trim point and will therefore give less weight to individual LOS.   
This method is an example of one country using information and data from another 
country in the absence of own sufficient data and also represents a variation of 
procedures used elsewhere. Denmark and Germany for instance do not calculate 
average prices for each DRG, but calculate cost weights to define a ratio between 
treatment episodes. Only the price for the DRG with a cost weight of one is negotiated 
and prices for the remaining DRGs are calculated by applying the respective cost 
weights (Schreyogg et al., 2006). 
4.2.2 Per diem costing (method 3) 
Per diem costing is frequently used in costing studies, especially in economic 
evaluations. Per diem costs might be available as either disease specific per diem costs, 
where the average daily cost for treatments in a certain disease area is provided, or as 
average per diem costs over all categories of patients or diseases. In Scotland per diem 
costs are available on a specialty level. To derive specialty specific per diems, 
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information on the total costs incurred by a specific specialty and the number of patients 
treated are routinely collected by ISD and then used to assign a per diem cost to a 
specialty level. Total costs are direct costs per case and include all medical and dental 
costs, costs for nursing, pharmacy, allied health professionals, theatre and laboratory 
costs. When per diem costs are applied to cost acute inpatient stays, the published per 
diem cost is multiplied with individual LOS in order to derive costs per episode. 
In general, a per diem costing approach assumes that the cost for the first day in 
hospital is equal to the cost of every subsequent day, thus neglects the split between 
‘hotelling costs’ and ‘medical costs’ and consequently places a very high weight on LOS. 
This might lead to an overestimation of costs for longer hospital episodes and a possible 
underestimation of costs for shorter hospital stays. 
4.2.3 Episode costing  
There are two variations of this method, both utilise cost data available at an episode 
level with costs specific to specialty and hospital of treatment. One approach (method 4) 
takes account of individual LOS and has been developed by researchers from ISD to 
review the resource allocation formula in Scotland (Bishop et al., 2006). This is a novel 
approach, and has not previously been applied in costing exercises. It distinguishes 
between a fixed and a variable cost component. The second variation (method 5) 
neglects information on individual LOS and applies a cost per episode based on national 
average LOS without distinction between fixed and variable costs. 
Episode costing- Individual LOS and fixed/variable cost split (method 4) 
This approach has been used in the latest review of resource allocation in Scotland. Its 
novelty is the distinction between fixed and variable costs, which is based on the 
assumption that some proportion of costs (fixed costs) is the same for all patients 
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treated in a specialty, regardless of their LOS (for example medical, theatre and 
laboratory costs). 
Variable costs, however, are assumed to be related to and vary proportionally with LOS 
(nursing costs, linen costs etc). Variable costs are assigned to each bed day and fixed 
costs to each episode. Using fixed treatment costs and variable LOS costs are aimed at 
providing a more transparent and accurate costing of hospital episodes (Bishop et al., 
2006). To derive a percentage split between fixed and variable costs per episode, 
national average specialty costs were split into a fixed and variable component. This 
method generates a cost per episode based on individual LOS and can so account for 
small variations in LOS as well as the fixed and variable components of a hospital 
episode.  
Internationally, this has also been estimated with clinical cost functions, for instance by 
the U.S. Department of Veteran Affairs. To estimate the cost of a hospital stay, 
researchers regress costs on characteristics of the hospital stay. Coefficients obtained 
from the regression model are then applied to hospital stays providing an estimated cost 
of each stay (U.S. Department of Veteran Affairs, 2011). 
Episode costing- national average LOS (method 5) 
This costing method also uses national average specialty costs per episode, but does 
not distinguish between fixed and variable costs, nor does it take into account individual 
LOS information. The rationale for the inclusion of this costing method is that if a 
representative sample were used to estimate costs, national averages should provide 
similar results to those obtained from more elaborate costing methods (cf. method 4). 
However, this assumption may not hold for a number of reasons: (a) the empirical 
sample is not representative of the population, (b) using historic hospital episodes with 
longer stays in previous decades and costs that are for more recent periods will not 
produce comparable results. 
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4.3 Methods 
4.3.1 Data 
The analysis in this chapter uses longitudinal data based on a large cohort study 
undertaken in the 1970s in the West of Scotland. The Renfrew/Paisley study, one of the 
Midspan studies, covers a total period of 35 years, and includes baseline survey data 
linked to subsequent acute hospital admissions (SMR01). The initial survey took place 
from 1972-1976 and includes men and women from the towns of Renfrew and Paisley, 
aged between 45 and 64 years at the time of study entry. Participants were asked to 
complete a questionnaire and invited to attend for a screening examination at clinics. 
Computer linkage was established for SMR01 from 1972 onwards, and study members 
have been followed up either until death or the end of the study period, currently 
December 2007 (Hart et al., 2005).  
This longitudinal cohort study will also be utilised in the subsequent empirical chapter 
(Chapter 5) which estimates the impact of population ageing and remaining TTD on 
expenditure for acute inpatient care. Further particulars and characteristics of this survey 
data will be explained in detail in this subsequent chapter. 
Hospital episode statistics (Scottish Morbidity Records, SMR01) have episode-based 
patient records that relate to all acute inpatient and day cases. Care episodes that are 
excluded from SMR01 are obstetric and psychiatric specialties. Geriatric long stay 
episodes were part of SMR01 until 1997 and due to this inconsistency and the nature of 
the care episodes, have been excluded from the analysis. The data that are collected to 
describe each episode include demographic information, episode management details 
and general clinical information. Diagnoses are recorded using ICD10 codes (previously 
ICD9) while procedures performed are recorded using OPCS-4 codes (ISD Data 
Dictionary, 2009). A more detailed description of the SMR01 dataset will be given in the 
following chapter. 
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116 observations were excluded as they showed very high costs due to very long stays 
mainly incurred in the specialty areas ‘Geriatric Assessment’ and ‘Orthopaedics’, which 
can not be classified as acute episodes. After taking account of missing observations for 
explanatory variables and missing cost variables (as the dependent variable) for any of 
the five analysed costing methods, regression models are run for 45,634 stays, coming 
from 10,415 individuals for the time period between 1980 and 2007. All regression 
models are run utilising the same sample. 
4.3.2 Implementation of costing methods 
Hospital stays can consist of multiple episodes. In Scotland, an entire hospital stay is 
conventionally called a ‘Continuous Inpatient Stay’ (CIS) and lasts from admission to 
hospital until discharge. Discharge can be from the same or a different hospital if the 
patient was transferred. A CIS is an uninterrupted period of time a patient spends as an 
inpatient in hospital. The patient can change consultants, specialty, significant facility 
and/or hospital during a CIS (ISD Data Dictionary, 2011). The different costing methods 
that are presented here have different levels at which their respective costs are 
available. For costing methods 4 and 5 costs are published on an episode level. For 
costing method 3 costs are available as daily costs, which then need to be multiplied 
with individual LOS information to obtain a cost for the entire episode. Methods 1 and 2 
however require the entire hospital stay (CIS) to be summarised for any costing 
exercise. In order to facilitate comparison of costing methods, a common denominator 
needs to be chosen. This common denominator is a CIS and 2006/07 was used as the 
cost reference year, as the dataset provides information on hospitalisation until 2007 at 
which point the dataset was censored. 
The following paragraphs describe in detail how a cost per CIS has been obtained for 
each of the costing methods using both formulae and also flowcharts to visualise the 
process of how costs build up to a cost per CIS. 
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Assigning HRG based costs (English and Scottish Tariff) (methods 1 and 2) 
Notably ISD only recently added an HRG code to their routinely collected SMR01 data, 
as such this variable was not available from the data set that is used here and had to be 
added. The HRGv3.5 Grouper software available from the Health and Social Care 
Information Centre (IC) in England was used to assign an HRG to every patient record 
(IC, 2010c). This software first carries out a validation check on the required data input 
fields and then assigns an HRG code based on diagnosis (ICD10), procedure performed 
(OPCS4), gender, age, LOS and the discharge method using a complex mapping 
algorithm. Each episode can have multiple diagnoses and procedure codes. Each 
procedure and diagnosis gets assigned a hierarchical level during the grouping process, 
which is associated with its resource consequences. These hierarchies provide a 
comparison tool and diagnoses and procedures are separately ranked in the order of 
their complexity (IC, 2011). If more than one procedure has been recorded for an 
episode of care, the HRG grouper selects the dominant procedure using the ranking.  
Because the HRGv3.5 Grouper software requires the diagnosis to be in the most recent 
version format, i.e. ICD 10, earlier admissions (pre 1992) with ICD9 codes had to be 
converted into ICD10 codes. This was done using a look-up file (New Zealand Health 
Information Service, 2010). As noted earlier, admissions with a historic ICD8 code had 
to be discarded from further analysis, since no conversion algorithm between ICD8 and 
ICD10 exists. 
After an HRG code is assigned to every episode, episodes that form a CIS need to be 
converted so that the dominant episode is selected by simultaneously taking into 
account any other ‘non-dominant’ episodes within this CIS. The ‘Episode to Spell 
Converter’ software (IC, 2010c) utilises information on the date of admission for the first 
episode of a CIS, the date of discharge of the last episode within that CIS, the episode 
Chapter 4  94 
 
 
order, episode LOS and the HRG, and so selects the dominant HRG within each CIS, 
which then gets a tariff assigned to it.  
The procedure of applying the ‘HRGv3.5 Grouper’ and the ‘Episode to Spell Converter’ 
software was carried out for both the English tariff (Department of Health, 2010), and the 
Scottish National Tariff (ISD, 2010). Information on the type of admission was used to 
distinguish between tariffs for elective and non-elective admissions, while LOS 
information guided the decision about assigning extra per diem costs. Information on 
extra per diem costs however was not available for the SNT. Equation (4.1) and Figure 
(4.1) detail the calculation of costs per CIS when LOS exceeds the trim point. Equation 
(4.2) and Figure (4.2) show how costs are calculated when LOS is less than or equal to 
the trim point.  
Both equations and figures are valid when using HRG costing based on the English 
Tariff, whereas Equation (4.1) and Figure (4.1) can not be applied in the context of costs 
for the SNT due to unavailable trim point information. The SNT can therefore be seen as 
a simplified version of the English tariff. 
))(*(TAR  C hrgECIS hrgCIShrg trimLOSPD −+=
     Equation (4.1) 
hrg
S
CIS TAR  C =         Equation (4.2) 
Where CCIS is the cost per CIS, TAREhrg and TARShrg are published tariffs for each HRG 
respectively (that is the dominant HRG in the CIS), LOSCIS is the LOS for that CIS, trimhrg 
is the specified trim point for each HRG, and PDhrg is the per diem cost for each HRG. 
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Processing data  through HRG grouper
Selecting dominant HRG by
processing data through 'Spell Converter'
Elective episode of care?
Yes No
Does dominant HRG exceed trimpoint?
Yes No
Assigning additional  
per diem cost
Hospital Episode Statistics with ICD 
codes and other patient characteristics
HRG code assigned to every episode
Dominant HRG within CIS
((Individual length of stay - 
trimpoint) * Extra per diem 
cost) 
+ Tariff
TOTAL COST PER CIS
Elective Tariff Non-elective 
Tarif f
 
Figure 4-1 Deriving a cost per CIS using the English Tariff based on HRGs (method 1) 
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Figure 4-2 Deriving a cost per CIS using the SNT based on HRGs (method 2) 
 
 
Assigning per diem costs (method 3) 
This method assigns costs based on hospital and specialty codes. Scottish health 
services costs (‘Costs Book’) are the only source of published cost information for 
Scotland. They are based on Scottish Financial Returns data provided by each of the 14 
health boards. 
Per diem costs were extracted from the ‘Costs Book’ and multiplied with the individual 
LOS to derive a cost per episode. In order to derive costs per CIS, costs for each 
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episode that belonged to a CIS, were summed over the entire CIS. Equation (4.3) and 
Figure (4.3) show how a cost per CIS was derived for this method. 
∑
=
+=
x
1e
eCIS )*(C  C hsiei PDLOS
 
     
 Equation (4.3) 
Where Cei is the cost per episode e for patient i, LOSei is each episodes LOS for patient i 
and PDhs is the per diem cost, both specialty and hospital specific. 
The hospital code served as one matching criterion, so that hospital codes that have 
ceased to exist, either because the hospital no longer exists or because hospitals have 
merged, were either replaced with the code of the hospital they now belong to or were 
discarded from hospital/specialty specific cost merging.  
Per diem costing, as well as the two following costing methods 4 and 5, also rely on the 
specialty as the second identifying entity and therefore require the specialty group/name 
to match those provided in the ‘Costs Book’ and particularly ‘R040’, which is one part of 
the Scottish Financial Returns data. Specialties provided in SMR01 data are on a more 
devolved level than those for which costs are provided in the ‘Costs Book’. Specialties 
therefore had to be re-categorised. A list of specialty groups and specialties can be 
found in Appendix II. 
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Matching specialty and 
hospital code
Multiplying with       individual LOS data
Does the CIS consist of one episode only?
No
Yes
Adding costs for all episodes that form the CIS
Hospital Episode 
Statistics with hospital 
and specialty code
Specialty and hospital 
specific costs per bed 
day (Scottish Cost 
Book)
Total Cost per bed day 
Total Cost per episode 
Total Cost per CIS
 
Figure 4-3 Deriving a cost per CIS using per diem costing (method 3) 
 
 
Assigning costs per episode– individual (method 4) and average LOS (method 5) 
For both, methods 4 and 5, costs were assigned on an episode level and were obtained 
from the ‘Costs Book’. Similar to per diem costs, episode costs are also specialty and 
hospital specific and the matching has been done using these two qualifiers.  
The percentage split for method 4, which had been used to assign a fixed and variable 
cost component was derived from regression analysis that was originally undertaken by 
researchers in ISD using 2004-2005 cost data. In order to derive the respective 
percentage splits for each of the specialties, average LOS for each specialty was 
regressed on ‘total gross cost per episode’. The value of the resulting constant term is 
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used as the fixed cost component and the value of the coefficient as the variable cost 
component. ISD focused their analysis on four main specialties: General Medicine 
(55.5% fixed, 44.5% variable), General Surgery (66.7% fixed, 33.3% variable), 
Gynaecology (71.8% fixed, 28.2% variable) and Obstetrics (60% fixed, 40% variable). 
Regression results from these specialties were used by ISD to calculate the percentage 
split for the remaining specialties. A list of the latest percentage splits for each specialty 
can be found in Appendix III. 
After costs were assigned to each episode utilising the percentage split provided by 
researchers from ISD, it was checked whether the CIS consisted of more than one 
episode. If this was the case, the cost of the most expensive episode within each CIS 
was selected. In order to also take account of any remaining less expensive episodes 
within that CIS, their variable cost component was added to the cost of the most 
expensive episode. Equation (4.4) and Figure (4.4) provide details on how costs per CIS 
were estimated for method 4. 
∑
=
+=
x
1e
vareCIS )*(C  C fixee CLOS
      Equation (4.4)
  
 
Where Cvare is the variable cost per episode e, Cfixe is the fixed cost per episode, and 
LOSe is the LOS for each episode. 
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Matching specialty and 
hospital code
Applying percentage split
Applying to individual
LOS data
Does the CIS consist of one episode only?
Yes No
Selecting the most expensive episode in the CIS
Adding the variable cost component from 
any additional episode to the cost per episode
of the most expensive episode within the CIS
Hospital Episode 
Statistics with hospital 
and specialty code
Specialty and hospital 
specific costs per episode 
(Scottish Cost Book)
Fixed costs per 
episode
Variable costs 
per episode
Variable costs per episode = 
(variable costs per episode/ average 
LOS) * individual LOS
Total Cost per Episode 
(fixed costs + variable costs)
Total Cost per CIS
 
Figure 4-4 Deriving a cost per CIS using per episode costing – individual LOS and a 
variable and fixed cost split (method 4) 
 
Costing method 5 does not take into account individual LOS or a split between fixed and 
variable costs. Costs for each episode belonging to a CIS are summed over the entire 
CIS. Equation (4.5) and Figure (4.5) provide guidance on how costs employing method 
5 build up.   
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=
=
x
1e
CIS   C hsNPE
       Equation (4.5) 
  
Where NPEhs is the net cost per episode. These costs are specialty and hospital 
specific. 
 
Matching specialty and 
hospital code
Does the CIS consist of one episode only?
Yes No
Adding costs for all episodes within the CIS
Hospital Episode Statistics 
with hospital and specialty 
code
Specialty and hospital 
specific costs per episode 
(Scottish Cost Book)
 Total Cost per Episode 
(based on average LOS)
Total Cost per CIS
 
Figure 4-5 Deriving a cost per CIS using per episode costing- average LOS (method 5) 
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4.3.3 Regression modelling 
Generalised Linear Models to estimate HC expenditure 
STATA10/SE was used as the statistical package for the analysis throughout Chapters 4 
and 5. GLMs are an extension of OLS and have been widely used to estimate HC 
expenditure data. As introduced in Section 3.4, GLMs offer a number of advantages 
over OLS or log OLS. They are estimated by specifying a distributional family and a link 
function. The distributional family that is specified corresponds to a distribution that 
reflects the mean-variance relationship. For instance if Gauss is chosen as the 
distributional family (as would be the case for OLS) a constant variance would be 
assumed. A gamma family would assume that the variance is proportional to the square 
of the mean (see Table 4.1 for commonly applied distributions and link functions).  
Conventionally, a Gamma distribution is chosen to model cost data as it offers means to 
account for heteroscedasticity and places less weight on very high costs (Dodd et al., 
2006). A misspecification of the distributional family would lead to less efficient 
estimates, but would not lead to a loss in consistency if the link function and covariates 
are specified correctly (Glick et al., 2007). 
The link function in GLMs specifies the relationship between the mean and the linear 
predictor of the covariates. The link function specifies how the mean on the 
untransformed scale is related to the linear predictor and allows transformation of the 
mean of regressors rather than the mean of the cost variable. If an identity link is 
specified the assumption is that the mean equals the linear predictor (as would be the 
case for OLS). If a log link is specified the log of the arithmetic mean costs is modelled 
(Equation (4.6)). 
(ln (E(y/x))= Xβ)                                                                                            Equation (4.6)
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Contrary to modelling log OLS, GLM with a log link models the log of the arithmetic 
mean and not the arithmetic mean of log costs (Equation 4.7). 
(E (ln(y)/x=Xβ)                                                                                              Equation (4.7)
  
A miss-specified link function could cause biased results. Commonly used link functions 
and distributional families are shown in Table 4.1 below. 
Table 4-1 Commonly used distributional families and link functions 
Distribution 
Gauss Constant Variance 
Gamma Variance proportional to the 
square of the mean 
Poisson Variance proportional to the mean 
Inverse Gaussian/Wald Variance proportional to the cube 
of the mean 
Link Function 
Identity g(u)=xiβi 
Square Root g(u)=(xiβi)2 
Log g(u)=exp(xiβi) 
Reciprocal g(u)=1/(xiβi) 
 
In order to specify the correct distributional family and link function, diagnostic tests 
need to be performed. This is not always easy to implement as family and link function 
need to be determined simultaneously, i.e. the specification of the link function is tested 
given the distributional family and vice versa. The recommended distribution can be 
derived from the coefficients obtained after executing the modified Park test (Glick et al., 
2007). The test is run after GLM regression and predicts the square of the residuals as a 
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function of the log of the predictions through using a GLM with a log link and Gamma 
distribution. A coefficient of 0 indicates a Gaussian distribution, a coefficient of 1 a 
Poisson distribution, 2 indicates that the data follow a Gamma distribution, and 3 
indicates an inverse Gaussian or Wald distribution. However, other considerations in 
addition to the comparison of results from diagnostic tests should be taken into account 
when deciding on the appropriate distribution. For instance when modelling costs that 
can take non-integer values, a Poisson distribution would not be appropriate. 
No single test is available to identify an appropriate link function. The Pregibon link test 
can be employed to check linearity (Pregibon, 1980). The Hosmer and Lemeshow test 
and the Pearson correlation test both check for systematic bias in fit on the original scale 
of estimation (Hosmer and Lemeshow, 2000; Pearson and Please 1975). Ideally all 
three tests will provide insignificant p-values. In this study a user written STATA 
programme ‘glmdiagnostic.do’ (Glick, 2008) has been employed, which conducts the 
modified Park test, the Pearson correlation test, the Pregibon link test and the modified 
Hosmer and Lemeshow test simultaneously. The do file can easily be implemented and 
a number of link function-family combinations can be tested, observing how p-values 
change. The combination with the highest p-values is chosen as the best fit for the data 
as this does not reject the null hypothesis of being the correct specification for the data 
that are analysed. 
In addition to being able to specify a distribution and a link function, GLMs also have the 
advantage over log OLS of being able to include zero cost observations. However if 
there is a substantial proportion of individuals that have incurred zero costs during the 
observational period for which costs are estimated, the application of a two-part model is 
more appropriate. As outlined in the review of econometric modelling techniques in 
Chapter 3, the common procedure is to estimate a two-part rather than a Heckman 
sample selection model when the zero costs are observed rather than unobserved.   
Chapter 4  105 
 
 
Model specification 
The cost of a CIS is estimated using a GLM clustered on patient identifier. A series of 
five regressions with cost as the dependent variable are run in order to highlight the 
influence that different costing methods have. Following conventions for determining the 
appropriate distribution and link function, diagnostic tests are performed using the user 
written programme ‘glmdiagnostic’ as described above (Glick, 2008). Variations in the 
recommended distributional family and link functions could be observed between costing 
methods and to facilitate comparison of results and interpretation of coefficients, a 
Gamma distribution with a log link is chosen as the most commonly used combination 
for analysing HC expenditure data (Dodd et al., 2006). In addition, the results of the 
correctly specified model are also reported in sensitivity analysis. 
Explanatory variables 
The magnitude of the effect that a set of a-priori identified regressors has on costs when 
using different costing methods is assessed. Cost per CIS is regressed on age at 
admission, gender, socio-economic status, and the time period of admission, which is 
represented in four categories (Table 4.2). Socio-economic status is measured on a 
scale from one to seven, using the Carstairs-Morris deprivation categories (Carstairs 
and Morris, 1991), with 1 representing the most affluent postcode sectors and 7 
representing the most deprived. The underlying assumption is that the expected value of 
HC expenditure (HCE) is a function of these explanatory variables. 
E[HCE] = g(xβ)                                                                                      Equation (4.8) 
with xβ representing the linear predictor for HCE.  
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The following equation provides details on the linear predictor. 
it
t
t
d
dd uTDSAHCEE +++++= ∑∑
==
4
2
7
3
21][ γµββα                                Equation (4.9) 
Where A is age at admission for patient i, S is patient’s gender, D is the deprivation 
category, T is a time period dummy and ui represents the error term. 
Sensitivity analysis  
As a first sensitivity test, OLS regression as a special case of GLM was performed (a 
GLM with a Gauss family and the identity link is equivalent to an OLS). Even though the 
assumption of normality and homoscedasticity might be violated, OLS provides a 
consistent estimator of mean arithmetic costs on the raw scale, thus allowing convenient 
comparison of results.  
Further sensitivity analysis was carried out by re-running regressions with their 
recommended distributional family and link function as suggested by the goodness of fit 
tests. In order to test the magnitude of the effect that explanatory variables have on cost 
estimates when using different distributions and link functions, the linear predictor was 
calculated after the regression analysis. In order to facilitate comparison between 
costing methods and their respective distributions and link functions, the linear predictor 
was re-transformed to obtain estimates on the raw, monetary scale. Equations 4.10 to 
4.12 show the appropriate re-transformations for the different link functions used in the 
analysis that had been applied to the linear predictor. 
Retransformation for log link: 
)exp()( xug β=                                                                              Equation (4.10)  
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Retransformation for power link -0.7: 
7.0
1
1)(
x
ug
β
=              Equation (4.11) 
Retransformation for power link -1: 
x
ug
β
1)( =              Equation (4.12) 
In order to obtain the re-transformed linear predictor of costs, all but the explanatory 
variable of interest (in this instance the socio-economic status) are held constant. 
Categories for socio-economic status are varied to show the impact on costs for the 
same cost variable, but different distributions and link functions. Changes in the re-
transformed linear predictor provide a measure of the relative effect of the explanatory 
variable of interest. The remaining explanatory variables are held constant at the 
following values: 
• Age at admission: 70 years 
• Gender: male 
• Period: period 3 (admissions between 1994 and 2000).  
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4.4 Results 
4.4.1 Descriptive results 
Table 4.2 shows descriptive results relating to a total number of 45,634 CISs, coming 
from 10,415 individuals. Mean age at admission was 72.2 years [SD 7.4]. A higher 
proportion of admissions for females could be observed (57.3%). Most admissions were 
observed between 1993 and 2000 with 39.1% of all admissions to hospital falling into 
this period. The highest proportion of admissions could be observed for deprivation 
category 5 (36%). 
 
Table 4-2 Sample characteristics 
Variable Name Mean (SD) or Frequency (%) 
Age at admission 72.2 (7.4) 
Male 4,450 (42.7) 
Female 5,965 (57.3) 
Deprivation Category 1* 693 (6.7) 
Deprivation Category 2** 0 (0) 
Deprivation Category 3 1,428 (13.7) 
Deprivation Category 4 2,315 (22.2) 
Deprivation Category 5 3,754 (36.0) 
Deprivation Category 6 1,803 (17.3) 
Deprivation Category 7 422 (4.1) 
Admissions in 1980-1986 2,338 (5.1) 
Admissions in 1987-1993 9,890 (21.7) 
Admissions in 1994-2000 17,830 (39.1) 
Admissions in 2001-2007 15,576 (34.1) 
45,634 admissions, relating to 10,415 sample members; * Most affluent area;  
**No observations for deprivation category 2 
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4.4.2 Cost estimates 
Average cost estimates that are calculated using HRGs with the English tariff (method 1) 
are lowest (£1,993), followed by the approach which employs HRGs and the SNT 
(method 2) (£2,378). As expected, episode costing with national average LOS 
information produces similarly low mean costs (£2,478) and has the lowest variance 
(SD=£1,460). The total cost for acute inpatient care between 1980 and 2007, using 
2006/2007 as the reference year for costs and for the sample analysed in this paper 
(N=10,415), ranges from £91,200,000 for HRG based costing using the English tariff to 
£137,000,000 using per diem costing. 
Table 4.3 presents mean HC expenditure, their standard deviation and the 95% CI over 
the entire observational period and for specific time periods for all 5 costing methods. 
Costs that are mainly driven by LOS, through the application of a per diem costing 
approach (methods 3 and 4), are higher on average (£3,002 and £2,764) than costs 
derived using any of the alternative methods that place less weight on LOS. The 
standard deviations of these costing approaches are also higher than for other cost 
variables (£4,505 and £3,181), suggesting substantial variation in individual LOS.  
The early decline is most likely due to a decrease in LOS on average over time. This is 
most evident in methods that rely heavily on individual LOS (methods 3 and 4). While 
the subsequent increase is possibly driven by the ageing cohort, which may experience 
more expensive chronic conditions that require longer stays. 
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Table 4-3 Mean costs per CIS in £ (2006/07)-different cost variables and periods 
Variable Mean SD 95% Conf. Interval 
All Years 
   
Method 1 1993 2043 1974, 2012 
Method 2 2378 2039 2359, 2397 
Method 3 3002 4505 2960, 3043 
Method 4 2764 3181 2735, 2793 
Method 5 2478 1460 2464, 2491 
1980-1986 
   
Method 1 2200 2101 2114, 2285 
Method 2 2239 1325 2185, 2293 
Method 3 4027 4632 3939, 4215 
Method 4 3420 3372 3283, 3557 
Method 5 2599 1991 2518, 2679 
1987-1993 
   
Method 1 1927 1994 1887, 1966 
Method 2 2249 1939 2210 2287 
Method 3 3415 4480 3327, 3504 
Method 4 2912 3056 2853, 2973 
Method 5 2278 1307 2252, 2304 
1994-2000 
   
Method 1 1898 1984 1869, 1928 
Method 2 2381 2088 2350, 2411 
Method 3 2757 4278 2694, 2820 
Method 4 2624 3002 2580, 2668 
Method 5 2461 1453 2439, 2482 
2001-2007 
   
Method 1 2113 2122 2080, 2146 
Method 2 2479 2127 2446, 2513 
Method 3 2867 4712 2793, 2941 
Method 4 2730 3406 2677, 2784 
Method 5 2606 1450 2583, 2629 
Method 1: Costs per CIS, based on HRGs (English Tariff) 
Method 2: Costs per CIS, based on HRGs (Scottish National Tariff) 
Method 3: Costs per CIS, based on specialty and hospital specific per diem costs 
Method 4: Costs per CIS, based on specialty and hospital specific episode costs, individual LOS 
Method 5: Costs per CIS, based on specialty and hospital specific episode costs, national average LOS 
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Figure 4-6 Distribution of LOS by year of admission 
 
Figure 4.6 shows the distribution of mean LOS for each year of admission with the 95% 
CIs. On average, mean LOS was observed to have decreased over time. In the 1980s 
mean LOS had a value of about 10 days. SDs seemed to be wider during this period 
indicating more variation around mean LOS. For more recent periods mean LOS was 
observed to be lower on average compared to more historic periods (~7 days) and SDs 
seem to be much tighter. The subsequent increase in LOS from the year 2001 might be 
explained with the ageing process of the cohort, requiring longer stays on average.  
Figure 4.7 shows the distribution of mean costs per CIS over time with the 95% CI for all 
five costing methods. Costs were generally higher on average in the earliest periods. 
Costing methods, that rely heavily on individual LOS information (methods 3 and 4 and 
to a lesser extend method 1) show higher costs on average and especially for more 
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historic periods. Average costs for these methods can also be observed to have wider 
CIs. Very little variation over time can be observed for method 2 (SNT). Average costs 
obtained employing this method also show very tight CIs. Differences between methods 
have become less marked with tighter CIs for more recent years. 
 
Figure 4-7 Distribution of mean costs per CIS over time 
 
In addition it was tested how the socio-economic status impacts on LOS on average. 
This was done since LOS is one major component that is used in the process of deriving 
the different costing methods and individuals’ socio-economic status is hypothesised to 
influence LOS. Figure 4.8 shows the distribution of LOS over deprivation categories and 
an increase in mean LOS is observed as individuals become more deprived. 
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Figure 4-8 Distribution of LOS by socio-economic status 
 
A test, whether these differences were statistically significant showed that individuals 
living in deprivation categories 6 and 7 have significantly longer stays at hospital 
compared to individuals living in the most affluent areas (deprivation category 1) 
(p=0.002). The size of this effect is on average one day for individuals from deprivation 
category 6 compared to individuals from category 1, and on average 1.4 days for 
individuals living in the most deprived postcode areas (category 7). 
4.4.3 GLM regression results 
Results for GLM regression analyses are shown in Table 4.4. The coefficients presented 
here have been re-transformed and are shown as cost ratios. They are presented with 
their associated standard errors (in parentheses) and their 95% CI. AIC and BIC 
goodness of fit measures are presented at the bottom of Table 4.4; they show similar 
values for all five costing methods. 
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GLM regression results show, that the association between age at admission and cost is 
highly significant and positive for all costing methods. Costs increase between 0.5 
percent (method 5) and 2.3 percent (method 3) for each additional year. 
Males are found to incur significantly lower costs than females. These differences range 
from 18% when applying per diem costing (method 3) to 2% for episode based costing 
using national average LOS (method 5). Socio-economic status has a small and 
generally non-significant effect on costs across most methods. The only two methods 
which are found to report a significant association with socio-economic status were HRG 
based costing applying the SNT (method 2) and episode based costing using national 
average LOS (method 5); the regression coefficients suggest that people living in more 
deprived postcode areas are less costly. For example, the size of the effect for method 5 
would suggest that people living in the most deprived postcode areas incurred costs that 
were 5% lower than costs for people living in the most affluent postcode areas. A joint 
hypothesis test, performed after estimation, rejects the hypothesis that a regression 
model excluding deprivation category indicators is correctly specified compared to a 
model including these measures for costing methods 2 and 5. The respective p-values 
for these tests are presented in Table 4.4.  
The indicator variables representing the period of admission show an increasing 
significant negative association with costs for later admissions compared to the very 
early years for costing methods 1 to 4. In general this suggests lower costs for more 
recent periods compared to the most historic period (1980-1986). The size of the effect 
was found to be largest for costing method 3, which used per diem costing. Here, costs 
were found to be about 55% lower in the most recent period (2001-2007) than in the 
most historic period (1980-1986). Compared to costing methods 1 to 4, a decreasing 
negative association of the period of admission with costs could be observed for costing 
method 5. 
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Table 4-4 Regression results - GLM 
Costing Method Method 1 95%CI Method 2 95%CI Method 3 95%CI Method 4 95%CI Method 5 95%CI 
Age at admission 1.022*** 1.019, 
1.024 
1.017*** 1.015, 
1.019 
1.023*** 1.019, 
1.026 
1.018*** 1.015, 
1.020 
1.005*** 1.004, 
1.007 
 (0.001) 
 
(0.001) 
 
(0.001) 
 
(0.001) 
 
(0.0009) 
 
Gender 0.893*** 0.870, 
0.918 
0.940*** 0.918, 
0.961 
 
0.822*** 0.791, 
0.854 
0.873*** 0.849, 
0.899 
0.980* 0.961, 
1.002 
(male=1) (0.013) 
 
(0.011) 
 
(0.019) 
 
(0.014) 
 
(0.010) 
 
Deprivation 0.966 0.911, 
1.031 
0.936** 0.889, 
0.991 
0.996 0.917, 
1.092 
1.010 0.949, 
1.081 
1.007 0.966, 
1.047 
Category 3 (0.031) 
 
(0.027) 
 
(0.044) 
 
(0.033) 
 
(0.020) 
 
Deprivation 0.991 0.939, 
1.053 
0.978 0.932, 
1.033 
1.001 0.925, 
1.093 
1.005 0.947, 
1.072 
0.975 0.940, 
1.015 
Category 4 (0.029) 
 
(0.026) 
 
(0.042) 
 
(0.031) 
 
(0.019) 
 
Deprivation 0.978 0.928, 
1.034 
0.948** 0.904, 
0.997 
0.983 0.913, 
1.064 
0.992 0.938, 
1.051 
0.976 0.941, 
1.009 
Category 5 (0.027) 
 
(0.024) 
 
(0.039) 
 
(0.029) 
 
(0.017) 
 
Deprivation 1.016 0.958, 
1.077 
0.984 0.933, 
1.038 
1.021 0.940, 
1.111 
1.010 0.949, 
1.075 
0.952** 0.916, 
0.990 
Category 6 (0.030) 
 
(0.027) 
 
(0.042) 
 
(0.031) 
 
(0.019) 
 
Deprivation 1.038 0.958, 
1.129 
1.000 0.932, 
1.080 
0.972 0.867, 
1.097 
0.969 0.890, 
1.060 
0.951* 0.902, 
1.002 
Category 7 (0.042)  (0.037)  (0.060)  (0.044)  (0.026)  
          
           
Chapter 4  116 
 
 
Table 4.4 continued          
Costing Method Method 1 95%CI Method 2 95%CI Method 3 95%CI Method 4 95%CI Method 5 95%CI 
Period 2 0.758*** 0.727, 
0.802 
0.901*** 0.865, 
0.938 
0.730*** 0.682, 
0.779 
0.750*** 0.717, 
0.800 
0.839*** 0.808, 
0.881 
(1987-1993) (0.027) 
 
(0.022) 
 
(0.036) 
 
(0.030) 
 
(0.023) 
 
Period 3 0.641*** 0.631, 
0.704 
0.861*** 0.834, 
0.911 
0.501*** 0.479, 
0.558 
0.599*** 0.582, 
0.657 
0.882*** 0.844, 
0.926 
(1994-2000) (0.030) 
 
(0.023) 
 
(0.040) 
 
(0.032) 
 
(0.025) 
 
Period 4 0.637*** 0.625, 
0.709 
0.827*** 0.795, 
0.882 
0.456*** 0.438, 
0.523 
0.563*** 0.548, 
0.630 
0.909*** 0.863, 
0.957 
(2001-2007) (0.034) 
 
(0.027) 
 
(0.047) 
 
(0.037) 
 
(0.027) 
 
Constant 593*** 500, 
697 
829*** 717, 
955 
1081*** 834, 
1339 
1219*** 996, 
1433 
1948*** 1674, 
2155 
 (0.083)  (0.072)  (0.119)  (0.091)  (0.064)  
Observations 45,634  45,634  45,634  45,634  45,634  
AIC 17.17369  17.53766  17.97354  17.82953  17.62603  
BIC -458792  -464713  -430255  -458372  -478756  
           
Joint Test for 
Deprivation 
p=0.207  p=0.012  p=0.823  p=0.845  p=0.023  
Robust standard errors in parentheses; *** p<0.01, ** p<0.05, * p<0.1; Deprivation category 1 (most affluent) serves as the reference category, no observations for deprivation 
category 2 in the sample; Period 1 (1980-1986) serves as the reference category
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4.4.4 OLS regression results (sensitivity analysis) 
OLS regression results are presented in Table 4.5, with their associated standard errors (in 
parentheses) and their 95% CI. Operating on the raw scale, coefficients can be interpreted 
in monetary terms. Overall, OLS regression results reveal a similar association between 
costs and explanatory variables in terms of sign and significance as GLM regression 
results.  
The association between age at admission and costs is highly significant and positive for all 
costing methods. However, the size of the effect is small and ranges from an additional 
£13.97 to £70.25 for every additional year of age at admission. The smallest effect can be 
observed for the costing method that uses episode costing based on national average LOS 
(method 5) and the largest effect is found for per diem costing (method 3).  
Male patients are found to incur significantly lower costs than females across all costing 
methods, again with the magnitude being largest for per diem costing (method 3) with 
£575.20 and smallest with £50.16 (although only marginally significant) for episode costing 
using average LOS (method 5).  
Overall the effect of socio-economic status on costs is small and mostly non-significant. A 
significant negative effect of socio-economic status could be observed for method 5, 
episode based costing using national average LOS and HRG based costing using the SNT 
(method 2). For costing method 5, individuals living in the most deprived and second most 
deprived postcode areas seem to incur ~£120.00 less on average than individuals living in 
the most affluent postcode areas. These findings imply that lower mean costs are incurred 
by people living in more deprived areas compared to people from more affluent areas, after 
adjustment for age, sex and period of admission.  
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The time period of admission has a consistent negative and significant association with 
costs across costing methods. The magnitude of the effect is generally smallest for episode 
based costing using national average LOS (method 5) with cost estimates being between 
£237.00 lower for the most recent period (2001-2007) and £413.90 lower for the period 
ranging from 1987-1993, both compared to the most historic time period (1980-1986). The 
period of admission was observed to have the largest effect on costs for per diem costing 
(method 3), ranging from estimates being £2,678 lower in the most recent period (2001-
2007) compared to the most historic period (1980-1986) and £1,082 lower for the period 
spanning the years 1987-1993 compared to the most historic period.  
Similar to results obtained from GLM regression modelling, method 5 was observed to be 
the only costing method to produce reversed effects of the period of admission. While for 
the remaining four methods an effect could be observed that had lower costs that increased 
in their magnitude over time, method 5 produced cost estimates that moved in the opposite 
direction, i.e. the magnitude of the effect, although still negative, that time had on costs 
decreased over time. While costs incurred in period 4 (2001-2007) were £237.00 lower than 
in period 1 (1980-1986), they were £413.90 lower in period 2 (1987-1993).  
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Table 4-5 Regression results- OLS 
Costing Method Method 1 95%CI Method 2 95%CI Method 3 95%CI Method 4 95%CI Method 5 95%CI 
Age at admission 44.40*** 
39.54, 
49.26 39.36*** 
34.61, 
44.10 70.25*** 
59.79, 
80.72 50.41*** 
42.90,  
57.91 13.97*** 
9.501,  
18.44 
 (2.48)  (2.42)  (5.34)  (3.83)  (2.28)  
Gender 
-229.0*** 
-280.2,  
177.9 -152.8*** 
-206.1 , 
-99.55 -575.2*** 
-683.1,  
467.3 -374.8*** 
-451.2,  
298.5 -50.16* 
-100.7, 
0.395 
(male=1) (26.08)  (27.18)  (55.03)  (38.95)  (25.79)  
Deprivation 
-60.44 
-184.0, 
63.08 -154.6** 
-286.9,  
22.25 7.847 
-245.8,  
261.5 36.03 
-143.1,  
215.2 13.12 
-88.40, 
114.6 
Category 3 (63.01)  (67.51)  (129.4)  (91.40)  (51.79)  
Deprivation 
-18.72 
-135.2,  
97.76 -53.17 
-180.4 , 
74.09 3.711 
-241.0, 
248.4 15.06 
-155.8, 
185.9 -57.80 
-154.6,  
39.00 
Category 4 (59.42)  (64.92)  (124.8)  (87.18)  (49.38)  
Deprivation 
-51.15 
-160.4, 
58.11 -133.7** 
-253.4,  
14.06 -60.41 
-285.5,  
164.7 -29.36 
-187.8, 
129.1 -64.68 
-152.9,  
23.52 
Category 5 (55.74)  (61.06)  (114.8)  (80.82)  (45.00)  
Deprivation 16.69 
-104.0, 
137.4 -45.93 
-177.2, 
85.30 17.03 
-229.7, 
263.7 8.885 
-164.4, 
182.2 -120.9** 
-217.9,  
-23.88 
Category 6 (61.58)  (66.95)  (125.9)  (88.43)  (49.49)  
Deprivation 
73.01 
-91.25,  
237.3 9.427 
-169.1, 
187.9 -90.32 
-428.8, 
248.1 -78.04 
-312.4, 
156.3 -120.5* 
-248.8,  
7.805 
Category 7 (83.80)  (91.06)  (172.7)  (119.5)  (65.44)  
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Table 4.5 continued          
Costing Method Method 1 95%CI Method 2 95%CI Method 3 95%CI Method 4 95%CI Method 5 95%CI 
Period 2 
-563.5*** 
-671.6, 
455.4 -247.0*** 
-338.5,  
155.4 -1,082*** 
-1,331, 
832.4 -843.5*** 
-1,022,  
665.3 -413.9*** 
-521.8,  
 -305.9 
(1987-1993) (55.16)  (46.72)  (127.2)  (90.90)  (55.08)  
Period 3 
-830.3*** 
-948.1,  
712.5 -326.6*** 
-427.0,  
226.2 -2,119*** 
-2,384,  
1,853 -1,404*** 
-1,595,  
-1,213 -307.4*** 
-423.7,  
 -191.1 
(1994-2000) (60.09)  (51.22)  (135.5)  (97.50)  (59.34)  
Period 4 
-843.4*** 
-977.5,  
709.3 -427.7*** 
-548.2,  
307.1 -2,380*** 
-2,678,  
2,083 -1,564*** 
-1,777,      
-1,351 -237.0*** 
-365.4,  
-108.5 
(2001-2007) (68.41)  (61.51)  (151.6)  (108.8)  (65.53)  
Constant 
-511.2*** 
-847.6,  
174.8 -120.3 
-455.8,  
215.2 -175.1 
-910.0,  
559.8 376.4 
-151.8, 
904.5 1,791*** 
1,474, 
2,107 
 (171.6)  (171.2)  (374.9)  (269.4)  (161.5)  
Observations 45,634 
 
 
45,634 
 
 
45,634 
 
 
45,634 
 
 
45,634 
 
 
R squared 0.021  0.016  0.018  0.015  0.011  
Robust standard errors in parentheses; *** p<0.01, ** p<0.05, * p<0.1; Deprivation category 1 (most affluent) serves as the reference category, no observations for deprivation 
category 2 in the sample; Period 1 (1980-1986) serves as the reference category 
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4.4.5 Results for sensitivity analysis using the recommended 
distributional family and link function 
Cost estimates obtained after GLM regression using the recommended distributional 
family and link functions are presented in Table 4.6. These represent the re-transformed 
linear predictors as detailed in Section 4.3.3. Cost estimates revealed a negligible 
difference between results obtained when using Gamma as the distributional family and 
a log link function (as presented in Table 4.4) compared to using the distribution and link 
function that were recommended through the goodness of fit tests provided in 
‘glmdiagnostic.do’. The difference in cost estimates when varying the deprivation 
category was very small for costing method 1, where results only varied by £2.00 (for 
deprivation category 6) to £24.00 (for deprivation category 3). Similar, very small 
variations in costs estimates were found for the remaining costing methods. However, 
comparing cost estimates between costing methods, differences are substantially larger, 
ranging from £906.00 for deprivation category 3 to £661.00 for deprivation category 7, 
when comparing costing method 1 with method 5. 
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Table 4-6 Cost estimates in £: Comparison of recommended family and link function with 
Gamma and log link (cf. Table 4.4) 
Costing 
Method 
1 1 2 2 3 3 4 4 5 5 
Distribution Gamma Gamma Poisson Gamma Poisson Gamma Gamma Gamma Poisson Gamma 
Link function Power   
-1 
log Log log Log log Power   
-0.7 
log log log 
Deprivation 
Category 3 
1547 1523 2023 2017 2156 2140 2233 2212 2422 2429 
Deprivation 
Category 4 
1574 1563 2112 2109 2156 2150 2222 2200 2355 2359 
Deprivation 
Category 5 
1554 1539 2041 2040 2109 2108 2192 2168 2348 2353 
Deprivation 
Category 6 
1594 1596 2117 2115 2163 2185 2219 2206 2295 2298 
Deprivation 
Category 7 
1630 1634 2167 2156 2085 2085 2154 2121 2295 2295 
Cost estimates for covariance matrix: Gender=male, age at admission=70, time period of admission=3  
 
4.5 Discussion 
The effects of five different costing methods, based on three main approaches, for 
costing hospital episodes have been considered in this chapter. The first two methods 
were based on disease classification (HRGs); the third utilised information based on per 
diem costs. The final two methods derived specialty specific costs on an episode level 
using individual LOS plus a variable and fixed cost component split, and national 
average LOS without a cost split. 
The initial research question was: How do different methods to cost inpatient hospital 
stays affect cost estimates and what marginal effect do various explanatory variables 
have?  
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Descriptive analysis revealed substantial differences in the scale of mean costs. Mean 
costs that include an element of individual LOS were higher on average with a greater 
variance. Using average LOS information produced the lowest mean cost with the 
smallest variance. The differences between mean costs however were found to narrow 
over time, which can be partly explained by decreasing LOS over time as shown in 
Figure 4.6 in Section 4.4.1. 
A further focus of this analysis was to assess whether alternative costing methods 
influence the magnitude of the effect a set of regressors has on costs. It was found that 
the costing method does have a substantial influence on the predictions observed. 
Results obtained when employing episode based costing using national average LOS 
seemed to differ consistently from results produced by alternative costing methods, 
especially in terms of the association between socio-economic status and costs and also 
in terms of a reversed effect that the time period of admission had on costs. The main 
difference between this method (method 5) and the four alternative methods is that it 
does not take account of individual LOS. An effect of socio-economic status on costs, 
which would be in line with previous research that suggests that ‘the poor cost more’ 
(Cookson and Laudicella, 2011), was not observed to the extent that was expected. A 
possible explanation for this might be that any effect that was present was modified by 
including LOS into the calculation of the cost variable. This is based on the assumption 
that individuals from more deprived postcode areas tend to have longer hospital stays 
on average, often due to a lack of care or support in their own homes, they may also 
delay seeking care until their condition is serious, thereby requiring a longer stay. Using 
this data it can not be confirmed when individuals seek medical care, however, it could 
be shown that individuals living in more deprived areas required longer hospital stays on 
average compared to individuals from the most affluent areas (see Figure 4.8). 
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Both sensitivity analyses, using OLS regression, as a special case of GLMs and using 
the recommended distributional family and link function, confirmed that the choice of the 
econometric modelling framework has a negligible impact on cost estimates. A much 
more substantial impact was observed in the actual costing method. This could easily be 
observed by comparing GLM regression results across different costing methods. This 
chapter has therefore laid important foundations by testing for such differences and 
found them to be negligible.  
It is recognised here that the costing approach is mainly determined by the research 
question, but this chapter highlights important issues that arise from the application of 
alternative methods. A comparison of HRG and per diem costing as the two most 
commonly used methods revealed substantial scale differences and some difference in 
the size of the effects that regressors have on costs. Studies that employ a per diem 
costing approach neglect the nature of a hospital stay, which is characterised by fixed 
costs being independent of LOS and variable costs varying with LOS. Although general 
conclusions in terms of sub group analysis, i.e. males are less costly than females, do 
not seem to be influenced by the type of costing, the magnitude of the effect is.  
The application of the HRG costing method (method 1) is therefore recommended for 
the analysis of costs in Chapters 5 and 6. This costing method is disease specific; it 
incorporates a fixed and variable cost approach through the application of a trim point 
payment, and also allows adequate costing of hospital stays that involve more than one 
episode.
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5 EMPIRICAL ANALYSIS – RENFREW/PAISLEY 
STUDY 
5.1 Introduction 
The empirical analysis in this chapter will add to the understanding of the association 
between population ageing, TTD and costs, mainly through the inclusion of previously 
unconsidered explanatory variables, such as health status and health risks at baseline. 
The analysis will make use of a survey based longitudinal dataset, which was introduced 
in the previous chapter.  
5.1.1 Rationale for including survivors 
If the analysis of the relationship between ageing, TTD and HC expenditure is to aid 
resource planning and resource allocation on a population level, the sample ought to 
include the surviving part of the population. The review of the literature in Chapter 3 
explained reasons for the inclusion of the surviving part of the sample into a model that 
estimates HC costs as people approach death. Issues of applying varying approaches to 
account for survivors’ unknown TTD were discussed and a summary of the main 
methods that were employed elsewhere was presented.  
The literature review concluded that this issue has to date not been addressed to a 
satisfactory extent in regression analysis. If right censoring of survivors is not correctly 
accounted for, cost estimates may be incorrect. For example, if the censoring date were 
used as the date of death, costs that are observed are assigned to the incorrect year, or 
quarter before death and results might be misleading. Costs observed in the last quarter 
before censoring are not costs in the last quarter of life. To account for survivor status in 
regression analyses researchers have reverted back to including an indicator variable. 
However, this does not correct cost observations.
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To guide future research, the analysis presented in this chapter aims to correct for 
limitations arising from varying methods through the implementation of an approach 
which could rectify problems of not adequately dealing with survivors’ right censoring. In 
a recent study Shang and Goldman (2008) have used survival analysis to predict the 
effect of life expectancy on HC expenditure. Their approach is extended here. As the 
authors used a cohort consisting of survivors only, they were not able to compare the 
magnitude at which estimated costs might differ, when employing alternative methods of 
correcting for survivors’ unknown TTD.  
The analysis (and data) presented in this chapter allows an in-depth examination of this 
issue, specifically this chapter estimates costs for the following scenarios:  
a) Inclusion of decedents only (scenario A),  
b) Inclusion of survivors only, using the censoring date as date of death (scenario B) 
c) Inclusion of decedents and survivors, using the censoring date as date of death for 
survivors (scenario C), 
d) Inclusion of decedents and survivors, using an imputed date of death for survivors 
(extended approach) (scenario D) 
A comparison of results from scenarios A, C and D provides insight into the magnitude 
of any over- or under-estimation of costs at the end of life produced in previous 
research. Results will also highlight differences in the size and significance of the effect 
that included covariates have on costs, thus reveal to what extent estimates are 
determined by sample selection. Estimation results obtained for scenario B add further 
information in terms of singling out the ‘pure’ survivor effect. This adds to the 
understanding and interpretation of results from scenarios C and D, where survivors are 
included, but two different approaches are used to do so. 
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The Renfrew/Paisley sample offers the advantage of having a very high number of study 
participants for which death could be observed over the study period. This facilitates 
means to test differences in estimated costs at the end of life when using the censoring 
date as the date of death for a sub-sample for which death could subsequently be 
observed. These results can be compared to cost estimates obtained when using the 
actual date of death for this sub-sample. This approach is novel and provides useful 
information on the magnitude of the difference in costs under two different methods.  
In addition, the nature of the data allows consideration of further bias in the form of 
omitted variables. Little is known about the role of previously omitted covariates such as 
baseline health status and health risks on future hospital costs. An understanding of this 
is important as it provides guidance on how important such characteristics are for the 
estimation of future HC costs.  
The remainder of this chapter is structured as follows. A detailed description of the 
utilised linked dataset is given in Section 5.2. This section also provides a detailed 
explanation of the comprehensive data manipulation and an account of how acute 
hospital care costs have been derived and assigned to episodes of inpatient care. 
Section 5.3 provides results for sample characteristics and the descriptive analysis of 
costs. Methods employed to predict survivors’ TTD are described in Section 5.4 and 
results for these analyses are presented in Section 5.5. Econometric methods used to 
estimate HC expenditure at the end of life are described in Section 5.6 and Section 5.7 
presents results. Section 5.8 provides a presentation of a method to validate the method 
of including survivors through survival analysis and the chapter concludes with a final 
discussion of the main findings and limitations in Section 5.9.  
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5.2 Methods - data description 
5.2.1 The Renfrew/Paisley Study (Midspan) 
Midspan is the name used for a series of surveys on occupational and general 
population health carried out in the West of Scotland. It included almost 30,000 people 
and started in the 1960s. The Midspan studies include three separate original studies, 
and one study undertaken 20 years after the original studies including the offspring of 
participants in one of the main studies.  
The Renfrew/Paisley study, as one of the Midspan studies, is a longitudinal study based 
on a large cohort. It was carried out between 1972 and 1976 in the towns of Renfrew 
and Paisley and covers a total observational period of 35 years (the current censoring 
date is 31st December 2007)11. It includes men and women, who were aged between 45 
and 64 years at the time of study entry. The total dataset includes 15,402 individuals 
7,049 of which are men and 8,353 of which are women. The Renfrew /Paisley study is 
the third largest study of its kind in the world. Remarkably, it is the only study in the UK 
of its time to include women. It studies a location which still includes a high proportion of 
socio-economically disadvantaged people.  
The data recorded from the Renfrew/Paisley study can be grouped into four areas: 
questionnaire data, clinical measurements, derived data and follow-up data. Study 
members were asked to complete a questionnaire, which collected information on 
participants’ sex, marital status, occupation, smoking habits, bronchitis and angina. 
Participants were also invited to attend screening examinations at clinics, which were 
set up specifically for the study. Clinical data were collected on height, weight, 
respiratory function (Forced Expiratory Volume (FEV) in 1 second; % predicted FEV1)12, 
                                               
11
 See http://www.gla.ac.uk/researchinstitutes/healthwellbeing/midspan/ 
12
 Derived by dividing actual FEV1 (in litres) through expected FEV1 value, where the expected value is 
derived from a healthy subset with similar characteristics 
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systolic and diastolic blood pressure and cholesterol. A chest x-ray was also performed. 
Data that were subsequently derived includes the age at screening, the 1981 Carstairs 
deprivation category (based on postcode information from 1972-1976, with category 1 
representing the most affluent postcode sectors and category 7 the most deprived 
ones), the Body-Mass-Index (BMI) and the Rose Angina classification.  
Computer linkage exists with SMR01 and individuals were followed up in terms of 
hospital use and death until December 2007. This provides a rich data set of 
hospitalisations for a wide range of causes. Indirect follow-up of mortality was 
established at the time of the study with the General Register Office Scotland (GROS) 
(Hart et al., 2005).  
A total of 23 participants (0.15%) have been lost to follow-up and consequently there is 
no information on their utilisation of hospital services. These observations were deleted 
from the dataset. For people, who have left the UK (N=121; 0.78%) there is no 
information on their use of HC services or on their date of death after they had 
embarked. These observations have therefore also been discarded from the analysis. 
1,565 individuals (10.16%) from the Renfrew/Paisley study had never accessed acute 
hospital care until their death or censoring of the study. These will remain part of the 
sample, but without any resource use data.  
The Renfrew/Paisley study provides very important baseline characteristics for 
individuals, allowing the inclusion of previously omitted explanatory variables and 
therefore adding to the understanding of the association between population ageing, HC 
expenditure and TTD. It is however based on a small sample of the Scottish population 
from a very confined area in the West of Scotland and therefore may not be 
representative of Scotland.  
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5.2.2 Scottish Morbidity Records 01 (SMR01) 
SMR01 has episode-based patient records that relate to all acute inpatient and day 
cases. Every record in SMR01 data reflects one episode of care. An SMR01 record is 
generated every time a patient completes an episode of inpatient or day case care. 
Completion of an episode includes discharge home, transfer to another consultant in 
either, the same or a different hospital, a change of specialty under either the same or a 
different consultant, or death. The data that are collected to describe each episode 
include clinical (diagnoses and procedures) and non-clinical (demographic information, 
episode management details) information. Diagnoses are recorded using the 
International Classification of Disease- ICD-10 (previously ICD-9 and ICD-8) while 
procedures performed while hospitalised are recorded using the ‘Office of Population, 
Censuses and Surveys Classification of Surgical Operations and Procedures’ - 4th 
revision (OPCS-4, previously OPCS-3)) (ISD Data Dictionary, 2009).   
SMR01 records have been computerised since 1968 (Scottish Public Health 
Observatory, 2010). Linked SMR01-Renfrew/Paisley data reach back to the 1970s, 
which has resulted in the allocation of different ICD coding schemes; specifically 
observations in the dataset have ICD8, ICD9 or ICD10 codes. Admissions with ICD9 
codes (pre 1992) have been converted into ICD10 codes using a look-up file (New 
Zealand Health Information Service, 2010). Very early hospitalisations (pre 1981) with 
an ICD8 code for disease classification cannot readily be converted into ICD10 codes, 
as there is no available conversion algorithm between these two.  
The episode information also included the specialty the patient was treated at. Length of 
stay (LOS) information is recorded in days with LOS being zero for day cases. After an 
informal discussion with ISD and their confirmation, one day is added to each of these 
admissions to facilitate inclusion of these episodes in the cost analysis. However this 
also means that day cases are treated as inpatient stays and receive the same cost as 
an inpatient stay of one day. 
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5.2.3 Linked SMR01- Renfrew/Paisley data 
SMR01 records for the Renfrew/Paisley sample consist of 98,262 completed hospital 
episodes that relate to 13,693 Renfrew/Paisley study members13. Data cleaning was 
carried out as a first step of the data manipulation process. To reduce measurement 
error, the SMR01 data was checked for data entry anomalies. An initial check of the 
data for duplicates in terms of patient identifier, date of admission, date of discharge and 
specialty revealed 107 episodes to be duplicates. To avoid potential double-counting of 
hospital episodes, these have been deleted from the dataset. The data were further 
screened for overlapping episodes for individual patients, which have occurred in the 
same specialty setting. For episodes that overlapped by ten days or more (N=26), those 
episodes with the shorter LOS have been deleted from the dataset. Further checks 
revealed episodes that were completely nested within another episode for the same 
patient and the same specialty. Nested episodes (N=7) were also deleted from the 
SMR01 dataset. 115 episodes were deleted as these related to individuals that had 
embarked.  
Merging of the SMR01 and the Renfrew/Paisley datasets resulted in 99,572 
observations that relate to 15,258 sample members. For individuals without any hospital 
records (N=1,565) data from the Renfrew/Paisley study provides their baseline 
characteristics.  
Further checks have been carried out after linkage of the two data files and four 
admissions were detected after the observed death of a sample member. LOS for these 
admissions was one day and they were deleted from the dataset. Geriatric long stay 
episodes were only part of SMR01 until 1997. Due to this inconsistency and the nature 
of the care episodes, six individuals who only had geriatric long stay episodes were 
discarded from the analysis and a further 540 admissions were also excluded from the 
                                               
13
 Note that 1,565 sample members do not have a resource use record and therefore do not 
appear in SMR01 data. 
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analysis. This provides a final dataset of 99,028 episode observations, relating to 15,252 
sample members. Figure 5.1 shows a flowchart of how the analysis sample was derived, 
looking at both the number of hospital episodes and the number of sample members 
these episodes relate to. 
Observations are episode based, i.e. each row in the dataset represents one hospital 
episode. Individuals who accessed hospital services can have several episodes of care. 
These episodes can either be unrelated, single hospital episodes, where the patient is 
discharged home, and at some point in the future, is admitted again, or they can form an 
entire hospital stay, where the patient is transferred within or between hospitals. Multiple 
episodes that form an entire stay are called continuous inpatient stays (CISs). A CIS 
lasts from admission to hospital until discharge (from the same or a different hospital if 
the patient was transferred) or death. In order to highlight all episodes that form a CIS 
for a patient, transfers were marked as follows: if the admission date of an episode is 
equal to the discharge date of the previous episode these episodes classify as 
belonging to a CIS. The discharge date for the last episode within a CIS and the 
admission date of the first episode within a CIS are used to calculate the total LOS for 
that CIS.  
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Renfrew/Paisley Sample
          N=15,402
     Lost to Follow-up
      N=23 (0.15%)
     Embarked UK
      N=121 (0.78%)
SMR01 Dataset
(N=98,262 episodes,          
relating to 13,693  
sample members)
Deleting duplicate 
episodes (N=107)
Deleting overlapping 
episodes (N=26)
Deleting nested episodes 
(N=7)
Deleting episodes for 
individuals that 
embarked (N=115)
Admission to Geriatric 
Long Stay Ward
N=6
Delet ing nested episodes 
(N=7)
Deleting Geriatric Long 
Stay Episode (N=540)
Merging Renfrew/Paisley sample and SMR01 records results in:
99,028 observations, relating to 15,252 sample members (1,565 
individuals do not have a resource use record)
15,252 sample members
Deleting Admissions 
after death (N=4)
 
Figure 5-1 Sample set-up 
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5.2.4 Quarterly cost assignment 
The initial set up of the data was a flat file. Every sample member appeared in the 
dataset either once or several times, depending on the number of hospital episodes that 
were observed. Sample members without any hospital records only appeared once in 
the dataset. The panel is in long format with each row representing one single hospital 
episode (or no episodes). In its original set up the panel was unbalanced and rows 
(episodes) did not represent a certain time point or period. The data also did not include 
any information on periods in which no costs were incurred, i.e. periods without a 
SMR01 record. As the interest of this study lies in the estimation of quarterly costs as 
people approach death the data needed to be manipulated so that each row 
represented one quarter (90 days) before death. Measuring costs in quarters instead of 
years will facilitate analysis for a very defined and narrow time period. Costs could then 
be assigned to the quarter in which they were incurred and quarters without a cost 
observation could be filled with zeros.  
The initial exploration of the data showed that costs increased markedly in the last two 
quarters of life. Exploratory regression analysis determined when TTD became an 
insignificant predictor for costs. It was therefore decided to analyse the last three years 
of life, measured in quarters (i.e. 12). Each sample member therefore has 12 rows of 
data, unless they could not be observed for 12 quarters because they died within three 
years of entering the study. These sample members contribute the maximum number of 
quarters they could be observed for and are represented by the respective number of 
rows in the dataset, e.g. a sample member who died two years after entering the study 
have eight rows of data. 416 sample members contribute less than 12 quarters. Sample 
members may have had several individual hospital stays (CIS) during one quarter. 
Costs for these CISs were aggregated so that one row represents one quarter with all 
incurred costs assigned to it.  
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A variable that indicates when the last 12 quarters (or less) of life start for each 
individual patient was generated by subtracting 1,080 days from the date of death. It 
was assumed that one quarter equals 90 days. If this date was smaller than the date at 
which individuals entered the study, i.e. individuals have not been in the sample for the 
entire 12 quarters this date was replaced with the date of study entry, so to mark the 
maximum period patients were observed for. Admissions that took place out with the 12 
quarters before death were discarded from any further analysis. 
Each hospital stay (CIS) was then assigned to a particular quarter before death. This 
was done separately for the admission and discharge date as a CIS can span more than 
one quarter. The quarter before death into which a CIS fell was first determined by the 
date of admission. It was then ascertained whether the CIS only belonged to one 
particular quarter before death or whether it lasted to span more than just one quarter. A 
marker for each CIS that lasted for more than one quarter was generated. 90.6% of all 
admissions only span one quarter (<=90 days) and 9.0% lasted between 91 and 180 
days. A check to confirm that the admission quarter was always greater than the 
discharge quarter was also performed. If a CIS lasted for more than one quarter, the 
assigned costs were split accordingly. This was done by dividing costs by the respective 
number of quarters. Costs were split evenly across quarters.  
Once all costs were assigned to the quarter before death in which they were incurred, 
using the date of admission as starting point for any cost incurrence, the next step was 
to add up all costs incurred in each quarter, and so obtain total quarterly costs.  
The dataset was then expanded to 12 rows for each individual, or less if sample 
members could not be observed for 12 quarters. The resulting dataset was not perfectly 
balanced due to individuals dying within three years of entering the study. It provides the 
exact number of rows needed for each individual determined by how many quarters they 
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had completed in the sample before dying (between 1 and 12) and also determined by 
the number of quarters before death that were analysed (12).  
Following the construction of the panel data set, quarters without any hospitalisation 
were assigned zero costs. If costs were split over two quarters these were equally 
shared between quarters. This seemed reasonable as the proportion of hospitalisations, 
where this could be observed was judged to be minimal.  
Finally, deletion of episodes before 1980 was carried out, since these had ICD-8 codes 
assigned, for which no conversion algorithm was available. After taking account of 
missing information for the dependent variable, and deprivation category, the following 
samples were analysed: scenario A: 127,982 observation quarters, relating to 11,579 
sample members; scenario B: 38,910 observation quarters relating to 3,281 sample 
members; scenario C: 166,892 observation quarters, relating to 14,860 sample 
members, and scenario D: 141,420 observation quarters, relating to 13,686 sample 
members.  
5.2.5 Costs 
Following recommendations based on results obtained from the analysis of alternative 
costing methods, as outlined in Chapter 4, this empirical analysis uses HRG based 
costing applying the English Tariff. This costing method has been chosen for the 
following advantages it possesses: it is disease and procedure specific and incorporates 
a fixed and variable cost component, thereby avoiding the assumption that the first day 
in hospital incurs the same cost as each subsequent day. It also allows adequate 
costing of hospital stays that involve more than one episode. The costing method 
followed the steps described fully in Section 4.3.2.  
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5.3 Results - sample characteristics 
5.3.1 Descriptive statistics  
The characteristics of the sample are presented in Table 5.1 for the entire sample and 
by survivor status at the end of the observational period. A total number of 14,860 
participants were analysed descriptively, a number that varied in regression analysis 
according to the sample scenario analysed. 22.1% of the sample population did not 
have a death record at the end of the study period (N=3,281).  
The proportion of females in the survivor group is significantly higher than in the 
decedent group (p<0.01). 10% of the sample population never accessed hospital care, a 
proportion that does not differ by survival status (p=0.63). A higher proportion of 
individuals living in the most affluent postcode areas could be found in the survivor 
group, with 8.3% in deprivation category 1, compared to 5.9% in the decedent group. 
15.1% of survivors were observed in deprivation category 3, compared to 13.1% in the 
decedent group. The differences between survivors and decedents in terms of their 
socio-economic status was highly significant (p<0.01). 
A higher proportion of the sample population (55.1%) was observed to have a BMI 
above 25, which is the threshold to being overweight. A higher proportion of individuals 
with an increased BMI can be observed in the decedent group (55.9%) than in the 
survivor group (52.2%). This difference is highly statistically significant (p<0.01). 
Individuals’ SBP measured at baseline is above a normal reading of 140mmHg for 
60.8% of the sample population. A significantly higher share of decedents have a SBP 
above what is regarded as normal (>140mmHg).  
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No significant differences between survivors and decedents could be found for two of 
the health risk and health status measures. The share of the population with a healthy 
cholesterol level (<6.2mmol/L) in both groups is about 54%. Another non-significant 
difference between groups can be found for the proxy measure that was used to capture 
physical activity, i.e. the number of minutes spent each day walking to and from work. In 
both groups, about 74% spent ten minutes or more walking. 
A higher proportion of smokers (66.9%) than non-smokers was found in the entire 
sample population. Significantly more smokers were present in the decedents group 
compared to the survivors group and a significantly higher share of decedents have a 
very low % predicted FEV1 reading (<70%). 
The mean age at study entry was 55.3 years (SD= 5.5) for decedents. Survivors were 
younger when they entered the study with a mean age of 50.7 years (SD= 4.3). 
Survivors were on average ten years older at censoring than decedents at death (84.1 
years [SD=4.4] and 74.2 years [SD=9.3] respectively). This could have been partly 
caused by the fact that survivors were on average five years younger than decedents at 
the time they entered the study. The distribution of age across the seven age categories, 
which are used in regression analyses throughout this chapter, is presented to aid 
interpretation of regression results. The average number of hospital episodes was 
observed to be 6.3 [SD=6.9] for the survivor group and 7.4 [SD=7.5] for the decedent 
group. This difference was found to be highly significant (p<0.01).  
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Table 5-1 Sample characteristics 
 
VARIABLE 
FREQUENCY 
(%) 
Sample 
N=14,860 
(100%) 
FREQUENCY 
(%) 
Decedents 
N= 11,579 
(77.9%) 
FREQUENCY 
(%) 
Survivors 
N=3,281 
(22.1%) 
Differences 
between 
survivors and 
decedents 
(t-test; chi2 
test) 
p-value 
Male 6,840 (46%) 5,711 (49.3%) 1,129 (34.4%)  
Female 8,020 (54%) 5,868 (50.7%) 2,152 (65.6%) p<0.01 
Age category at death < 65 years 1,901 (12.8%) 1,901 (16.4%) 0  
Age category at death 65-69 years 1,655 (11.1%) 1,655 (14.3%) 0  
Age category at death 70-74 years 2,098 (14.1%) 2,098 (18.1%) 0  
Age category at death 75-79 years 2,819 (19%) 2,344 (20.2%) 475 (14.5%)  
Age category at death 80-84 years 3,453 (23.2%) 1,988 (17.2%) 1,465 (44.7%)  
Age category at death 85-89 years 2,033 (13.7%) 1,125 (9.7%) 908 (27.7%)  
Age category at death >= 90 years 901 (6.1%) 468 (4%) 433 (13.2%) Overall p<0.01 
Number of HC users 13,300 (89.5%) 2,929 (89.3%) 10,371(89.6%)  
Number of non-users 1,560 (10.5%) 352 (10.7%) 1,208 (10.4%) p=0.63 
Deprivation Category 1 948 (6.4%) 677 (5.9%) 271 (8.3%)  
Deprivation Category 3 2,008 (13.5%) 1,514 (13.1%) 494 (15.1%)  
Deprivation Category 4 3,234 (21.8%) 2,465 (21.3%) 769 (23.4%)  
Deprivation Category 5 5,381 (36.2%) 4,221 (36.5%) 1,160 (35.4%)  
Deprivation Category 6 2,674 (18.0%) 2,193 (18.9%) 481 (14.7%)  
Deprivation Category 7 615 (4.1%) 509 (4.4%) 106 (3.2%) Overall p<0.01 
BMI <= 25 6,670 (44.9%) 5,103 (44.1%) 1,567 (47.8%)  
BMI > 25 8,190 (55.1%) 6,476 (55.9%) 1,714 (52.2%) p<0.01 
Syst. Blood Pressure <140mmHg 5,824 (39.2%) 4,183 (36.1%) 1,641 (50.0%)  
Syst. Blood Pressure >=140mmHg 9,036 (60.8%) 7,396 (63.9%) 1,640 (50.0%) p<0.01 
Cholesterol < 6.2mmol/L 7,991 (53.8%) 6,219 (53.7%) 1,772 (54.0%)  
Cholesterol > = 6.2mmol/L 6,869 (46.2%) 5,360 (46.3%) 1,509 (46.0%) p=0.76 
Walking >= 10 min 11,058 (74.4%) 8,635 (74.6%) 2,423 (73.9%)  
Walking < 10 min 3,802 (25.6%) 2,944 (25.4%) 858 (26.1%) p=0.41 
Smoker 9,939 (66.9%) 8,130 (70.2%) 1,809 (55.1%)  
Non-Smoker 4,921 (33.1%) 3,449 (29.8%) 1,472 (44.9%) p<0.01  
FEV in 1 sec <70% 2,532 (17.0%) 2,255 (19.5%) 277 (8.4%)  
FEV in 1 sec >= 70% 12,328 (83.0%) 9,324 (80.5%) 3,004 (91.6%) p<0.01 
 
MEAN (SD) MEAN (SD) MEAN (SD) 
 
Age at death or Censoring n/a 74.2 (9.3) 84.1 (4.4) p<0.01 
Age at study entry 54.3 (5.6) 55.3 (5.5) 50.7 (4.3) p<0.01 
Number of Hospital Episodes 6.5 (7.1) 6.3 (6.9) 7.4 (7.5) p<0.01 
*No observations for deprivation category 2 
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5.4 Methods – Inclusion of survivors  
5.4.1 Censoring date  
Under scenario C, the surviving part of the sample is censored at the date when hospital 
use could be observed last (31st December 2007). Their date of death is assumed to be 
at censoring. Consequently, quarters observed before death start on that date and count 
back to the 12th quarter before censoring (death). Each survivor therefore, has exactly 
the same observational period that is declared to be their last 12 quarters of life (1st 
January 2005 until 31st December 2007).  
Estimates from a regression model using this approach are compared with the new 
approach of employing survival analysis (scenario D), which is detailed below. A 
comparison is also made with estimates obtained from the approach of analysing a 
sample of decedents only (scenario A). To complement this analysis and to add to the 
understanding of the impact that different sample scenarios have on estimated costs at 
the end of life, regression results are also obtained for the surviving part of the sample 
only (scenario B).  
5.4.2 Survival analysis to predict additional life time after censoring 
The proposed novel approach in this thesis in order to include survivors in a TTD study 
is based on the projection of remaining lifetime to aid assignment of observed costs to 
the correct period before death. The survival function is denoted as: 
S(t)=1-F(t)         Equation (5.1) 
Where F(t) is the failure function and t is the time elapsed since state 0 (study entry) 
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Survival analysis allows for the survival time to be estimated indirectly via a ‘hazard 
rate’, which reflects the chance of making a transition at each defined time period given 
survival up to that point (Equation 5.2) (Cleves et al, 2008).    
h(t)=f(t)/S(t)         Equation (5.2) 
with f(t) representing the probability density function, the probability of failing at time t 
and S(t) representing the survival function, i.e. the probability of surviving to at least time 
t. 
This analysis uses the density function in survival analysis for that part of the sample 
that is uncensored, i.e. for which failure can be observed, and the survival function for 
that part of the sample that is censored, i.e. for which it is only known that they survived 
until at least time t.  
Regression analysis is undertaken in order to estimate the hazard of failing (dying) using 
a parametric modelling approach. A Gompertz distribution of the hazard of dying is 
assumed. A Gompertz distribution has been used extensively by researchers to model 
mortality data and is suitable for modelling hazard rates that increase or decrease 
exponentially, with the shape parameter ‘gamma’ providing information on whether the 
hazard increases (positive gamma) or decreases (negative gamma) with time (Cleves et 
al, 2008). Alternative distributions were explored (Weibull, exponential), but were not 
found to perform better than a Gompertz distribution. 
Using a Gompertz regression, time until failure (death) is predicted using the following 
covariates: age at study entry, gender, and the socio-economic status (measured on a 
scale from one to seven, using the Carstairs deprivation score) (Carstairs and Morris, 
1991). Age is assumed to be the main predictor for death. Males are known to have a 
shorter life expectancy than females. In Scotland the socio-economic status, amongst 
others, has been shown to be a predictor for life expectancy (Popham et al., 2010).  
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Other variables representing health risks and health status measures that were available 
from the Renfrew/Paisley data, such as smoking status, SBP and BMI were considered 
in exploratory survival analysis. However, given that the survival analysis in this present 
chapter is to inform the method of using survival analysis in order to predict TTD for the 
SLS sample (representative sample of the Scottish population), and these measures are 
not available from the SLS, a decision was made in favour of consistency.  
The coefficients obtained from the Gompertz regression are utilised to calculate the 
linear predictor of time until failure for each surviving participant using their respective 
covariate values. Based on these results the probability of surviving each year after 
study entry can be calculated using the respective survival function for a Gompertz 
distribution (Equation 5.3). This is extended up to t=100 with the probability of survival 
becoming infinitesimal.  
)}1)*(exp()exp(exp{)( 1 −−= − jj ttS γγλ    Equation (5.3)   
Where: jλ = linear predictor; γ = Ancillary or shape parameter; t= time period indicator. 
In order to obtain a value for survivors’ additional predicted years of life, the area under 
the survival curve resulting from the Gompertz regression is calculated for that part of 
the curve that is beyond the censoring date.  
The area under the curve is calculated by applying the trapezoid rule, where the region 
of interest is divided into trapezium shaped segments, with each segment representing 
one year (Equation 5.4). Adding up values for each of the segments beyond censoring 
provides a prediction of the number of additional years of life for survivors.  
)]1[(*2/)]1[( YnYHnHT −+++=       Equation (5.4) 
Where T= trapezoid segment; H=hazard; Y=years after study entry 
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Predicted additional years of life are converted into quarters (i.e. additional quarters of 
life) and added to the observed censored quarters before the end of the study. For 
example, if the predicted remaining life expectancy was four quarters, what was to be 
the last quarter of life when using the censoring date as the death date, becomes the 
fifth quarter before death. This ensures that survivors’ incurred costs are estimated for 
the ‘correct’ quarter before death. Another adjustment that is made is the correction of 
the age at death, which is the sum of the age at censoring plus additional years of life, 
obtained from the application of the trapezoid rule.  
The application of this method means that even though cost observations for survivors 
can be re-classified, there are missing cost observations for the period between 
censoring and predicted death, since there is only information on resource utilisation up 
until the 31st December 2007. This also means that survivors are still effectively right 
censored, however, it allows the surviving part of the sample to be included in the 
analysis with their adjusted remaining quarters before death instead of making the 
assumption that sample members have either died at the censoring date, or have a 
constant TTD.  
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5.5 Results - survival analysis 
Kaplan-Meier survival estimates for males and females are shown in Figure 5.2. The 
probability of survival for males is lower at any given point compared to the probability of 
survival for females. 
 
Figure 5-2 Kaplan-Meier SE by gender 
 
Figure 5.3 shows the Kaplan-Meier survival estimates for different deprivation 
categories. Differences in the probability of survival can be observed with individuals 
living in more affluent areas having a higher probability of survival at any given point in 
time than individuals living in more deprived areas. 
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Figure 5-3 Kaplan-Meier SE by socio-economic status 
 
Regression results for the survival analysis using a Gompertz distribution undertaken for 
the entire sample population to aid prediction of survivors’ TTD are shown in Table 5.2. 
Coefficients are presented as hazard ratios. All explanatory variables for time until 
failure (death) have a highly significant impact and also show the expected sign.  
Table 5-2 Results- Gompertz Regression 
Variable Hazard Ratio Standard Error 
Gender 1.638*** (.031) 
Age at Study Entry 1.100*** (.002) 
Deprivation Category=3 1.172*** (.054) 
Deprivation Category=4 1.226*** (.053) 
Deprivation Category=5 1.314*** (.054) 
Deprivation Category=6 1.148*** (.065) 
Deprivation Category=7 1.733*** (.101) 
Gamma .081*** (.001) 
No. of subjects 14,868  
No. of failures 11,587  
*** p<0.01; Deprivation Category 1 serves as the reference category, no observations for deprivation category 2  
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On average, male individuals show a risk of dying that is 63.8% higher than that of 
female participants. Each additional year of age at study entry increased the risk of 
dying by 10%. Individuals living in more deprived areas compared to the most affluent 
area also have a higher risk of dying with the size of the effect increasing as socio-
economic status decreases. Individuals living in the most deprived areas (deprivation 
category = 7) show a risk of dying that is on average 73.3% higher than the risk of those 
individuals living in the most affluent areas (deprivation category 1). One possible 
explanation might be the issue of access to HC services and a higher risk of mortality for 
less affluent areas could serve as a further explanation (Popham et al., 2010). 
The ancillary parameter ‘gamma’ is positive, confirming an exponentially increasing 
hazard of dying as time progresses. Figure 5.4 shows the resulting survival curve. The 
censoring point is at 33 years, marked by the shaded area representing the average 
follow-up time with recruitment into the study being between 1972 and 1976 and the 
study end being in 2007. 
 
Figure 5-4 Survival curve 
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5.6 Methods- cost estimation 
5.6.1 Descriptive analysis of costs 
Costs are observed on a quarterly level and as a result the distribution of these costs is 
heavily skewed to the right, as can be seen from the histogram of quarterly costs in 
Figure 5.5 below. Survivors are included here and overall it can be observed that most 
quarters do not have a cost observation, i.e. hospitalisation. The histogram is truncated 
at £10,000 in order to facilitate plotting and visualisation of quarterly costs. 
 
Figure 5-5 Histogram of quarterly costs 
 
Initial descriptive exploration of mean costs incurred in each of the 12 quarters before 
death is undertaken for decedents and survivors. Figure 5.6 shows observed quarterly 
costs for the entire sample. Overall, a substantial increase in costs can be observed 
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from about the third quarter before death. This increase becomes most noticeable when 
moving from the penultimate quarter of life to the last quarter of life. Further investigation 
of observed costs towards the end of life is undertaken below using different sample 
scenarios in order to highlight differences in costs. These are shown in Figures 5.7a, 
5.7b, 5.7c and 5.7d, where observed costs for the sample including decedents only 
(scenario A) seem to be higher in the last quarter of life, compared to scenarios C and 
D, which also include survivors. Mean observed quarterly costs for scenario D seem to 
be slightly higher compared to scenario C. Looking at scenario B (Figure 5.7b) it is 
evident that the distribution of costs follows a different pattern when only survivors are 
considered and included with the censoring date as their date of death.  
 
Figure 5-6 Distribution of observed hospital costs (£ sterling, 2006/07 prices) for the entire 
sample 
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Figure 5-7a, b, c, d Observed hospital costs (£ sterling, 2006/2007 prices) for different 
sample scenarios 
 
Descriptive analysis of costs by age groups 
Figures 5.8a, 5.8b, 5.8c, 5.8d to 5.10a, 5.10b, 5.10c, 5.10d show how observed mean 
quarterly hospital costs are distributed over different age groups. Figures 5.8a, 5.8b, 
5.8c and 5.8d show the distribution of costs as an average over all observed quarters for 
the three sample scenarios and also separately for sample members that were observed 
to be alive at the end of the study period. Participants’ age was categorised into seven 
age groups. For sample scenario B (Figure 5.8b) only the four oldest age groups could 
be observed, as by the time the last 12 quarters before censoring are reached, the 
surviving part of the cohort is aged at least 75 years, since the minimum age at study 
entry over 30 years ago was 45 years (see also Table 5.1).  
Overall, the distribution of mean quarterly costs shows costs to be higher for the older 
age groups. This is most pronounced for the sample including decedents only (scenario 
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A) and less pronounced for the two scenarios including survivors as well (scenarios C 
and D). Costs for the eldest group (>=90 years) tend to be lower on average than costs 
for participants aged 85-89 years. When looking at the surviving sample members only 
(Figure 5.8b), however, an increase in costs for individuals aged 90 and older can be 
observed, compared to younger age groups. Costs are on average considerably lower 
for survivors than they are for decedents. When using a sample that includes both 
survivors and decedents (Figures 5.8c and 5.8d) no marked difference in average costs 
can be observed between the two methods of accounting for survivors’ unknown TTD. 
Subsequent figures therefore look at certain quarters before death or censoring to 
investigate differences in more detail. 
 
Figure 5-8a, b, c, d Mean observed hospital costs (£ sterling, 2006/07 prices) by age group 
for different sample scenarios 
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Figures 5.9a, 5.9b, 5.9c and 5.9d show mean quarterly observed costs for the quarter 
furthest away from death or censoring (12th quarter). Again, observed costs increase 
with increasing age and are found to be highest for the oldest age group. The same 
distribution of costs can be observed for all sampling scenarios with the sample 
including decedents only showing higher average costs in the 12th quarter before death 
than the samples including survivors as well as decedents. This could be explained by 
lower observed costs in the sample that includes survivors only (Figure 5.9b). 
 
Figure 5-9a, b, c, d Mean observed hospital costs (£ sterling, 2006/07 prices) by age group 
for different sample scenarios in the 12th quarter before death 
 
 
 
 
Finally, Figures 5.10a, 5.10b, 5.10c and 5.10d show the distribution of mean quarterly 
hospital costs by age group for the last quarter before death/censoring. Costs are 
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substantially higher on average than those 12 quarters away from death/censoring. 
Unlike the distribution of costs that could be observed in the 12th quarter before death or 
the average distribution over all quarters, costs for older individuals tend to be lower in 
the last quarter before death/censoring. This pattern can be observed for all sampling 
scenarios and is more pronounced for sample scenarios C and D (Figures 5.10c and 
5.10d) and less pronounced for the sample that does not include survivors (Figure 
5.10a).  
 
Figure 5-10a, b, c, d Mean observed hospital costs (£ sterling, 2006/07 prices) by age 
group for different sample scenarios in the last quarter before death 
 
Overall, differences in the distribution over age groups between sample scenarios are 
more marked in the last quarter before death/censoring than in the 12th quarter. For the 
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sample containing only decedents (scenario A), costs for participants aged 90 years and 
older are lower than costs for individuals that are aged between 75-89 years (Figure 
5.10a). Costs that are observed for the sample containing only survivors (scenario B) 
are also lower for the three oldest age groups compared to individuals aged 75-79 years 
(Figure 5.10b). Costs for survivors are substantially lower on average than they are for 
the other three samples that include decedents as well as survivors.  
Interestingly, costs for the two samples including survivors and decedents using different 
methods to account for unknown TTD show a different distribution over age groups. 
Costs for the sample including survivors using the censoring date as their date of death 
(Figure 5.10c) are substantially lower for participants aged over 80 years and no marked 
difference can be found between age groups beyond the age of 80. Costs are highest 
for individuals aged between 65 and 79 and lowest for the youngest age group (<65 
years). For the sample including survivors, using a predicted TTD (Figure 5.10d) it can 
be seen that costs also tend to increase up to the age of 75-79 years, however 
compared to the sample in Figure 5.10c, costs then steadily decline beyond the age of 
80 instead of showing no marked difference as seen in Figure 5.10c.     
To summarise these findings, there does not seem to be a marked difference in costs by 
age group that is incurred through the application of different methods to account for 
survivors’ unknown TTD when looking at the quarter furthest away from 
death/censoring. However, there is a substantial difference in the quarter closest to 
death. This is an important finding of how age is associated with costs at the end of life 
from descriptive analysis. The inclusion of survivors seems to alter observed costs for 
the eldest age groups considerably, which might be caused, either by the fact that 
survivors are healthier on average or that these are cared for in different settings, such 
as nursing homes and therefore do not appear in the acute inpatient dataset (SMR01).   
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5.6.2 Econometric modelling- explanatory variables 
Regression models are employed to estimate the probability of utilising acute inpatient 
HC services and related costs conditional on positive utilisation, for the three scenarios 
of accounting for survivors’ unknown TTD outlined earlier in this chapter and the 
comparative scenario where only survivors are included. The following explanatory 
variables have been identified for inclusion to estimate the model in order to assess the 
independent effect that population ageing and TTD have on hospital costs.  
TTD itself was included as a categorical variable, representing each quarter before 
death. A series of 12 quarter dummy variables represent the quarter in which an 
individual’s incurred costs were observed with the quarter furthest away from death (12th 
quarter) serving as the reference category.   
Age at death was measured in seven categories (<65 years, 65-69, 70-74, 75-79, 80-84, 
85-89, 90 years and over) with the youngest age group serving as the reference 
category. Interactions between TTD in quarters and age at death categories were 
included to capture any combined effect of ageing and TTD on HC costs. This has been 
well documented in the literature (Stearns and Norton, 2004, Moorin and Holman, 2008). 
Gender was included to account for any differences in costs incurred by male and 
female participants. Such differences may be due to gender specific differences in 
morbidities and/or necessary treatment.14  
A series of health status and health risk indicators were included. These were % 
predicted FEV1 (<70%); SBP (>140 mmHg); the cholesterol level (>= 6.2mmol/L); the 
BMI (>25); a measure of the time individuals spend each day walking to and from work 
as a proxy for physical activity (<10 minutes); and the smoking status (smoker, i.e. 1 or 
more cigarettes or pipe/cigars per day).   
                                               
14 Please note that maternity hospitals and the specialty of obstetrics are not part of SMR01 
Chapter 5  155 
 
 
The Carstairs deprivation score, with category 1 representing the most affluent postcode 
sectors (reference category) and category 7 the most deprived, was included to account 
for differences in costs incurred by socio-economic status.15 The period of admission in 
which each quarter before death lies, accounts for advances in medical technology over 
time. This variable is represented in four categories (time1: 1980-1986, time2: 1987-
1993, time3: 1994-2000, time4: 2001-2007), with the most historic period serving as the 
reference category. Finally, for the model including survivors with the censoring date as 
their date of death, an additional variable is added, which indicates whether sample 
members were alive at the end of the study period (Dead=0) or whether death could be 
observed before the 31st December 2007 (Dead=1). This is to control for survivor status 
and has been conventionally applied in the literature that has used this censoring 
method to include survivors. 
5.6.3 Model structure 
The underlying assumption for the model is that the expected value of HC expenditure is 
a function of these explanatory variables detailed above. A two-part model is employed 
rather than a Heckman sample selection model. This was discussed in Chapter 3, a two-
part model is more appropriate when zero costs (quarters without hospitalisations) are 
observed rather than unobserved.  
The first modelling part employs a probit link and a binomial distribution to estimate the 
probability of utilising hospital care in any given quarter before death conditional on a set 
of regressors X (Equation 5.5). 
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          Equation (5.5) 
                                               
15
 Note that the data set included no postcode areas classified as being in deprivation category 2. 
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Where: A is age at death categories; S represents gender; H is a vector of health status 
and health risk indicators; Q is the remaining quarters of life (such that Q*A is the 
interaction of TTD and age); Y a time period dummy indicating the quarter before death 
into which the admission to hospital falls; and D a dummy for deprivation category16, ui 
represents robust standard errors. 
From the second part of the model estimates of HC expenditure are obtained, 
conditional on HCE being greater than zero and conditional on the same set of 
regressors X (Equation 5.6).  
E [HCE] = g (xβ)                                      Equation (5.6) 
with xβ representing the linear predictor for HC expenditure (HCE). 
Quarterly HC expenditure is estimated fitting a GLM clustered on patient identifier. GLM 
as an extension of OLS has the advantage of being able to specify a link function, which 
allows transformation of the mean of regressors rather than the mean of the cost 
variable and therefore mitigates cumbersome re-transformation of cost estimates.  
Following conventions for determining the appropriate distribution and link function, 
diagnostic tests were performed using a user written programme (Glick, 2008), which 
conducts the modified Park test, the Pearson correlation test, the Pregibon link test and 
the modified Hosmer and Lemeshow test simultaneously. Details of these goodness of 
fit tests were described in Section 4.3.3.  
Predicted probabilities of positive HC utilisation, obtained from the first part of the model 
are multiplied with cost estimates from the second part of the model in order to derive 
average cost estimates conditional on having incurred positive HC expenditure 
(Equation 5.7).  
                                               
16
 For sample scenario b), using survivors’ censoring date as their date of death an additional 
variable ‘L’ was included, indicating whether an individual is dead or alive at the end of study. 
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E (HCE | X) = Pr (HCE>0 | X) * E (HCE | HCE>0, X)   Equation (5.7) 
Coefficients obtained from the GLM modelling part are on a log scale and are presented 
as cost ratios in order to facilitate interpretation of results relating to the original 
monetary scale. 
These estimates are used to compare differences in mean costs by admission quarter 
before death when estimating the three different modelling scenarios. Scenarios use the 
same regressors but differ in sample size due to the exclusion of survivors and the 
unbalanced nature of the panel when predicting survivors’ TTD and adjusting observed 
quarters before death. Four two-part models are estimated in order to facilitate 
comparison of differences in mean cost estimates that result from the 
inclusion/exclusion of survivors.  
 
5.7 Results- econometric modelling 
5.7.1 Probability of hospital utilisation 
The first part of the model estimated the probability of accessing hospital care in any 
given quarter before death as outlined in Equation 5.5. Table 5.3 presents results for the 
probit model. Columns (1) and (2) in Table 5.3 show results for the sample based on 
decedents (scenario A), columns (3) and (4) show results for survivors only (scenario B), 
columns (5) and (6) show results for decedents and survivors, using the censoring date 
as the date of death (scenario C), and columns (7) and (8) show results for decedents 
and survivors, using the predicted date of death for survivors – obtained through survival 
analysis and extrapolation (scenario D).  
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Table 5-3 Regression Results: Probability of Hospital Utilisation 
 
DECEDENTS 
N=127,982 (11,579) 
SURVIVORS 
N=38,910 (3,281) 
SURVIVORS- 
CENSORED 
N= 166,892 (14,860) 
SURVIVORS-
PREDICTED 
N=141,420 (13,686) 
Scenario A B C D 
Column (1) (2) (3) (4) (5) (6) (7) (8) 
Variable β SE β SE β SE β SE 
TTD=1 1.821*** (0.114) 0.140 (0.114) 1.819*** (0.114) 1.820*** (0.114) 
TTD=2 0.802*** (0.120) 0.064 (0.112) 0.802*** (0.120) 0.802*** (0.119) 
TTD=3 0.631*** (0.123) 0.126 (0.108) 0.629*** (0.123) 0.631*** (0.123) 
TTD=4 0.512*** (0.123) 0.108 (0.113) 0.511*** (0.123) 0.511*** (0.122) 
TTD=5 0.277* (0.122) 0.222* (0.110) 0.276* (0.122) 0.276** (0.122) 
TTD=6 0.417*** (0.132) 0.162 (0.111) 0.415*** (0.128) 0.416*** (0.128) 
TTD=7 0.271* (0.126) 0.023 (0.112) 0.269* (0.125) 0.270* (0.126) 
TTD=8 0.016 (0.134) 0.113 (0.115) 0.014 (0.145) 0.015 (0.145) 
TTD=9 0.211 (0.140) 0.163 (0.114) 0.210 (0.140) 0.210 (0.139) 
TTD=10 0.127 (0.134) 0.047 (0.112) 0.127 (0.134) 0.127 (0.134) 
TTD=11 0.137 (0.122) -0.028 (0.115) 0.137 (0.122) 0.137 (0.122) 
Age at death 65-69= (2) 0.197 (0.133) ~  0.196 (0.133) 0.195 (0.133) 
Age 70-74= (3) 0.247** (0.123) ~  0.245** (0.123) 0.243* (0.123) 
Age 75-79=(4) 0.313*** (0.120) ~  0.349*** (0.119) 0.313** (0.119) 
Age 80-84=(5) 0.348*** (0.121) 0.049 (0.097) 0.440*** (0.118) 0.355*** (0.118) 
Age 85-89=(6) 0.381*** (0.125) 0.145 (0.103) 0.502*** (0.120) 0.286*** (0.119) 
Age > 90= (7) 0.318** (0.140) 0.133 (0.120) 0.467*** (0.129) 0.419*** (0.128) 
TTD x Age1 Figure  5.12a Figure  5.12b Figure  5.12c Figure  5.12d 
Male 0.018 (0.016) 0.035 (0.029) 0.024* (0.014) 0.003 (0.015) 
Deprivation Category=3 0.102*** (0.036) -0.080 (0.052) 0.045 (0.029) 0.082** (0.015) 
Deprivation Category=4 0.100*** (0.033) -0.047 (0.047) 0.052* (0.027) 0.078** (0.031) 
Deprivation Category=5 0.113*** (0.032) -0.002 (0.045) 0.073*** (0.026) 0.088*** (0.030) 
Deprivation Category=6 0.079** (0.034) -0.100* (0.053) 0.027 (0.028) 0.054* (0.032) 
Deprivation Category=7 0.099** (0.044) -0.172** (0.082) 0.028 (0.038) 0.064 (0.041) 
Smoker 0.066*** (0.017) 0.058** (0.026) 0.0610*** (0.014) 0.069*** (0.016) 
BMI <=25 -0.059*** (0.015) -0.081*** (0.025) -0.064*** (0.013) -0.064*** (0.014) 
SBP <=140mmHg 0.065*** (0.015) 0.051** (0.026) 0.058*** (0.013) 0.058*** (0.014) 
FEV1 <70% -0.021 (0.019) -0.014 (0.046) -0.017 (0.017) -0.014 (0.018) 
Walking >=10 min 0.003 (0.017) -0.053* (0.031) -0.011 (0.015) 0.003 (0.016) 
Cholesterol <6.2mmol/L 0.039*** (0.015) 0.020 (0.026) 0.034*** (0.013) 0.037** (0.015) 
Time period= 1985-1992 0.561*** (0.027) ~  0.562*** (0.027) 0.561*** (0.027) 
Time period=1993-2000 0.866*** (0.031) ~  0.868*** (0.030) 0.875*** (0.031) 
Time period=2001-2007 0.988*** (0.034) ~  0.998*** (0.033) 0.854*** (0.034) 
Dead=1 n/a n/a n/a  0.413*** (0.018) n/a n/a 
Constant -2.724*** (0.115) -1.404*** 
 
(0.099) 
 
-3.073*** (0.114) -2.690** (0.113) 
LR Test (TTD*Age) p<0.001  p<0.001  p<0.001  p<0.001  
*** p<0.01; **p<0.05, *p<0.1; Robust standard errors in parentheses; Deprivation category 1 (most affluent) serves as the 
reference category; Age category 1 (<65) serves as the reference category; TTD=12 serves as the reference category; ~ 
age categories 1 to 3: no observations, age category 4 (75-79) serves as the reference category and all admissions fall 
into the period 2001-2007; 1 Estimates for TTD and Age interactions can be found Appendix IV. 
 
 
Chapter 5  159 
 
 
Generally, the TTD results are not substantially different in terms of the size of the effect 
and statistical significance between scenarios A, C and D. Overall, the probability of 
being admitted to hospital increases significantly as people approach death. Results for 
scenario B however are very different compared with the remaining scenarios. No 
significant effect of TTD (time to censoring) on the probability of accessing hospital 
services can be observed for this sample. Figures 5.11a, 5.11b, 5.11c and 5.11d show 
the estimated probability of being hospitalised for all four sample scenarios in their last 
12 quarters before death or censoring. For scenarios A, C and D an exponential 
increase of the probability of accessing hospital care can be observed from the 
penultimate to the last quarter of life. The sample including decedents only (Figure 
5.11a) has a higher probability of accessing HC in their last two quarters of life than the 
samples including survivors as well as decedents (Figures 5.11c and 5.11d). For 
scenario B (Figure 5.11b) no increase in the probability of being admitted to hospital as 
the censoring date approaches can be observed.  
 
Figure 5-11a, b, c, d Estimated probability of utilising hospital care 
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The age effects presented in Table 5.3 relate to the 12th quarter before death. Because 
of the included interaction terms, age is allowed to have a different effect on costs in 
each quarter before death (Figures 5.12a, 5.12b, 5.12c and 5.12d). An increased 
probability of accessing hospital care can be observed for individuals aged 70 and older 
compared to the youngest age group (<65 years) in the sample that includes decedents 
only (columns (1) and (2)). A similar effect can be found for the samples that include 
both, decedents and survivors but with a generally increased size of the effect, which is 
even more pronounced for the sample that uses the censoring date as the date of death 
for survivors (columns (5) and (6)). No significant effect of age on the probability of being 
admitted to hospital is found for sample scenario B (columns (3) and (4)). 
The model that excludes survivors (columns (1) and (2)) shows that individuals from 
deprivation categories 3, 4, 5, 6, and 7 are significantly more likely to be admitted to 
hospital compared to individuals from the most affluent category 1. This significant effect 
disappears for the two most deprived categories (6 and 7) in the models that include 
survivors, while for the remaining deprivation categories the size of the effect decreases. 
For modelling scenario B (survivors only) a significant, but negative association is found 
between deprivation categories 6 and 7 and the probability of accessing hospital 
services. Individuals from more deprived areas seem to be less likely to be admitted to 
hospital than individuals from the most affluent postcode areas.  
The coefficient estimates for health status baseline measures reveal that: smokers have 
a significantly higher probability of being admitted to hospital compared with non-
smokers. This effect can be observed across all sample scenarios. Individuals with a 
BMI below 25 are less likely to access hospital care than people with a BMI above 25. 
Again this negative association is observed for all samples, with the sample including 
survivors only (scenario B) showing the strongest effect.  
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Individuals with a normal SBP (<=140mmHg) are significantly more likely to access 
hospital care than people with an SBP of over 140mmHg and individuals with a 
cholesterol level below 6.2mmol/L are significantly more likely to access hospital 
services than people with a level over 6.2mmol/L. Although statistically significant, the 
size of the effect for these two health status measures is found to be very small and it 
has to be noted that the cut-off chosen for these binary variables could have also 
impacted on results.  
No statistically significant association could be found between the probability of being 
admitted to hospital and the % predicted FEV1, and walking to and from work for more 
than ten minutes per day for scenarios A, C and D. ‘Walking’ is marginally statistically 
significant for scenario B and shows a negative association with the probability of being 
admitted to hospital, but the effect is very small. The period of admission shows an 
increased probability for the more recent periods compared with the most historic period 
(1980-1986). Overall, the results for baseline health indicators and periods are very 
similar across all sample scenarios, although there are some differences in the 
magnitude of the coefficients. 
For the sample that includes survivors with the censoring date as their date of death 
(columns (5) and (6)) an indicator variable was added to account for the fact that people 
were still alive at the end of the study period (Dead=1). Individuals, whose death was 
observed, showed a higher probability of accessing hospital services than survivors. 
Detailed coefficients from the probit model, showing the interaction terms between age 
and TTD (relative to the youngest age group and the 12th quarter before death) are 
presented in Appendix IV. Coefficients for interaction terms between age and TTD, 
varying the reference category for age, are shown graphically in Figures 5.12a, 5.12b, 
5.12c and 5.12d. These are presented relative to the 12th quarter before death. A 
steeper gradient is observed for the younger age groups, especially in the last quarters 
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of life. This is especially apparent in the two scenarios that include decedents and 
survivors (Figures 5.12c and 5.12d). Interactions can particularly be observed in Figure 
5.12c using the censoring date as date of death for survivors, for the last two quarters of 
life and also in Figure 5.12d, where TTD was predicted. Sample scenario B (Figure 
5.12b) also shows some interactions between age and TTD, or in this case time to 
censoring. For the sample including decedents only (Figure 5.12a) almost no interaction 
effects can be found in the last two quarters of life as shown through the parallel lines. A 
conclusion that could be drawn from these figures is that decedents represent a very 
homogenous group and that differences in the effect that TTD has in different age 
groups on the probability of being admitted to hospital are mainly driven by the surviving 
part of the sample. 
 
Figure 5-12a, b, c, d Coefficients for probability of hospitalisation by admission quarter: 
TTD and age interaction terms 
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5.7.2 Cost estimates 
Regression results for the second part of the model, estimating costs given positive HC 
utilisation, are presented in Table 5.4, columns (1) to (8), again for all sample scenarios. 
These results are estimates obtained from Equation 5.6 above, so they are conditional 
on having incurred positive costs. Inverse Gaussian is the recommended distributional 
family and log has been recommended as the appropriate link function (results for 
goodness of fit tests are shown in Appendix VI). 
Costs are significantly higher in the last eight quarters of life compared with the 12th 
quarter before death (serving as the reference category), as shown by the indicator 
variables, representing the quarter before death. This association is found for sample 
scenarios A (columns (1) and (2)), C (columns (5) and (6)) and D (columns (7) and (8)). 
The size of the effect decreases the further away from death individuals are, up until the 
fifth quarter before death, after which an increase is observed up until the eighth quarter 
before death. From the ninth quarter before death a decrease in costs is found, but this 
association is not statistically significant. For sample scenario B (columns (3) and (4)) a 
significant association between costs and the quarter before censoring is only found for 
TTD=1 and TTD=10, where estimated costs are significantly higher than in the 12th 
quarter before censoring. 
Age at death is a significant predictor of mean quarterly costs for sample scenarios A, C 
and D, apart from the second youngest age group (65-69). The age effects relate to the 
12th quarter before death or censoring. Some of the interaction terms between TTD and 
age show a statistically significant association with costs (regression results are 
presented in Appendix V), i.e. the effect on costs of being in a particular quarter before 
death compared to the 12th quarter also depends on age. Interaction terms show a 
statistically significant association with costs especially for the older age groups and up 
until the eighth quarter before death.  
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Table 5-4 Regression Results 2nd part – Cost Estimates 
 
DECEDENTS 
N=13,855 (6,762) 
SURVIVORS 
N=3,496 (1,798) 
SURVIVORS- 
CENSORED 
N= 17,351 (8,560) 
SURVIVORS-
PREDICTED 
N=15,052 (13,686) 
Scenario A B C D 
Column (1) (2) (3) (4) (5) (6) (7) (8) 
Variable Cost 
Ratio 
SE Cost 
Ratio 
SE Cost 
Ratio 
SE Cost 
Ratio 
SE 
TTD=1 2.021*** (0.143) 1.730*** (0.209) 2.031*** (0.143) 2.027*** (0.144) 
TTD=2 1.957*** (0.180) 1.090 (0.203) 1.975*** (0.180) 1.973*** (0.180) 
TTD=3 1.757*** (0.221) 1.249 (0.191) 1.763*** (0.218) 1.757*** (0.218) 
TTD=4 1.792*** (0.182) 1.202 (0.244) 1.815*** (0.183) 1.809*** (0.183) 
TTD=5 1.588** (0.236) 1.119 (0.191) 1.639** (0.245) 1.604** (0.239) 
TTD=6 2.041*** (0.239) 1.050 (0.209) 2.070*** (0.237) 2.064*** (0.239) 
TTD=7 3.189** (0.567) 1.047 (0.165) 3.228** (0.570) 3.188** (0.567) 
TTD=8 2.693** (0.428) 1.175 (0.200) 2.671** (0.419) 2.684** (0.425) 
TTD=9 1.367 (0.224) 1.213 (0.190) 1.374 (0.223) 1.376 (0.225) 
TTD=10 0.940 (0.189) 1.746*** (0.200) 0.944 (0.186) 0.942 (0.187) 
TTD=11 1.136 (0.222) 1.168 (0.184) 1.116 (0.212) 1.124 (0.218) 
Age at death 65-69= (2) 0.890 (0.174) ~  0.887 (0.172) 0.889 (0.174) 
Age 70-74= (3) 1.578** (0.196) ~  1.577** (0.193) 1.571** (0.196) 
Age 75-79=(4) 1.912*** (0.176) ~  1.893*** (0.167) 1.955*** (0.179) 
Age 80-84=(5) 1.989*** (0.165) 1.031 (0.162) 1.921*** (0.153) 1.963*** (0.158) 
Age 85-89=(6) 2.134*** (0.167) 1.200 (0.168) 2.147*** (0.156) 1.836*** (0.160) 
Age > 90= (7) 2.231*** (0.215) 1.698* (0.300) 2.601*** (0.212) 2.487*** (0.242) 
TTD x Age1 Figure  5.13a Figure 5.13b Figure  5.13c Figure  5.13d 
Male 0.858*** (0.024) 0.882*** (0.041) 0.868*** (0.021) 0.849*** (0.023) 
Deprivation Category=3 0.894* (0.066) 0.975 (0.092) 0.914 (0.057) 0.913 (0.062) 
Deprivation Category=4 0.912 (0.064) 0.974 (0.082) 0.923 (0.054) 0.915 (0.059) 
Deprivation Category=5 0.942 (0.063) 0.960 (0.079) 0.937 (0.053) 0.944 (0.058) 
Deprivation Category=6 1.028 (0.067) 0.941 (0.094) 1.009 (0.056) 1.009 (0.062) 
Deprivation Category=7 0.937 (0.078) 1.178 (0.132) 0.978 (0.069) 0.940 (0.073) 
Smoker 0.923*** (0.027) 0.944 (0.041) 0.928*** (0.023) 0.935*** (0.025) 
BMI <=25 0.997 (0.023) 0.961 (0.038) 0.987 (0.020) 0.986 (0.022) 
SBP <=140mmHg 0.946** (0.022) 1.003 (0.039) 0.969 (0.020) 0.953** (0.021) 
FEV1 <70% 1.084** (0.034) 0.909 (0.063) 1.051 (0.031) 1.084** (0.033) 
Walking >=10 min 0.985 (0.026) 0.996 (0.044) 0.991 (0.023) 0.998 (0.024) 
Cholesterol <6.2mmol/L 1.025 (0.022) 1.002 (0.038) 1.013 (0.020) 1.014 (0.021) 
Time period= 1985-1992 0.880** (0.051) ~  0.877* (0.052) 0.880** (0.052) 
Time Period=1993-2000 0.724*** (0.054) ~  0.721*** (0.055) 0.724*** (0.055) 
Time Period=2001-2007 0.710*** (0.057) ~  0.706*** (0.058) 0.685*** (0.057) 
Dead=1 n/a  n/a  1.348*** 
 
(0.028) n/a  
Constant 1897*** 
 
(0.159) 
 
1677 
 
(0.171) 
 
1383*** 
 
(0.158) 
 
1877*** (0.158) 
 LR Test (TTD*Age) p<0.001  p<0.001  p<0.001  p<0.001  
*** p<0.01; **p<0.05, *p<0.1; Robust standard errors in parentheses; Deprivation category 1 (most affluent) serves as the 
reference category; Age category 1 (<65) serves as the reference category; TTD=12 serves as the reference category, ~ 
age categories 1 to 3: no observations, age category 4 (75-79) serves as the reference category and all admissions fall 
into the period 2001-2007 
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A marginally statistically significant association of age with costs is found for scenario B, 
where only the eldest seem to incur higher costs compared to the age group aged 70-
74. These results are very different and it has to be noted again, that this sample does 
not include decedents and the reference group is different from the one used for the 
other three sample scenarios. 
Figures 5.13a, 5.13b, 5.13c and 5.13d show interaction effects for each age group 
plotted against the admission quarter before death relative to the 12th quarter. On 
average, the two youngest age groups seem to incur higher costs in their last 11 
quarters of life compared with the 12th quarter and also compared with the last 11 
quarters of life of all other, older age groups. For sample scenarios A, C and D 
increasing costs can be observed for the last three quarters of life, compared with the 
12th quarter before deaths for all age categories. Costs in the last quarters of life seem to 
be much more influenced by age if individuals are younger, as can be seen from the 
blue and red line in the graphs, which show a much more unparallel pattern than the 
lines representing the interactions between TTD and age for the older ages. Also, costs 
seem to be higher for the younger age groups. For the four oldest age groups, beyond 
the age of 75, interaction effects are less pronounced and show a similar pattern across 
all sample scenarios. 
On average, male individuals incur significantly less costs than females (~14%). This 
effect can be observed in all four modelling scenarios. The effect that the socio-
economic status has on costs, given positive utilisation is very small. Interestingly, it also 
does not seem to have a significant association with costs incurred, which can be 
observed across all four sample scenarios. The significant effect of deprivation category 
on the probability of hospitalisation that was observed earlier (Table 5.3) for scenario A 
(decedents), was found to disappear for the two most deprived post code areas when 
survivors (scenarios C and D) were included in the regression (while the magnitude of 
the coefficients on the other deprivation categories was reduced); this may mean that 
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any effect of socio-economic status might be spurious, which seems to be confirmed by 
the results obtained from this second part of the regression model, where no effect of 
deprivation could be observed. 
Once hospitalised, the deprivation effect for those in categories 3, 4 and 5 disappears 
entirely, so while these individuals might be more likely to be admitted to hospital, they 
do not consequently incur higher costs. The significant association for the two most 
deprived categories regarding the probability of accessing hospital care for the 
‘decedent sample’, which subsequently disappears when survivors are included may be 
caused by the higher socio-economic status in the survivor group (see Table 5.1). An 
alternative explanation may lie in the method of deriving the cost variable. People from 
more deprived areas are known to have longer stays in hospital, often due to a lack of 
available care in their own homes. Any deprivation category effect that might be present 
could have been modified by the fact that LOS plays a role when assigning costs using 
the HRG-Grouper software. This is an issue that could be explored in future research 
that could investigate the effect that different costing methods have on costs incurred at 
the end of life. 
Smokers seem to incur less costs on average than non-smokers (~7%), although this 
association can only be found in sample scenarios A, C and D. The effect of the BMI is 
found to be very small and not statistically significant across sample scenarios. An SBP 
of below 140mmHg at baseline leads to a significant reduction in costs by about 5% for 
scenarios A and D, whereas a % predicted FEV below 70% leads to a significant 
increase in costs in these two sampling scenarios (~8%). No significant effect can be 
found for the health status indicator of walking to and from work for more than ten 
minutes a day. 
The period of admission shows a negative association with costs, with costs being on 
average about 30% percent lower for the two most recent periods compared with 
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admissions between the years 1980-1986. Again, a similar effect can be observed for 
sample scenarios A, C and D. Since for sample scenario B all admissions in the last 12 
quarters before censoring were observed to be in the most recent period, this variable 
was omitted from regression analysis. The indicator variable to control for survivor status 
in columns (5) and (6) reveals that deceased individuals incurred significantly higher 
costs than surviving sample members in sample scenario C. 
 
 
Figure 5-13a, b, c, d Cost estimates (ratios) by admission quarter: TTD and age interaction 
terms 
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5.7.3 Comparison of quarterly costs  
Table 5.5 compares quarterly costs estimates for all modelling scenarios. These are 
predicted costs that were calculated from Equation 5.7, which multiplied the first 
modelling part (probability of accessing hospital services) with the second modelling part 
(cost estimates, given positive utilisation). Differences in costs can especially be 
observed in the last quarter before death, where estimates range from £1,179 (SD=429) 
for the sample including decedents and survivors (using the censoring date as their date 
of death; scenario C) to £1,670 (SD=469) for a sample which excludes survivors 
(scenario A). It has to be noted though that there might be some bias in results, since 
the samples are not independent from each other. For sample scenario B (survivors 
only) very low costs are observed in the quarter closest to censoring (£184; SD=62).  
Costs show a sharp decrease when moving from the last quarter of life to the 
penultimate quarter of life for scenarios A, C and D. Overall, differences in costs 
between groups become less marked the further away from death an individual is. 
However, given interaction effects between TTD and age, these estimates are also 
influenced by age. Figure 5.14 shows these effects for all age groups for the last four 
quarters before death or censoring. Cost predictions can so be compared across sample 
scenarios and across age groups. In particular for the last quarter of life differences in 
costs by age group can be observed between sample scenarios. For the sample 
including decedents only (scenario A) slightly higher costs for the older ages are 
observed compared to the two scenarios that also include surviving sample members, 
where costs for the older ages seem to be lower in the last quarter of life compared with 
the younger sample members. A difference in costs is also found between scenario C 
and D, with the sample predicting the remaining TTD producing higher cost estimates in 
the last quarter of life across all ages, but in particular for the three oldest age groups.  
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Table 5-5 Mean Hospital Costs in GBP (2006/07 prices) 
 
DECEDENTS SURVIVORS SURVIVORS 
CENSORED 
SURVIVORS 
PREDICTED 
Scenario A B C D 
TTD Mean  SD Mean  SD Mean     SD Mean     SD 
1 1,670 469 184 62 1,179 429 1,658 462 
2 463 223 156 57 386 190 456 212 
3 296 163 163 28 261 147 289 154 
4 233 137 183 43 233 141 233 126 
5 193 111 183 34 200 122 196 107 
6 196 111 154 22 192 111 191 95 
7 173 122 145 39 179 124 173 105 
8 168 108 151 24 168 108 170 97 
9 150 90 174 27 166 105 153 81 
10 156 118 177 38 161 117 160 105 
11 129 99 145 45 148 117 133 87 
12 119 92 127 38 130 102 129 87 
Chapter 5     
 
 
170 
0
200
400
600
800
1000
1200
1400
1600
1800
2000
<65 65-69 70-74 75-79 80-84 85-89 >=90 <65 65-69 70-74 75-79 80-84 85-89 >=90 <65 65-69 70-74 75-79 80-84 85-89 >=90 <65 65-69 70-74 75-79 80-84 85-89 >=90
Q4
Q3
Q2
Q1
Decedents Survivors only Survivors-censored 
TTD
Survivors-predicted TTD
 
Figure 5-14 Interactions between TTD and age for the last four quarters before death
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5.8 Validation of the survival analysis approach 
Given the very long period for which sample members of the Renfrew/Paisley study 
were observed for, it is possible to validate the method of applying survival analysis to 
predict TTD for survivors and further test how accurately this would predict costs at the 
end of life. The rationale behind this is to apply an earlier censoring date than the 31st 
December 2007, thus right censor observations artificially.  
5.8.1 Methods - early censoring 
The new ‘artificial’ censoring date chosen for this example is the 31st December 2000. 
Any ‘real’ survivors, i.e. individuals, who had not died by the 31st December 2007, were 
discarded from the analysis of this validation approach. At the end of the year 2000, 
there were 24% survivors and 76% decedents. For all participants who survived until the 
end of December 2000, a date of death could subsequently be observed. These were 
individuals who died between the 1st January 2001 and the 31st December 2007.  
This experiment is to show what the estimated costs would be in the last 12 quarters of 
life if these were predicted from survival analysis for those sample members that were 
observed to be alive on the 31st December 2000. These cost estimates are then 
compared with cost estimates obtained using survivors’ observed date of death after the 
31st December 2000 and before the 31st December 2007 (akin to scenario A). A 
comparison of cost estimates from both approaches provides an estimate of the 
magnitude by which costs at the end of life might be over-or under-estimated if survival 
analysis is used to predict remaining TTD compared to having perfect information of the 
actual TTD. 
Following the methods outlined in Section 5.4.2, a Gompertz regression is employed, 
using the earlier censoring date and the same set of regressors. The Kaplan-Meier 
survival estimate for this sub-sample is shown in Figure 5.15.  
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Figure 5-15 Kaplan-Meier SE- early censoring 
 
Coefficients obtained from the Gompertz regression are used to calculate the linear 
predictor of time until failure for each surviving participant. Again, the interest lies in 
calculating the area under the survival curve resulting from the Gompertz regression for 
that part of the curve that is beyond the new censoring date (>29 years in Figure 5.16 
below). By applying the trapezoid rule and adding up values for each segment that is 
beyond the censoring date, additional predicted years of life are calculated for survivors 
(that is survivors on the 31st December 2000). These are then converted into additional 
days and added to the censoring date. The resulting date constitutes the predicted date 
of death and TTD is calculated counting 12 quarters backwards. Cost observations are 
adjusted accordingly. 
Following this procedure, the two-part model which had been described in detail in 
Section 5.6.3 is run first for the entire sample using the predicted date of death for the 
surviving part of the sample (that is alive on 31st December 2000) and a second time, for 
the same sample using the observed date of death for those alive on the 31st December 
2000. Estimates from the first (see Equation 5.5) and the second (see Equation 5.6) 
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modelling part are multiplied and the resultant predicted costs (see Equation 5.7), given 
positive utilisation are compared for the two different approaches of including survivors’ 
TTD. 
5.8.2 Results - early censoring 
This analysis was undertaken as a sensitivity test for the method using survival analysis 
to account for survivors’ unknown TTD. Results for the survival analysis using an earlier 
censoring date, as outlined above, are presented in Table 5.6.  
Table 5-6 Results- Gompertz Regression- early censoring  
Variable Hazard Ratio Standard Error 
Gender 1.491*** (0.032) 
Age at Study Entry 1.054*** (0.002) 
Deprivation Category=3 1.111** (0.060) 
Deprivation Category=4 1.133*** (0.058) 
Deprivation Category=5 1.214*** (0.059) 
Deprivation Category=6 1.339*** (0.068) 
Deprivation Category=7 1.494*** (0.100) 
Gamma 0.100***  
No. of subjects 11,587  
No. of failures 8,802  
*** p<0.01; Deprivation Category 1 serves as the reference category, no observations for deprivation 
category 2 
Regression results are presented as hazard ratios. Male individuals show a higher risk 
of dying. Each additional year of age at study entry increases the risk of dying by about 
5%. Individuals’ socio-economic status also has a significant impact on the risk of dying. 
Study participants from more deprived areas show an increased risk compared to those 
living in the most affluent areas. The size of the effect increases as deprivation 
increases. The positive shape parameter gamma determines an exponentially 
increasing hazard of dying as time progresses. The resulting survival function following 
the Gompertz regression is presented in Figure 5.16. 
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Figure 5-16 Survival curve- early censoring 
 
Regression results for both approaches and for both modelling parts are presented in 
Table 5.7. Columns (1) and (2) show results for the probability of being admitted to 
hospital when using survival analysis to predict TTD and columns (3) and (4) present 
probabilities for the same sample, but using observed rather than predicted TTD. 
Columns (5) and (6) show cost ratios for the second part of the model using predicted 
TTD and in columns (7) and (8) these cost ratios are presented using the observed TTD. 
Probability estimates obtained from the two approaches are very similar for almost all 
explanatory variables and show the same statistical significance. One exception is 
gender which is positive for males and significant at a 5% level in the model that uses 
the predicted TTD (columns (1) and (2)), but seems to lose its significance when the 
observed TTD is used (columns (3) and (4)). Other differences can be found for the 
second oldest age group, where the size and statistical significance of the effect on 
costs seems to depend on the approach that is being employed to measure TTD. 
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Table 5-7 Regression results- early censoring 
 
PREDICTED TTD 
Probability 
Estimates 
N= 129,149 
(11,551) 
OBSERVED TTD 
Probability 
Estimates 
N= 129,149 
(11,551) 
PREDICTED TTD 
Cost Ratios 
N= 13,588 (6,780) 
OBSERVED TTD 
Cost Ratios 
N= 13,588 (6,780) 
Column (1) (2) (3) (4) (5) (6) (7) (8) 
Variable β SE β SE Cost 
Ratio 
SE Cost 
Ratio 
SE 
TTD=1 1.946*** (0.066) 1.947*** (0.066) 2.074*** (0.142) 2.038*** (0.136) 
TTD=2 0.963*** (0.068) 0.963*** (0.068) 2.071*** (0.183) 2.041*** (0.176) 
TTD=3 0.724*** (0.066) 0.724*** (0.066) 1.921*** (0.228) 1.925*** (0.222) 
TTD=4 0.578*** (0.069) 0.578*** (0.069) 1.874*** (0.193) 1.890*** (0.190) 
TTD=5 0.369*** (0.071) 0.369*** (0.071) 1.776** (0.260) 1.791** (0.269) 
TTD=6 0.407*** (0.071) 0.407*** (0.071) 1.511** (0.183) 1.495** (0.172) 
TTD=7 0.305*** (0.075) 0.305*** (0.075) 2.974** (0.556) 2.841* (0.561) 
TTD=8 0.246*** (0.075) 0.246*** (0.075) 2.303** (0.355) 2.245** (0.345) 
TTD=9 0.202*** (0.075) 0.202*** (0.075) 1.156 (0.211) 1.142 (0.204) 
TTD=10 0.128* (0.075) 0.128* (0.075) 0.908 (0.180) 0.879 (0.175) 
TTD=11 0.140* (0.073) 0.139* (0.073) 1.044 (0.184) 0.990 (0.171) 
Age at death 65-69=(2) 0.128 (0.080) 0.129 (0.080) 0.911 (0.183) 0.898 (0.174) 
Age 70-74=(3) 0.169** (0.075) 0.169** (0.075) 1.427* (0.210) 1.519** (0.211) 
Age 75-79=(4) 0.176** (0.074) 0.186** (0.077) 1.740** (0.241) 1.631*** (0.163) 
Age 80-84=(5) 0.211*** (0.074) 0.251*** (0.081) 1.413* (0.200) 2.089*** (0.181) 
Age 85-89=(6) 0.135* (0.080) 0.259*** (0.094) 1.636** (0.218) 2.555*** (0.223) 
Age > 90= (7) -0.019 (0.101) 0.175 (0.123) 3.986*** (0.301) 2.874*** (0.354) 
Male 0.026** (0.014) -0.007 (0.015) 0.752*** (0.039) 0.854*** (0.025) 
Deprivation Category=3 0.080** (0.032) 0.090*** (0.033) 1.115 (0.080) 0.972 (0.053) 
Deprivation Category=4 0.056* (0.030) 0.073** (0.031) 1.250*** (0.076) 1.010 (0.051) 
Deprivation Category=5 0.067** (0.029) 0.081*** (0.030) 1.232*** (0.075) 1.023 (0.051) 
Deprivation Category=6 0.035 (0.031) 0.058* (0.031) 1.442*** (0.078) 1.128** (0.054) 
Deprivation Category=7 0.011 (0.040) 0.041 (0.040) 1.370*** (0.102) 1.036 (0.070) 
Smoker 0.047*** (0.015) 0.047*** (0.015) 0.972 (0.040) 0.948** (0.026) 
BMI <=25 -0.043*** (0.013) -0.042*** (0.013) 0.962 (0.033) 0.998 (0.023) 
SBP <=140mmHg 0.068*** (0.014) 0.066*** (0.014) 0.946 (0.034) 0.961* (0.022) 
FEV1 <70% -0.015 (0.016) -0.013 (0.016) 1.060 (0.047) 1.076** (0.036) 
Walking >=10 min -0.008 (0.015) -0.006 (0.016) 0.994 (0.040) 0.968 (0.026) 
Cholesterol <6.2mmol/L 0.053*** (0.013) 0.052*** (0.013) 0.983 (0.034) 1.020 (0.023) 
Time period= 1985-1992 0.232*** (0.021) 0.234*** (0.021) 0.989*** (0.063) 0.967 (0.056) 
Time Period=1993-2000 0.437*** (0.025) 0.418*** (0.025) 0.681*** (0.061) 0.745*** (0.053) 
Time Period=2001-2007 0.816*** (0.030) 0.505*** (0.030) 0.179*** (0.079) 0.728*** (0.058) 
Constant -1.976*** (0.069) -1.974*** (0.069) 1436*** (0.168) 1637*** (0.146) 
*** p<0.01; **p<0.05, *p<0.1; Robust standard errors in parentheses; Deprivation category 1 (most affluent) serves as the 
reference category; Age category 1 (<65) serves as the reference category; TTD=12 serves as the reference category 
Interaction terms for TTD*Age have been included in the estimation, but a presentation is not shown here 
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Estimated cost ratios for both approaches (columns (5) to (8)) also show very similar 
results in terms of the size and statistical significance of the effect. Differences can be 
observed for the association of socio-economic status with estimated costs, where the 
approach that uses the predicted TTD for survivors seems to produce estimates that are 
statistically significant and larger compared with the approach of using observed TTD. 
This could potentially be caused through the inclusion of the socio-economic status in 
survival analysis regression in order to predict remaining TTD. 
It is very difficult to draw any conclusions from the comparison of coefficients or cost 
ratios regarding the effect on predicted costs. Table 5.8 below therefore provides cost 
estimates obtained from multiplying the two modelling parts as specified in Equation 5.7.  
Table 5-8 Predicted costs in £- early censoring 
 
PREDICTED TTD 
 
OBSERVED TTD 
 
Admission Quarter 
before Death 
Mean Costs 
 
SD Mean Costs SD 
TTD=1 2,163 661 2,087 328 
TTD=2 745 246 730 152 
TTD=3 433 149 455 114 
TTD=4 339 128 373 103 
TTD=5 289 104 297 71 
TTD=6 247 90 297 85 
TTD=7 221 94 266 98 
TTD=8 209 68 269 86 
TTD=9 179 87 242 95 
TTD=10  169 90 236 153 
TTD=11 132 54 183 105 
TTD=12 123 59 157 99 
 
Using survivors’ predicted TTD through survival analysis seems to produce predicted 
costs that are slightly higher than those obtained from using their actual, observed TTD 
in quarters one and two before death. In the last quarter of life costs are on average £76 
higher. From quarter three before death cost predictions are found to be lower for the 
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method of predicting TTD. However differences are found to be small and decrease the 
further away from death people are.  
 
5.9 Discussion  
The main focus of this chapter was to estimate the independent effect that TTD and age 
have on HC expenditure for acute inpatient care. For the first time in Scotland this could 
be done using a longitudinal survey based dataset (Renfrew/Paisley study) linked to 
acute inpatient records (SMR01).  
5.9.1 Effect of TTD and age on HC expenditure 
Results from the analyses undertaken in this chapter show that TTD, age at death and 
the interaction between these two have a significant effect on HC costs. This confirms 
previous results obtained by other researchers (Zweifel et al., 1999, Stearns and Norton, 
2004, Seshamani and Gray, 2004b) for a sample of the Scottish population. TTD is 
found to influence HC expenditure differently for different age groups. Special attention 
was paid to the interactions between TTD and age and it was shown that estimated 
costs at the end of life were higher for the younger age groups in the sample compared 
with the older ages. This highlights the importance of the inclusion of both TTD and age 
when endeavouring to explain the impact that an ageing population might have on HC 
expenditure.  
5.9.2 Impact of health measures 
This chapter also sought to investigate how health status and health risk measures that 
were obtained at baseline influenced future costs. In total, six of these indicators were 
included. Although the size of the effect that these variables had on the probability of 
being admitted to hospital was small, statistical significance could be observed for four 
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of these measures. Interesting results were found for two measures, SBP and the 
cholesterol level, where individuals with healthy readings were observed to have a 
higher probability of accessing hospital care. This might be explained with the ‘worried 
well’ seeking medical attention earlier and perhaps more frequently. This seems to be 
confirmed when looking at estimated costs (the second modelling part), given positive 
utilisation, where the significant effect on the probability of accessing hospital care does 
not translate into significantly higher costs being incurred, i.e. medical interventions may 
not need to be performed on these individuals. However, if this was the case much 
lower costs would be expected. Another possible explanation could be provided through 
the cut-offs that was chosen for these measures, i.e. different thresholds might reveal 
different results. Significant effects on costs could be found for the following health 
indicators: smoking status, SBP, % predicted FEV1. Of interest is the effect that 
smoking has on costs. On average, smokers seem to incur lower quarterly costs in their 
last 12 quarters of life (£283) than non-smokers (£318). 
Findings for the impact that health status and health risk indicators have on costs are 
very informative, given the time span over which individuals were followed up in terms of 
their HC utilisation. Health status and health risk measures seem to be able to provide a 
good indication of individuals probability of needing medical attention later in life (as far 
as 30 years away) and also of associated costs. This shows that utilising a linked 
dataset, where such measures can be used in regression modelling can add 
substantially to our ability of being able to explain the relationship between TTD and 
costs. 
5.9.3 Right censoring of survivors 
As outlined in Section 5.1.1, this chapter presented different methods of accounting for 
survivors’ unknown TTD due to right censoring. It was shown how various sample 
scenarios impact on results obtained for the probability of being admitted to hospital and 
any subsequently incurred costs. Survival regression analysis was presented as a novel 
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method to predict remaining TTD for surviving sample members and to adjust their cost 
observations accordingly (scenario D). This was compared with alternative methods of 
using the censoring date as date of death (scenario C) and also excluding survivors 
from the regression analysis (scenario A). Observed differences in age between model 
scenarios are most likely caused by the fact that survivors are older on average, as seen 
in the analysis of scenario B. The validation experiment presented in Section 5.8 
compared predicted costs using survival analysis to estimate remaining TTD for a 
sample that was censored artificially and for which a ‘real’ date of death could 
subsequently be observed. Cost predictions were also obtained using the observed date 
of death and costs were compared. Small differences were found when analysing 
quarterly costs, providing evidence that the method of using survival analysis in order to 
predict TTD produces estimates that are very close to the ‘true’ estimates. This 
validation means that a similar approach is implemented in Chapter 6 which uses a 
representative sample of the Scottish population to investigate further research 
questions, i.e. how are HC expenditure projections influenced through the application of 
two different approaches, a demographic approach and an approach that also accounts 
for the TTD component.  
Another question that is investigated in more detail in Chapter 6 is that of the association 
between socio-economic status and costs at the end of life. An initial investigation of this 
association was included in the analysis undertaken in this present chapter, however, 
some interesting results, such as the finding that costs, given positive utilisation, are not 
affected by socio-economic status to the extent that would be anticipated, deserve 
further attention.  
5.9.4 Limitations 
One limitation of the data arises as study participants may have had hospital admissions 
outside Scotland, i.e. the rest of the UK, which are not recorded in the linked 
Renfrew/Paisley -SMR01 data. One further issue stems from using survival analysis to 
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predict survivors’ additional TTD. Any hospital episodes that might have occurred after 
the official study end are unobserved, however, hospital episodes are also unobserved 
before 1980.  
Age, gender and socio-economic status were utilised to predict remaining TTD. Future 
analysis could also include a measure of seasonality, which would very likely influence 
mortality. 
The admission quarter has been used to assign costs to a specific quarter before death. 
This has been done, since this marks the time when costs are incurred. However, using 
the admission quarter as an indicator of when costs are incurred will have the effect of 
pushing costs away from death which could lead to an underestimation of costs in the 
quarters closest to death. As older people tend to be closer to death on average, this 
may also affect the distribution of costs in the last quarters of life by age category. 
The approach of utilising different samples for the four scenarios presented could also 
have lead to biased results. Also, the health risk and health status measures were only 
obtained once, when sample members entered the study and no repeated measures 
were taken after the 1970s. Hence, careful interpretation of these results is required. 
One final limitation is that the Renfrew/Paisley sample might not be representative of the 
whole of Scotland in terms of its geographic measures of deprivation, something that 
could be rectified in the following chapter.
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6 POPULATION AGEING IN SCOTLAND: 
IMPLICATIONS FOR HC EXPENDITURE USING 
LINKED SLS – SMR01 DATA 
 
6.1  Introduction 
6.1.1 Socio-economic status and costs at the end of life 
The previous empirical chapter analysed the association between TTD, population 
ageing and HC expenditure using baseline survey data from the West of Scotland linked 
to hospital admission records and death records. The analysis focused on the 
implications of excluding survivors from the analysis and estimated the effect that TTD 
and age had on costs for acute inpatient care. In addition to health risk and health status 
measures, the association between the socio-economic status and costs at the end of 
life was analysed. This association was not found to be as strong as expected.  
In order to further investigate and validate these results and to fully explain the driving 
factors behind HC expenditure at the end of life in Scotland it is vital to expand the 
analysis using a sample that is representative of the Scottish population. This is 
especially important for any inferences that can be made for the association between 
socio-economic status and HC expenditure, as previous research suggested that ‘the 
poor cost more’ (Cookson and Laudicella, 2011). Although, potentially confounding this 
is that those with lower socio-economic status are closer to death due to their shorter 
than average life expectancy. This is highly relevant particularly in Scotland, where life 
expectancy for males is as low as 54 years in one area of Glasgow (WHO, 2007) and 
where there is a generally poor record of premature deaths in areas with very high levels 
of deprivation. Previous studies analysing Scottish data have shown a clear association 
between socio-economic status and premature death (Chalmers and Capewell, 2001)
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A review of the wider international literature also suggested differences in HC costs 
incurred by socio-economic status, which is mostly measured using individuals income 
as a proxy for socio-economic status. Research from Sweden showed that people with a 
lower income incurred higher HC costs (Beckman et al., 2004). A study carried out in 
Canada looked at differences in HC utilisation between income groups and found that 
individuals with a lower income were responsible for a disproportionate utilisation of 
hospital services. The authors argued that this was mainly due to a higher prevalence of 
diseases (Lemstra et al., 2009). A comparative study of U.S. and Canadian individuals 
however found a similar pattern of hospital utilisation across socio-economic status 
(Blackwell et al., 2009).  
As pointed out in the previous chapter, in this thesis, the association between HC costs 
and socio-economic status is determined by two processes. The first one being access 
to HC services, i.e. utilisation and the second is the costs incurred given positive 
utilisation. The question remains: do individuals from more deprived areas cost more, 
and to what extent are costs influenced by utilisation? 
Preliminary, descriptive analysis undertaken in Scotland suggested a socio-economic 
gradient in terms of costs incurred towards the end of life, with decedents from more 
deprived areas incurring lower costs in younger age groups with the effect reversing in 
the very old age groups (over 75), where significantly higher costs were observed for 
people living in more deprived areas (Graham and Normand, 2001). Limitations 
occurring from this study were described in detail in Section 3.9, which reviewed the 
existing TTD literature in Scotland. Other research undertaken for the Health Board 
‘Ayrshire and Arran’ has shown that the association between socio-economic status and 
the probability of accessing hospital services and subsequent costs is not as clear cut as 
might be expected (Lowe, 2005). 
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This chapter expands preliminary research that has been undertaken in Scotland to date 
(Lowe, 2005, Graham and Normand, 2001) by estimating the independent effect that 
TTD, age and socio-economic status have on HC expenditure while utilising a 
representative sample of the Scottish population. In addition, two methods of costing 
hospital episode statistics are compared in order to highlight implications that costing 
methods have when analysing the association between HC expenditure, population 
ageing and TTD. This will be based on the analysis of alternative costing methods for 
hospital episode statistics that was presented in Chapter 4, and will provide a second 
empirical application. 
6.1.2 HC expenditure projections 
The main challenge that HC systems and policy makers face in light of an ageing 
population is the potential, although difficult to quantify, increase in future HC 
expenditure. The review of the literature in Chapter 3 outlined the main methods that 
have been employed in order to project future HC expenditure. It has been found that 
the standard method of assuming a constant age profile for HC expenditure over time, 
as used in some studies (Dang et al., 2001, Jacobzone, 2000, Serup-Hansen et al., 
2002), might lead to an overestimation of the future financial burden an ageing 
population might be responsible for. Constant age profiles for HC expenditure do not 
account for changing morbidity scenarios as described in Chapter 3 and ignore that a 
compression of morbidity might lead to lower HC costs at any given age.  
The analysis in this chapter is able to utilise to its advantage a large and representative 
sample which allows for an estimation of future HC expenditure for Scotland. In order to 
draw conclusions about any hypothesised overestimation of future HC costs two 
scenarios will be investigated. The first scenario projects HC costs, purely based on 
demographic changes and not accounting for remaining TTD, while the second scenario 
also takes into account remaining TTD.  A comparison of projected costs between both 
scenarios quantifies the extent of a possible overestimation of costs, thus emphasises 
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the implications of including/excluding TTD on projected HC expenditure and providing 
valuable information for any budgeting and resource allocation decisions. 
6.1.3 Inclusion of survivors 
Also in Chapter 5, a method to account for survivors’ unknown TTD with censoring was 
presented and the subsequent analysis concluded that a modelling approach that is 
based on the exclusion of survivors is at risk of overestimating costs. It was also shown 
that methods employed in previous research might not be appropriate in order to 
account for survivors’ unknown TTD. Two methods of accounting for survivors’ unknown 
TTD were presented: using the censoring date as their date of death and employing 
survival analysis to predict remaining TTD and adjustment of cost observations. Both 
methods produced lower cost estimates than the approach of excluding survivors. 
Section 5.8 presented an experiment to validate the method of utilising survival analysis 
in order to account for right censoring of survivors and concluded that differences in 
costs obtained through regression analysis were small and that survival analysis 
performed well in terms of predicting TTD and associated costs. It seems therefore valid 
to apply survival analysis in the context of analysing the SLS in this chapter. 
One difference of the SLS sample compared with the Renfrew/Paisley sample is the fact 
that the Renfrew/Paisley sample is characterised by a very high proportion of observed 
deaths at the end of the study period and a reasonably high average age for survivors, 
which meant their date of death was predicted as being not too far away in the future. 
The sample utilised in this chapter, however is characterised by a younger population on 
average and a higher proportion of surviving sample members at censoring. The 
analysis period is therefore extended to five years before death instead of three years. 
The remainder of this chapter is structured as follows. Section 6.2 describes in detail the 
linked dataset. This section also summarises the data manipulation procedure and the 
resulting number of available observations for the analysis. The two costing methods 
Chapter 6  185 
 
 
employed are also briefly summarised in Section 6.2, followed by a presentation of 
descriptive results. Section 6.3 outlines methods and results for the survival analysis. 
The econometric modelling framework and regression results are presented in Section 
6.4 and Section 6.5 describes the methods for projecting future HC expenditure as well 
as presenting their results. The final Section 6.6 discusses the main findings and 
concludes. 
 
6.2 Methods - Data and descriptive analysis 
6.2.1 Scottish Longitudinal Study  
The Scottish Longitudinal Study (SLS) is an anonymised dataset of a representative 
sample of the Scottish population (5.3%), which draws on data from a series of 
statistical and administrative sources, such as the Scottish Census, Vital Events (births, 
marriages and deaths), data from the National Health Service Central Register 
(NHSCR), which collects data on migration in and out of Scotland and NHS data on 
health events of sample members (maternity data, cancer registrations and hospital 
admissions). Through its longitudinal nature, the SLS provides a means to draw 
conclusions about the health status and socio-economic indicators of the Scottish 
population and how these have changed over time. 
The SLS started with data from the 1991 census from which about 270,000 SLS 
members were identified based on 20 semi-random dates of birth in any year. It has a 
very large sample size, very low attrition rates and very high rates for successful linkage 
of events as it collects data that is either required by law (Census, birth registration, 
death registration, marriage registration) or is a standard administrative function within 
Scotland. The linkage mechanism is provided by the National Health Service Central 
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Register (NHSCR), which holds a database of people who have at any point been 
registered with a General Practitioner in Scotland.  
The SLS contains some sensitive and personal information about sample members. 
Due to its confidential nature, only a small group of researchers who are responsible for 
maintaining the dataset are aware of the 20 birthdates based on which sample members 
are selected. After linkage across datasets, the final dataset is de-identified and neither 
names nor addresses are included. Furthermore no raw micro-data is provided to users. 
Instead, access to the data is via a strict application/access process, including an 
application to the Privacy Advisory Committee (PAC) if the SLS is to be linked to 
hospital admission records. The application is further reviewed by the SLS Research 
Board and a final decision is made- on access- based on the quality of the proposed 
project (the ethics approval form and the project clearance form can be found in 
Appendices VII and VIII). Data analysis can be undertaken in a ‘Safe Setting’ at the 
National Records of Scotland in Edinburgh alongside an assigned support officer. 
Datasets can also be accessed remotely by sending syntax to the support officer, who 
will then run it on the respective dataset. All results from the analyses are checked for 
possibly disclosive contents and need to be cleared by the SLS support officer. All 
output files are emailed in encrypted form to the SLS user (Hattersley and Boyle, 2007). 
One main advantage of the SLS over its English equivalent, the Longitudinal Study, is 
the ability to link with data on hospital admissions. Information on hospitalisations (and 
its associated costs) together with SLS data on economic activity, socio-economic 
status, health and demographic provides a novel platform from which to analyse the cost 
of ageing and the cost of dying. One additional advantage of using linked data is the 
possibility of including individuals without HC utilisation towards the end of life. This is 
something not all previous studies were able to do, especially when relying on 
expenditure claims data, which would only cover HC users in any period. 
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Further information on selection, tracing and linkage of SLS sample members as well as 
on the quality of sampling and linkage methods can be found in a series of SLS working 
papers by Hattersley and Boyle (2007, 2009a, 2009b) and Hattersley et al. (2007). 
Data Preparation and Manipulation 
A subset of the SLS dataset is used for this study, which is initially based on all traced 
SLS members enumerated at either the 1991 census or the 2001 census and aged 45 
or older at the 2001 census. This age group was chosen, as it was required that a 
sufficient number of deaths could be observed before censoring. This subset was then 
linked with SMR01 resulting in an initial number of 1,110,169 hospital records. These 
records relate to 141,964 sample members whose hospital use was observed between 
1986 and the 29th April 2010, which was the censoring date for the linked dataset. 
SMR01 has been described in detail in Sections 4.3.1 and 5.2.2 and a repeated 
explanation is dispensed with. 
Due to the fact that there can be multiple observations (that is hospital episodes) for 
individuals there are also different observation levels. The following paragraph describes 
the manipulation of the dataset on an individual’s level. STATA 11/MP was used 
throughout the analysis for this present chapter. 
SLS sample members, which could not be successfully flagged through the NHSCR 
(N=803) were deleted and not used for the analysis. Further, those SLS sample 
members that were present at the 1991 census, but not traceable afterwards were also 
discarded from the analysis (N=28). Additional checks for inconsistencies in the data 
revealed individuals that were aged less than 35 years in 1991 (N=1,198) and those that 
were aged less than 45 years in 2001 (N=561). These were also discarded from the 
analysis.  
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Subsequent data manipulation that was undertaken on an episode level includes the 
following. 3,863 episodes were deleted as these were admissions to ‘Geriatric Long 
Stay’ wards. These episodes were only part of SMR01 until 1997 and, due to this 
inconsistency could not be used for the analysis. 139 observations (episodes) were 
identified where the admission date was observed to be after the discharge date; these 
observations were discarded from any further analyses.  
The analysis in this chapter examines HC expenditure in the last five years (20 quarters, 
the justification for using quarters is explained below) of life. Any hospital episodes that 
occurred out with these five years before death (N= 519,792) were deleted. 17,382 
sample members never had any recorded acute inpatient hospital episodes during the 
observational period. These sample members only provide information from the SLS 
part of the linked dataset. These observations are important and have been neglected in 
previous research in Scotland (Graham and Normand, 2001, Lowe, 2005) that only 
analysed hospital admission records without establishing a link to a survey based 
dataset that contributes information on important baseline characteristics of those 
individuals, who subsequently do not access hospital services.  
The set up of the data is in long format with each row representing one episode of care. 
There is no information for periods in which no hospital costs were incurred, i.e. periods 
without a SMR01 record. The data are manipulated such that each row now represents 
one quarter (90 days) before death. Quarters in which no hospitalisation was observed, 
as recorded by a row of zeros, enter the model as zero cost observations. This provides 
an initial sample size of 2,095,060 observations (quarters), relating to 104,753 sample 
members (e.g. 20 quarters, four each year for five years).  
The remaining TTD in quarters for surviving sample members is predicted using the 
method of survival analysis as presented in the previous chapter. For instance, if an 
individual’s death is predicted to occur in April 2011, the last 20 quarters of life for that 
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individual start in April 2006. This is extended to April 2015, which results in the 
censoring date (April 2010) being the latest start date for the last 20 quarters of life 
which will be included in subsequent analyses. Observations for sample members who 
were predicted to live beyond 2015 were deleted and the final number of observations 
that is used in subsequent analyses is 1,131,361, relating to 60,808 SLS sample 
members, 42,668 of which had a death record at the time of censoring on 29th April 
2010 and 18,140 were alive and projected to die within the following five years. Five 
years (20 quarters) were chosen as compared to three years in Chapter 5, since the 
SLS sample was younger on average with deaths to be observed further away in the 
future. Figure 6.1 below illustrates how the data were set up and manipulated. 
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SLS: 5.3% sample of the 
Scottish Population
(N~270,000)
Linkage of SMR01 and 
death records
1,110,169 hospital 
records, relating to 
141,964 sample members
Exclusion of sample 
members after data 
cleaning
(N=1,168)
Exclusion of sample 
members < 45 years
(N~132,000)
Exclusion of sample 
members not in their last 
20 quarters of life
(N=36,043)
2,095,060 records relating 
to 104,753 sample 
members
Exclusion after survival 
analysis if projected date 
of death > year 2015 
(963,699 records relating 
to 43,945 sample 
members)
1,131,361 records 
(quarters) relating to 
60,808 sample members
Dead at censoring
(N=42,668 sample 
members)
Alive at censoring
(N=18,140 sample 
members)
Extending dataset to 20 
rows per sample 
member (=20 quarters 
before death)
 
Figure 6-1 Flowchart of dataset manipulation 
 
6.2.2 Costs for hospital episode statistics 
The costing methods that are applied in this analysis utilise HRGs as the basis on which 
unit costs are assigned to episodes of care. The same reference year for costs was 
chosen (2006/07) to ensure consistency within this thesis. Following the methods 
outlined in Section 4.3.2, admissions (as detailed in the SMR01 data) with ICD9 codes 
(pre 1992) were converted into ICD10 codes using a look-up file (New Zealand Health 
Information Service, 2010).  
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The procedure of assigning HRGs and costs to hospital episodes has been described in 
detail in Section 4.3.2 and is only briefly summarised here: The HRGv3.5 Grouper 
software is used to assign an HRG to every patient record (The Health and Social Care 
Information Centre, 2010a). After that episodes that form a CIS are taken account of by 
selecting the dominant HRG within each CIS. This is achieved by using the ‘Spell 
Converter’ software (The Health and Social Care Information Centre, 2010b). Both, the 
English Tariff and the SNT are assigned to the chosen dominant HRG and summarised 
into quarterly costs. Information on the type of admission was used to distinguish 
between tariffs for elective and non-elective admissions and LOS information has 
provided the basis for the decision whether to assign extra per diem costs. As outlined 
previously, the SNT does not provide information on extra daily costs for hospital stays 
that exceed a trim point. It will consequently give less weight to individual LOS.  
The application of two different costing methods facilitates a further empirical analysis of 
how alternative methods impact on regression results obtained- not only on an absolute 
level, but also in terms of the marginal effects that explanatory variables have on costs.   
6.2.3 Results - descriptive analysis 
Characteristics for the sample utilised in the regression analyses (N=60,808) are 
presented in Table 6.1, for the entire sample and by survivor status at the end of the 
observational period. 18,140 individuals (29.8%) did not have a death record at the end 
of the study period on the 30th April, 2010. Survivors are those individuals who are 
predicted to die within the following five years (until 2015) given how the data have been 
set up for the analysis. A significantly higher proportion (62.98%) of decedents is found 
to have been enumerated at the 1991 census only, compared to 10.89% of survivors. A 
higher proportion of survivors than decedents is observed to have been enumerated at 
the 2001 census and a similar observation can be made for survivors and decedents 
that were part of both, the 1991 and the 2001 census. This reflects mainly the younger 
age groups present at the later census. A similar distribution of males and females can 
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be found in both, the survivor group and in the decedent group, proportions that 
nevertheless are significantly different from each other (p<0.01). The distribution of 
females and males in the decedent and survivor subgroup is very similar to their overall 
distribution in the entire sample.  
7.3% of the entire sample population had never accessed hospital care, a proportion 
that also differs significantly (p<0.01) by survival status. A higher proportion of 
individuals that had never accessed hospital care while observed can be found in the 
survivor group (13.3%). A slightly higher proportion of survivors live in postcode areas 
that belong to the most affluent deprivation quintile compared to the decedent group, 
while a slightly lower proportion of survivors can be found living in areas that belong to 
the most deprived quintile, compared to the decedent group. The difference between 
survivors and decedents in terms of their socio-economic status was found to be highly 
significant (p<0.01). Socio-economic status is measured using the Carstairs deprivation 
score quintiles. These are based on postcode sectors and the lowest quintile (1) 
represents the most affluent areas, while the highest quintile (5) represents the most 
deprived areas (Carstairs and Morris, 1991)17. Area based variables such as the 
deprivation quintiles were available at different geographical levels. Since information 
from both the 1991 and the 2001 census is used in this analysis it was decided that a 
spatial level should be chosen that would facilitate comparability of variables in 1991 
and 2001. The so called ‘Consistent Areas Through Time’ (CATT) possesses these 
characteristics and are still meaningful as areas are relatively small (10,058 CATTs in 
Scotland18). 
 
                                               
17
 Please note that this measure of deprivation, although using the same definitions, is different 
from the one used in Chapter 5, where the seven categories were used instead of quintiles.  
18
 To put CATTs into perspective; there are 32 council areas in Scotland that are split into 1,222 
electoral wards 
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Overall, 53.2% of all sample members reported to have a limiting long-term illness (LTI) 
in either census. A significantly higher proportion of decedents reported having a limiting 
long-term illness (56.3%), while 45.8% of survivors stated that they suffered from an LTI. 
This proportion differs significantly between both groups (p<0.01). 
On average deceased SLS sample members spent 20.6 days in hospital (SD=59.7), 
whereas individuals who had survived until the censoring date had spent an average of 
12.5 days in hospital (SD=31.0). LOS differs significantly between survivors and 
decedents (p<0.01). Overall mean age at study entry was 67.9 years (SD=10.9). 
Decedents were significantly older at study entry than survivors (68.8 years vs. 65.8 
years).  
Age at death was measured in seven categories. Sample characteristics for age at 
death are presented for observed deaths for decedents and for predicted deaths for the 
surviving part of the sample. For decedents, most deaths were observed to occur 
between 80-84 years and most survivors are predicted to die between the age of 85 and 
89. 
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Table 6-1 Sample characteristics 
 
VARIABLE 
FREQUENCY 
(%)  
Sample  
N=60,808 
(100%) 
 FREQUENCY 
(%)  
Decedents 
N=42,668  
(70.2%) 
 FREQUENCY 
(%)  
Survivors 
N=18,140 
(29.8%) 
Differences 
between 
survivors and 
decedents 
p-value* 
Enumerated at 1991 Census 28,848 (47.44%) 26,873 (62.98%) 1,975 (10.89%)  
Enumerated at 2001 Census 3,631 (5.97%) 1,401 (3.28%) 2,230 (12.29%)  
Enumerated at both Censuses 28,329 (46.59%) 14,394 (33.73%) 13,935 (76.82%) Overall: p<0.01 
Male 28,481 (46.8%) 19,978 (46.8%) 8,503 (46.9%)  
Female 32,314 (53.1%) 22,686 (53.2%) 9,628 (53.1%) p<0.01 
Missing Gender 13 (0.02%) 4 (0.01%) 9 (0.05%)  
Number of HC users 56,362 (92.7%) 40,633 (95.2%) 15,729 (86.7%)  
Number of non-users 4,446 (7.3%) 2,035 (4.8%) 2,411 (13.3%) p<0.01 
Deprivation Score Quintile 1 8,445 (13.9%) 5,855 (13.7%) 2,590 (14.3%)  
Deprivation Score Quintile 2 14,150 (23.3%) 9,822 (23.0%) 4,328 (23.9%)  
Deprivation Score Quintile 3 14,056 (23.1%) 9,886 (23.2%) 4,170 (23.0%)  
Deprivation Score Quintile 4 12,603 (20.7%) 8,826 (20.7%) 3,777 (20.8%)  
Deprivation Score Quintile 5 11,495 (18.9%) 8,221 (19.3%) 3,274 (18.0%)  
Deprivation Score Quintile 
(missing) 
59 (0.1%) 58 (0.1%) Low cell count** Overall: p<0.01 
LTI - Yes 32,318 (53.2%) 24,005 (56.3%) 8,313 (45.8%)  
LTI - No 28,177 (46.3%) 18,535 (43.4%) 9,642 (53.2%)  
LTI (missing) 313 (0.5%) 128 (0.3%) 185 (1.0%) p<0.01 
Age at death <65 years*** n/a 6,078 (14.24%) 22 (0.12%)  
Age at death 65-69 years n/a 4,489 (10.52%) 4 (0.02%)  
Age at death 70-74 years n/a 6,127 (14.4%) Low cell count**  
Age at death 75-79 years n/a 7,249 (16.99%) 22 (0.12%)  
Age at death 80-84 years n/a 7,679 (18%) 1,671 (9.21%)  
Age at death 85-89 years n/a 6,184 (14.49%) 8,410 (46.36%)  
Age at death >= 90 years n/a 4,862 (11.39%) 8,009 (44.15%) p<0.01 
Mean age at study entry (SD) 67.9 (10.3) 68.8 (11.4) 65.8 (6.7) p<0.01 
Total LOS (SD) 18.3 (53.4) 20.6 (59.7) 12.5 (31.0) p<0.01 
* p-values were obtained through t-tests or chi2-tests; ** low cell count: results with cell counts <3 can not 
be displayed as these might potentially be disclosive, this is a requirement of accessing the SLS; *** Age at 
death for survivors is the age that was predicted through survival analysis and extrapolation 
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6.2.4 Results - descriptive analysis of costs 
The initial exploration of observed mean costs in each quarter before death (observed 
and predicted through survival analysis) shows a substantial increase in costs as people 
approach death. This increase is most pronounced for the last three quarters of life and 
shows an almost threefold rise when moving from the penultimate quarter of life to the 
last quarter of life. A similar distribution of costs towards the end of life can be observed 
for both costing methods, the English Tariff (blue line) and the SNT (red line) (Figure 
6.2), with the SNT producing marginally higher mean costs than the English Tariff.  
 
Figure 6-2 Mean quarterly costs in the last 20 quarters of life 
 
Similar to the descriptive analysis of mean costs undertaken in Chapter 5, it can be 
observed here that quarterly costs are highly skewed to the right. Figure 6.3 (English 
Tariff) and Figure 6.4 (SNT) show the distribution of quarterly costs. The presentation is 
restricted to £10,000 to facilitate plotting of the histogram. 
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Figure 6-3 Histogram quarterly costs (English Tariff) 
 
 
Figure 6-4 Histogram quarterly costs (SNT) 
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Figure 6.5 (English Tariff) and Figure 6.6 (SNT) illustrate how observed mean quarterly 
costs are distributed over different age groups. This is done for three periods, with the 
first graphs showing average costs over 20 quarters, the second graph showing mean 
costs for the last quarter of life and the third graph showing mean costs for the quarter 
furthest away from death (20th quarter before death). Average costs over all 20 quarters 
before death show very little differences in costs by age groups. A very small decrease 
in costs can be observed for the oldest age groups (>= 90 years) compared to 
individuals age 85-89 years. Comparing the two costing methods, no difference in mean 
costs over the entire period of 20 quarters can be found.  
Examining how costs are distributed over age groups for the last quarter of life shows a 
difference that is much more pronounced. Overall a slight increase in costs is found up 
until the age of 80, after which costs seem to decrease steadily. Costs are observed to 
be lowest for the oldest age group. A similar pattern is found for both, the English Tariff 
and the SNT. Similar to the distribution of costs by age group over the entire 20 
quarters, little difference in costs is found between age groups for the quarter furthest 
away from death for both costing methods. To summarise these descriptive findings, 
there does not seem to be an observed difference in costs that is caused through the 
application of alternative costing methods. Differences in costs by age groups can 
mainly be found in the last quarter of life, where older individuals seem to incur lower 
costs than their younger counterparts. 
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Figure 6-5 Mean quarterly costs by age group- English Tariff 
 
 
Figure 6-6 Mean quarterly costs by age group- SNT 
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Further investigation of observed differences in costs is undertaken for individuals’ 
socio-economic status. Figure 6.7 (English Tariff) and Figure 6.8 (SNT) show the 
distribution of mean quarterly costs over all 20 quarters, over the last quarter of life and 
over the 20th quarter before death by deprivation score quintiles. No marked differences 
in costs by socio-economic status can be observed when using average costs over the 
entire 20 quarters before death. A very small difference in observed costs can be seen 
when comparing the English Tariff with the SNT, which seems to produce slightly higher 
costs for all deprivation score quintiles, however this seems to be a very small effect. 
The distribution of costs over deprivation score quintiles in the last quarter of life does 
not show any marked differences, although costs using the SNT are marginally higher 
over all deprivation score quintile compared to costs produced when using the English 
Tariff to cost hospital episodes. Costs by socio-economic status in the quarter furthest 
away from death are, again, very similar for both costing methods and no marked 
difference is observed between deprivation score quintiles. Therefore, further 
investigation in regression analyses that is to follow in Section 6.4 is to reveal whether 
there is a statistically significant effect of the socio-economic status on the probability of 
hospital utilisation and subsequent costs towards the end of life in a multivariate model 
and, equally important, what the size of any such effect might be. 
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Figure 6-7 Mean quarterly costs by deprivation quintile- English Tariff 
 
 
Figure 6-8 Mean quarterly costs by deprivation quintile- SNT 
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6.3 Survival analysis - SLS sample 
6.3.1 Methods - survival analysis 
The survival analysis to predict additional quarters of life beyond censoring for SLS 
sample members in this chapter follows the methods described earlier in Section 5.4.2. 
Based on findings in Chapter 5, which outlined the implications of excluding surviving 
sample members from the analysis, the analysis in this chapter includes individuals that 
were observed to be alive at censoring (April, 2010) and were projected to die within the 
next five years. This is especially important as results obtained from regression analysis 
are to be utilised to project future HC expenditure in Section 6.5. Projections of future 
HC expenditure should ideally be performed on a population level, which requires the 
inclusion of survivors as well as individuals, who did not utilise HC services. This second 
empirical application of using survivors’ predicted TTD after survival analysis will also 
highlight implications of applying this method for a sample that has a higher proportion 
of surviving participants at the censoring date, which were on average noticeably 
younger than participants from the Renfrew/Paisley study, analysed in Chapter 5. 
In order to obtain a predicted date of death, time until failure (death) is predicted for both 
survivors and decedents utilising the entire sample (N=140,753). Results then guided 
the decision to exclude those, whose death was predicted to be beyond April 2015. The 
resulting sample (N=60,808) had consequently been used in the analysis. The following 
covariates are included to predict failure (death): age at study entry (in either 1991 or 
2001), gender, and the socio-economic status (measured in deprivation score quintiles 
and with quintile 1 serving as the reference group). These covariates are similar to those 
utilised in Chapter 5. 
 
Chapter 6  202 
 
 
Predicted additional years of life are transformed into quarters and the observed 
quarters before death are adjusted according to the number of additional quarters of life 
that were predicted. Adjustment of quarters is displayed in Figure 6.9 below. In addition 
to adjusting observed quarters before death, the age at death is aligned accordingly. 
Surviving individuals will not contribute any cost observations for the quarters closest to 
death, which had been predicted as additional quarters of life. This will result in missing 
cost observations and right censoring in a similar way as any cost observations are 
missing and left censored before the observation of SLS sample members started, i.e. 
1986.  
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Figure 6-9 Adjusting quarters before death 
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6.3.2 Regression results - survival analysis 
Regression results for the Gompertz survival analysis are presented in Table 6.2. 
Estimates are presented as hazard ratios and show the expected signs with the risk of 
failing (dying) increasing as age at study entry increases. Similar to results found in 
Section 5.5, each additional year at study entry increases the risk of dying by about 
10%. Male SLS sample members also show a higher risk (47%) of dying than their 
female counterparts and an overall significant effect of socio-economic status on the risk 
of dying is observed. Individuals from the most deprived quintile show a risk of dying that 
is 65% higher than that of individuals living in the most affluent quintile. The size of the 
effect increases as deprivation increases. The shape parameter ‘gamma’ shows a 
positive value, indicating an exponentially increasing risk of failure.  
Table 6-2 Regression results Gompertz regression 
Variable Hazard Ratio Standard Error 
Gender 1.469*** (.009) 
Age at Study Entry 1.094** (.0004) 
Deprivation Score Quintile=2 1.169** (.016) 
Deprivation Score Quintile=3 1.284** (.017) 
Deprivation Score Quintile=4 1.429** (.017) 
Deprivation Score Quintile=5 1.650*** (.017) 
Gamma .044*** (.0009) 
No. of subjects 104,567  
No. of failures 42,516  
*** p<0.01; **p<0.05, *p<0.1;  
Robust standard errors in parentheses;  
Deprivation quintile 1 (most affluent) serves as the reference category 
Chapter 6  204 
 
 
 
Figure 6-10 Kaplan Meier (average over 1991 and 2001) 
 
Both Figures, 6.10 and 6.11 relate to the survival analysis undertaken for the entire 
sample (N=104,753) as this guided the subsequent exclusion of survivors whose 
predicted death was further away than five years. Figure 6.10 shows the Kaplan Meier 
survival estimates averaged over participants who entered the SLS in 1991 and 2001. A 
reasonably high proportion of surviving sample members can be observed, which is 
mainly caused by SLS sample members that entered the study in 2001. However the 
analysis in this chapter does not utilise the entire proportion of surviving sample 
members as their last 20 quarters of life were judged to be too far in the future to be of 
use in the analysis of costs towards the end of life.  
In Figure 6.11 Kaplan Meier survival estimates are shown for the entire sample by socio-
economic status, confirming the regression results shown in Table 6.2. On average, 
individuals from less affluent areas show a higher risk of dying at any one point in time. 
This risk increases with increasing deprivation. 
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Figure 6-11 Kaplan Meier survival estimates by socio-economic status 
 
 
6.4 Methods - econometric modelling 
Following the methods detailed in Section 5.6.3, costs for acute inpatient care are 
estimated using a two-part model with the first part estimating the probability of 
accessing HC and the second part estimating costs conditional on positive HC 
utilisation.  
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6.4.1 Explanatory variables 
The following explanatory variables have been identified within the SLS dataset in order 
to assess the independent effect that population ageing and TTD have on hospital costs 
utilising a representative sample from the SLS.  
To represent TTD, a series of 20 quarter dummies are defined, where 1 represents the 
last quarter of life, 2 the penultimate quarter of life, etc. The quarter furthest away from 
death (20th quarter) serves as the reference category. 20 quarters (five years) have been 
chosen based on exploratory analysis of observed hospital costs as people approached 
death. These were shown to increase substantially during the last year (four quarters) of 
life. Costs in the last quarter of life were found to be substantially higher than in the 
preceding three quarters. The same pattern was found for the probability of being 
admitted to hospital. It was therefore deemed appropriate to use a small observational 
unit (quarters), which has also been used in previous studies (Zweifel et al., 1999, 
Seshamani and Gray, 2004b).  
Consistent with age categories from the previous empirical example in Chapter 5, age at 
death is measured in seven categories (<65 years, 65-69, 70-74, 75-79, 80-84, 85-89, 
90 years and over) with the youngest age group serving as the reference category 
which, in both datasets, are ages 45 to 65. Interaction terms between TTD in quarters 
and age at death are included to capture any combined effect of ageing and TTD on HC 
costs.  
Gender is included to account for differences in costs incurred by males and females. To 
account for differences in costs incurred by socio-economic status a measure of 
deprivation is included using the Carstairs deprivation score quintiles, where the lowest 
quintile (1) serves as the reference category. Interaction terms between TTD and 
deprivation quintiles are included to control for any combined effects. The assumption is 
that TTD affects costs differently for different socio-economic groups. 
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An indicator to capture any time trends, especially to reflect advances of medical 
technology is included. This variable is measured in 6 categories (1986-1990; 1991-
1995; 1996-2000; 2001-2005; 2006-2010 and 2011-2015), with the most historic period 
serving as the reference group.  
A measure of individuals’ health status at baseline is included using information on self 
reported health problems (yes/no). In 1991 participants were asked whether they had a 
health problem or not. This question was worded slightly different in 2001, asking SLS 
sample members whether they would perceive themselves as having a limiting long-
term illness, a health problem or disability that limits them in carrying out their daily 
activities and the work they are able to do. Therefore, a composite measure is used 
whereby an individual was categorised as having a health problem if they had replied 
‘yes’ in either 1991 or 2001 or in both years. Individuals, who had replied ‘no’ in both 
years or in one of the two years if they were only present at either the 1991 or the 2001 
census were classed as not having a health related problem. 
The underlying assumption is that the expected value of HC expenditure is a function of 
these explanatory variables. 
6.4.2 Econometric model 
Similar to the model used in Section 5.6.3, the first modelling part employs a probit link 
and a binomial distribution to estimate the probability of utilising hospital care in any 
given quarter before death conditional on regressors X (Equation 6.1). 
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Equation (6.1) 
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Where: A is age at death categories; S represents gender; H is a dummy variable 
representing self reported health; Q is the remaining quarters of life (such that Q*A is the 
interaction of TTD and age); Y a time period dummy for hospital admissions; and D a 
dummy for deprivation score quintiles (such that Q*D is the interaction of TTD and 
deprivation), ui represents robust standard errors. 
From the second part of the model estimates of HC expenditure are obtained, 
conditional on HCE being greater than zero and conditional on the same set of 
regressors X (equation (6.2)).  
E [HCE] = g(xβ)                           Equation (6.2) 
with xβ representing the linear predictor for HC expenditure (HCE). 
Quarterly HC expenditure is estimated fitting a Generalised Linear Model (GLM) 
clustered on patient identifier. Diagnostic tests were run in order to determine the 
appropriate distributional family and link function that would fit the data best. This follows 
the procedure described in Section 4.3.3.  
Predicted probabilities of positive HC utilisation, obtained from the first part of the model 
are multiplied by cost estimates from the second part of the model in order to derive 
average cost estimates conditional on having incurred positive HC expenditure 
(Equation 6.3).  
E (HCE | X) = Pr (HCE>0 | X) * E (HCE | HCE>0, X)   Equation (6.3) 
In order to mitigate problems arising from serial correlation a CIS was used as the basis 
for the cost variable, summarising single hospital episodes if more than one episode 
formed the entire hospital stay. Clustering on individual identifier was applied to account 
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for any serial correlation that still existed because multiple observations (CISs) can 
come from the same individual. 
6.4.3 Results - probability of HC utilisation 
Regression results for the first part of the model, the probability of hospital utilisation, are 
presented in Table 6.3. Column (1) shows the resulting coefficient (probit) and column 
(2) the related standard error. Up to the 15th quarter before death, TTD has a highly 
statistically significant and positive association with the probability of being admitted to 
hospital (p<0.01). The size of the effect is largest for the last quarter before death and 
generally increases as people approach death. Estimates for TTD are compared with 
the quarter furthest away from death (20th quarter before death).  
Regression results for the association between age and the probability of utilising acute 
inpatient services reveal a significant effect only for the three oldest age groups, where 
the effect is positive. The size of the effect is largest for the second oldest age group 
and slightly smaller for the oldest ages. These estimates are compared with the 
youngest age group (<65 years). Age effects are also influenced by TTD as can be seen 
from the regression results for interactions between TTD and age at death (Table 6.4). 
Significant interaction effects can especially be found for the older age groups and up 
until the 12th quarter before death. A likelihood ratio test showed that a model including 
TTD and age interactions terms was better specified than a model excluding these 
interactions (p<0.01). Figure 6.12 shows the interactions between TTD and age in terms 
of the probability of utilising HC services graphically and confirms that interactions can 
mainly be observed for the older ages and up until about the 12th quarter before death 
as shown through the unparallel lines. A steeper gradient (i.e. a larger effect of TTD) can 
be observed for the younger age groups and a slightly flatter gradient is found for the 
two oldest age groups. 
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Table 6-3 Regression results - probability of hospital utilisation 
N= 1,124,537 (60,436) Coefficient SE 
Column (1) (2) 
Variable   
TTD=1 2.045*** (0.038) 
TTD=2 1.030*** (0.037) 
TTD=3 0.820*** (0.038) 
TTD=4 0.685*** (0.037) 
TTD=5 0.610*** (0.037) 
TTD=6 0.455*** (0.038) 
TTD=7 0.400*** (0.038) 
TTD=8 0.318*** (0.038) 
TTD=9 0.302*** (0.038) 
TTD=10 0.220*** (0.038) 
TTD=11 0.230*** (0.038) 
TTD=12 0.170*** (0.038) 
TTD=13 0.128*** (0.038) 
TTD=14 0.133*** (0.038) 
TTD=15 0.092** (0.038) 
TTD=16 0.047 (0.038) 
TTD=17 0.069* (0.037) 
TTD=18 0.011 (0.037) 
TTD=19 0.017 (0.036) 
Age 65-69= (2) -0.030 (0.036) 
Age 70-74= (3) -0.009 (0.033) 
Age 75-79=(4) 0.023 (0.031) 
Age 80-84=(5) 0.063** (0.030) 
Age 85-89=(6) 0.122*** (0.028) 
Age > 90= (7) 0.120*** (0.028) 
TTD x Age Table 6.4 & Figure 6.12 - 
Dep Quintile 2 0.032 (0.024) 
Dep Quintile 3 0.014 (0.024) 
Dep Quintile 4 0.047* (0.025) 
Dep Quintile 5 0.028 (0.026) 
TTD x Dep Quintile Table 6.5 & Figure 6.13 - 
LTI 0.165*** (0.006) 
Male -0.045*** (0.007) 
1991-1995 0.185*** (0.010) 
1996-2000 0.295*** (0.010) 
2001-2005 0.331*** (0.011) 
2006-2010 0.284*** (0.118) 
Constant -1.650*** (0.032) 
LR test TTD*Age LR chi2(114)= 7369.91 p<0.01 
LR test TTD*Dep Quintile LR chi2(76)= 111.86 p<0.01 
*** p<0.01; **p<0.05, *p<0.1; Robust standard errors in parentheses; Deprivation quintile 1 (most affluent) 
serves as the reference category; Age category 1 (<65) serves as the reference category; TTD=20 serves 
as the reference category; the most historic time period<1991 serves as the reference category 
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Table 6-4 Interaction terms TTD and age groups (Probability) 
TTD 65-69 
years 
70-74 years 75-79 years 80-84 years 85-89 years >= 90 years 
1 0.064 0.036 -0.062 -0.240*** -0.813*** -1.203*** 
2 0.006 -0.090 -0.196*** -0.335*** -0.586*** -0.830*** 
3 -0.058 -0.118*** -0.226*** -0.348*** -0.545*** -0.740*** 
4 -0.065 -0.105*** -0.192*** -0.310*** -0.457*** -0.628*** 
5 -0.082* -0.119*** -0.221*** -0.289*** -0.410*** -0.558*** 
6 -0.040 -0.053 -0.100** -0.221*** -0.282*** -0.408*** 
7 -0.017 -0.062 -0.120*** -0.210*** -0.280*** -0.378*** 
8 -0.024 -0.044 -0.088** -0.129*** -0.201*** -0.291*** 
9 -0.037 -0.060 -0.108*** -0.140*** -0.213*** -0.276*** 
10 -0.009 -0.006 -0.073* -0.111*** -0.173*** -0.189*** 
11 -0.065 -0.031 -0.064 -0.090* -0.152*** -0.177*** 
12 0.005 0.026 0.012 -0.043 -0.112*** -0.115*** 
13 0.038 0.004 -0.016 -0.047 -0.067** -0.067* 
14 -0.004 -0.016 -0.047 -0.050 -0.069** -0.081** 
15 0.017 0.006 -0.050 -0.026 -0.054 -0.042 
16 0.050 0.046 0.029 0.026 -0.003 -0.043 
17 0.036 0.017 0.011 -0.040 -0.038 -0.068 
18 0.021 -0.010 0.030 0.013 -0.019 0.005 
19 0.036 0.044 0.048 0.019 0.019 0.016 
*** p<0.01; **p<0.05, *p<0.1 
 
Figure 6-12 TTD and age interaction terms 
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Regression results in Table 6.3 also show that individuals’ socio-economic status does 
not have an impact on their probability of utilising hospital services. Similar to the effect 
that age has on the probability of utilising HC, these main effects can not be interpreted 
directly and results for the interaction terms between TTD and deprivation score 
quintiles (Table 6.5) reveal that any effect that the socio-economic status has on the 
probability of accessing HC services is also influenced by TTD. This can be observed 
especially for the last quarter of life, where the association is highly significant and 
negative. As individuals approach death, those living in more deprived areas are less 
likely to reach hospital than those individuals living in the most affluent areas. This is a 
very important finding, highlighting the importance of the inclusion of these interactions, 
something that could have been missed if only main effects for deprivation score 
quintiles were included.  
Table 6-5 Interaction terms TTD and deprivation score quintiles (Probability) 
TTD Deprivation 
Score 
Quintile =2 
Deprivation 
Score 
Quintile=3 
Deprivation 
Score 
Quintile =4 
Deprivation 
Score 
Quintile =5 
1 -0.099*** -0.092*** -0.104*** -0.136*** 
2 -0.084*** -0.042 -0.087*** -0.090*** 
3 -0.081** -0.045 -0.072** -0.046 
4 -0.073** -0.026 -0.073** -0.057* 
5 -0.066** -0.035 -0.083** -0.063* 
6 -0.049 -0.044 -0.049 -0.020 
7 -0.062* -0.033 -0.047 0.011 
8 -0.036 -0.018 -0.067** -0.008 
9 -0.010 -0.010 -0.045 0.009 
10 0.000 0.014 0.007 0.013 
11 -0.057* -0.014 -0.033 0.007 
12 -0.043 -0.023 -0.030 -0.010 
13 -0.027 -0.007 -0.021 0.010 
14 -0.039 -0.038 -0.030 -0.009 
15 -0.037 -0.014 -0.011 -0.001 
16 -0.045 -0.016 -0.016 0.004 
17 -0.019 -0.005 -0.048 0.006 
18 0.022 0.000 -0.006 0.022 
19 -0.039 -0.042 -0.014 -0.011 
*** p<0.01; **p<0.05, *p<0.1 
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Figure 6.13 shows the interaction terms between deprivation score quintile and TTD 
graphically. 
 
Figure 6-13 TTD and socio-economic status interaction terms 
 
Estimation results in Table 6.3 further reveal that male SLS members are significantly 
less likely to access hospital care than their female counterparts (p<0.01). Individuals, 
who had stated that they suffered from a long-term illness are shown to have a higher 
probability of being admitted to hospital (p<0.01) compared with those who do not suffer 
from an LTI.  
The year of admission that was included in six year bands in order to account for 
advances in medical technology is shown to have a positive and highly significant 
association with the probability of accessing hospital care. Compared to the most 
historic period (1986-1990), the subsequent periods show a higher probability of 
accessing hospital care, apart from the ‘projected period (2011-2015), which has a 
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negative association with the probability of accessing hospital care, due to missing 
hospital records for that period for surviving sample members.  
6.4.4 Results - cost estimation  
Regression results (cost ratios and corresponding standard errors) for the 2nd modelling 
part estimating costs given positive HC utilisation and applying the English Tariff 
(columns (1) and (2)) and the SNT (columns (3) and (4)) are presented in Table 6.6. The 
recommended distributional family was gamma and the recommended link function was 
a log link (Goodness of fit test results can be found in Appendix IX). Estimates 
presented in the table have been retransformed using exponentiation as they had been 
estimated on a log scale. 
English Tariff – Table 6.6, columns (1) and (2) 
Costs increase as people approach death. They are estimated to be about 85% higher 
in the last quarter of life compared to the 20th quarter before death. The association 
between TTD and costs is statistically significant up to the 4th quarter before death. Age 
at death is a significant predictor for mean quarterly costs for all but the second 
youngest age group. Compared to the youngest age group, costs incurred by the oldest 
age group are estimated to be about 50% higher. However, the effect that age has on 
costs is not influenced by TTD to the same extent as in the first modelling part as shown 
in Table 6.7. A statistically significant effect of the interaction between TTD and age is 
only observed for the last quarter of life and the two oldest age groups.  
 
 
 
 
 
 
 
 
Chapter 6  215 
 
 
Table 6-6 Regression results - cost estimation 
 
English Tariff SNT 
Observations N= 101,422 (39,079) N= 124,117 (42,553) 
Column (1) (2) (3) (4) 
Variable Cost Ratio SE Cost Ratio SE 
TTD=1 1.859*** (0.091) 1.515*** (0.059) 
TTD=2 1.386*** (0.087) 1.329*** (0.063) 
TTD=3 1.372*** (0.093) 1.324*** (0.064) 
TTD=4 1.244** (0.094) 1.299*** (0.066) 
TTD=5 1.120 (0.089) 1.280*** (0.068) 
TTD=6 1.153 (0.093) 1.222*** (0.067) 
TTD=7 1.190* (0.100) 1.253*** (0.068) 
TTD=8 1.162 (0.101) 1.228*** (0.070) 
TTD=9 1.033 (0.097) 1.209*** (0.071) 
TTD=10 1.075 (0.097) 1.153** (0.072) 
TTD=11 1.105 (0.098) 1.143** (0.070) 
TTD=12 1.230* (0.103) 1.169** (0.073) 
TTD=13 1.086 (0.103) 1.108 (0.075) 
TTD=14 1.990 (0.430) 1.085 (0.075) 
TTD=15 1.087 (0.105) 1.047 (0.075) 
TTD=16 0.983 (0.100) 1.062 (0.074) 
TTD=17 1.028 (0.104) 1.131 (0.084) 
TTD=18 1.075 (0.105) 1.068 (0.078) 
TTD=19 1.017 (0.108) 1.025 (0.077) 
Age 65-69= (2) 1.100 (0.090) 0.989 (0.073) 
Age 70-74= (3) 1.125* (0.067) 1.054 (0.061) 
Age 75-79=(4) 1.186*** (0.065) 1.120** (0.056) 
Age 80-84=(5) 1.259*** (0.074) 1.062 (0.054) 
Age 85-89=(6) 1.391*** (0.061) 1.136*** (0.053) 
Age > 90= (7) 1.481*** (0.061) 1.123*** (0.052) 
TTD x Age See Table 6.7 See Table 6.9 
Dep Quintile 2 0.911 (0.073) 0.931 (0.044) 
Dep Quintile 3 0.942 (0.076) 0.975 (0.046) 
Dep Quintile 4 0.910 (0.075) 0.955 (0.045) 
Dep Quintile 5 0.996 (0.075) 1.057 (0.047) 
TTD x Dep Quintile See Table 6.8 See Table 6.10 
LTI 1.065*** (0.008) 1.004 (0.005) 
Male 1.111*** (0.008) 1.079*** (0.005) 
 1991-1995 0.921*** (0.018) 0.979*** (0.005) 
1996-2000 0.900*** (0.017) 1.128*** (0.011) 
2001-2005 0.887*** (0.017) 1.123*** (0.011) 
2006-2010 0.888*** (0.019) 1.141*** (0.011) 
Constant 1542.915*** (0.080) 1814.777*** (0.058) 
LR test TTD*Age LR chi2(114)= 256.56, p<0.01 LR chi2(114)= 98.80, p=0.8438 
LR test TTD*Dep Quintile LR chi2(76) = 117.82, p<0.01 
 
LR chi2(76)=52.92, p=0.9798 
 
*** p<0.01; **p<0.05, *p<0.1 
Robust standard errors in parentheses 
Deprivation Score Quintile 1 (most affluent) serves as the reference category 
Age category 1 (<65) serves as the reference category 
TTD=20 serves as the reference category 
The most historic time period<1991 serves as the reference category 
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Table 6-7 Interaction terms TTD and age groups - English Tariff (Cost Ratios) 
TTD 65-69 
years 
70-74 years 75-79 years 80-84 years 85-89 years >= 90 years 
1 0.891 0.926 0.905 0.906 0.808*** 0.779*** 
2 0.931 1.046 0.978 1.066 1.058 1.058 
3 0.854 0.925 0.934 0.914 0.915 1.007 
4 0.837 0.938 0.891 0.866 0.891 1.024 
5 0.978 1.005 1.050 1.117 1.048 1.015 
6 0.872 1.015 1.028 1.019 0.950 1.019 
7 0.887 0.921 0.927 1.030 0.856* 0.953 
8 0.937 0.997 0.968 1.054 0.965 1.044 
9 0.988 1.046 1.041 1.005 1.008 1.063 
10 0.935 1.032 1.025 1.045 1.016 1.016 
11 0.882 0.988 0.957 0.961 0.906 0.977 
12 0.929 0.920 0.904 0.912 0.896 0.956 
13 0.832 1.141 0.893 0.913 0.943 0.941 
14 0.634 0.663 0.668 0.729 0.620* 0.688 
15 0.852 0.872 0.882 0.963 0.974 0.976 
16 0.927 0.951 0.955 1.012 1.047 1.101 
17 0.952 0.876 0.918 1.018 0.960 1.045 
18 1.030 1.001 0.979 1.016 1.006 1.060 
19 1.006 0.967 1.054 0.937 0.949 0.991 
*** p<0.01; **p<0.05, *p<0.1 
 
 
 
Figure 6.14 shows the interaction terms graphically. Individuals in the two oldest age 
groups (85-89 years and 90 years and older) seem to incur lower costs in their last 
quarter of life compared to their younger counterparts. This figure also shows that TTD 
does not only have an effect on the probability of reaching hospital, but also seems to 
impact on costs, given that individuals have reached hospital. 
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Figure 6-14 TTD and age interaction terms, Cost estimation 
  
The socio-economic status has a negative impact on costs for those individuals living in 
the 2nd, 3rd, 4th or 5th quintile compared to individuals living in the most affluent quintile, 
however, this effect is not statistically significant. In order to investigate whether the 
effect that the socio-economic status has on costs is influenced by TTD, the interaction 
effects are presented in Table 6.8. Results only show very small effects for some 
quarters without any recognisable pattern. Interaction effects are presented graphically 
in Figure 6.15. 
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Table 6-8 Interaction terms TTD and deprivation - English Tariff (Cost Ratios) 
TTD Deprivation 
Score Quintile =2 
Deprivation Score 
Quintile=3 
Deprivation Score 
Quintile =4 
Deprivation Score 
Quintile =5 
1 1.117 1.069 1.098 1.018 
2 1.139 1.050 1.119 1.041 
3 1.129 1.083 1.119 1.039 
4 1.159* 1.223** 1.276*** 1.154 
5 1.216** 1.055 1.160 1.041 
6 1.158* 1.129 1.154 1.058 
7 1.118 1.043 1.129 1.061 
8 1.126 1.109 1.080 1.003** 
9 1.256 1.141 1.221* 1.060 
10 1.208* 1.120 1.137 1.066 
11 1.145 1.129 1.168* 1.110 
12 1.014 1.017 1.040 1.015 
13 1.119 1.168 1.203** 0.971 
14 0.840 0.760 0.839 0.744 
15 1.189* 1.191* 1.176* 1.049 
16 1.193* 1.088 1.172* 1.065 
17 1.160 1.196* 1.154 1.085 
18 1.089 1.039 1.057 0.947 
19 1.167 1.055 1.159 0.992 
*** p<0.01; **p<0.05, *p<0.1 
 
 
Figure 6-15 TTD and deprivation quintile interaction terms, Cost estimation 
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Results in Table 6.6 also show that on average, male individuals incur significantly 
higher costs than females (~11%) and individuals, who reported a limiting long-term 
illness, incur significantly higher costs compared to those without any long-term illnesses 
(6%). 
SNT – Table 6.6, columns (3) and (4) 
Similar to regression results obtained from the application of the English Tariff, the 
association between TTD and costs is highly significant (columns (3) and (4) in Table 
6.6). However, unlike employing the English Tariff, this effect can be observed up until 
the 12th quarter before death when using the SNT. Costs in the last quarter of life are 
estimated to be about 52% higher than in the 20th quarter before death. This is 
considerably lower than estimates obtained from applying the English Tariff. Table 6.6 
also shows that, similar to employing the English Tariff, male individuals incur 
significantly higher costs than females (~8%). Contrary to using the English Tariff, 
however, having a long-term illness does not seem to have an effect on costs incurred in 
the last 20 quarters of life when using the SNT.  
Age at death only appears to be a significant predictor for costs for the two oldest age 
groups and the 4th youngest age group. Again, estimates are lower compared to the 
English Tariff. The oldest age groups are estimated to incur costs that are only 13% 
higher on average than those incurred by the youngest age group. Interaction terms 
between TTD and age show a highly significant association with costs up until the 
seventh quarter before death and mainly for the two oldest age groups (Table 6.9).  
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Table 6-9 Interaction terms TTD and age groups - SNT (Cost Ratios) 
TTD 65-69 
years 
70-74 years 75-79 years 80-84 years 85-89 years >= 90 years 
1 1.016 1.005 0.924 0.986 0.924 0.949 
2 0.958 0.983 0.842*** 0.940 0.926 0.913 
3 0.949 0.899 0.851*** 0.895* 0.815*** 0.878** 
4 0.903 0.916 0.853** 0.841*** 0.830*** 0.887* 
5 0.938 0.899 0.870** 0.897* 0.852** 0.864** 
6 0.928 0.958 0.923 0.891* 0.894* 0.950 
7 0.913 0.947 0.908 0.939 0.834*** 0.913 
8 1.002 0.974 0.883* 0.921 0.885* 0.945 
9 0.961 0.952 0.909 0.941 0.926 0.960 
10 0.987 0.997 0.942 1.011 0.950 1.020 
11 0.951 0.947 0.899 0.938 0.895* 0.951 
12 1.036 0.884 0.905 0.936 0.879* 0.975 
13 0.889 0.962 0.912 0.950 0.885* 0.951 
14 0.975 0.929 0.954 0.998 0.882 1.004 
15 0.916 0.962 0.939 0.982 0.953 0.963 
16 1.039 0.927 0.966 1.002 0.931 1.005 
17 0.937 0.852 0.863* 0.974 0.914 0.978 
18 1.037 1.001 0.943 1.025 0.967 1.037 
19 1.059 0.964 1.037 1.029 0.967 1.021 
*** p<0.01; **p<0.05, *p<0.1 
 
Table 6-10 Interaction terms TTD and deprivation - SNT (Cost Ratios) 
TTD Deprivation 
Score Quintile =2 
Deprivation Score 
Quintile=3 
Deprivation Score 
Quintile =4 
Deprivation Score 
Quintile =5 
1 1.059 1.009 1.023 0.907** 
2 1.032 0.974 0.995 0.888** 
3 1.074 1.001 0.994 0.883** 
4 1.073 1.012 1.066 0.878** 
5 1.112* 1.003 0.949 0.867** 
6 1.073 1.023 0.988 0.895* 
7 1.027 0.977 0.989 0.892* 
8 0.999 0.988 0.939 0.858** 
9 1.037 0.976 1.014 0.874** 
10 1.037 0.984 1.007 0.896* 
11 1.067 1.004 1.015 0.920 
12 1.048 0.969 1.014 0.919 
13 1.084 1.017 1.069 0.877** 
14 1.055 0.984 1.057 0.900* 
15 1.154** 1.076 1.076 0.958 
16 1.033 1.055 1.046 0.904 
17 1.072 1.006 1.039 0.894* 
18 1.027 0.996 0.988 0.895* 
19 1.057 0.987 1.034 0.914 
*** p<0.01; **p<0.05, *p<0.1 
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The socio-economic status seems to have a negligible effect on costs towards the end 
of life and no significant association could be observed. The inclusion of interaction 
terms between TTD and deprivation score quintiles however reveals a highly significant 
association (p<0.05) that can be observed for the most deprived quintile (5) and quarters 
1-9 before death (Table 6.10). Individuals living in the most deprived areas seem to 
incur significantly lower costs compared to people from the most affluent areas.  
Predicted costs by socio-economic status 
Average cost estimates by deprivation score quintile and admission quarter before death 
for the English Tariff and the SNT are presented in Table 6.11. These were obtained 
from multiplying the first part of the model (probability of hospitalisation) and the second 
modelling part (costs incurred given positive utilisation), as outlined in Equation 6.3. 
Estimates vary between £1,960 (SD=587) for the least deprived quintile and £2,054 
(SD=521) for the most deprived quintile in the last quarter of life (English Tariff). This 
shows that in the last quarter of life nearly £100 more is spent on individuals from the 
most deprived areas compared to people from the most affluent areas.  
A less pronounced difference between deprivation score quintiles is found for the 
application of the SNT in the last quarter of life. Differences in costs between socio-
economic groups become less marked the further away from death an individual is. The 
same comparison is made in Figure 6.16 which visualises the differences between 
employing the English Tariff and the SNT looking at different times away from death by 
deprivation score quintile. As already described for Table 6.11, some differences can be 
observed for the quarter closest to death between the two costing methods however, 
these seem to be very small. In the preceding analyses in this chapter it is therefore 
considered only to apply the English Tariff, as this is in line with the analysis in Chapter 
5 and also the recommendations from Chapter 4. 
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Table 6-11 Predicted costs in GBP (SD) [CI] by deprivation score quintile 
Admission quarter 
before death 
Deprivation 
Quintile 1 
Deprivation 
Quintile 2 
Deprivation 
Quintile 3 
Deprivation 
Quintile 4 
Deprivation 
Quintile 5 
English Tariff 
     
1 1,960 (587) 1,947 (592) 1,948 (578) 1,998 (558) 2,054 (521) 
 [1,946; 1,974] [1,936; 1,957] [1,938; 1,958] [1,988; 2,009] [2,044; 2,065] 
2 724 (205) 714 (203) 714 (195) 738 (194) 760 (184) 
 [719; 728] [710; 717] [711; 717] [734; 742] [757; 764] 
10 255 (70) 298 (79) 287 (76) 292 (75) 294  (75) 
 [253; 257] [297; 299] [285; 288] [291; 294] [292; 295] 
20 192 (68) 185 (64) 187 (65) 188 (66) 195 (69) 
 [190; 193] [184; 186] [186; 188] [187; 190] [194; 197] 
SNT 
     
1 1,992 (691) 1,910 (672) 1,926 (659) 1,984 (649) 1,975 (590) 
 [1,976; 2,008] [1,898; 1,922] [1,914; 1937] [1,972; 1996] [1,964; 1,987] 
2 718 (287) 654 (261) 680 (262) 693 (261) 704 (250) 
 [711; 725] [650; 659] [675; 684] [688; 698] [700; 709] 
10 287 (88) 294 (88) 295 (87) 310 (91) 302 (87) 
 [285; 289] [293; 296] [293; 296] [308; 312] [301; 304] 
20 200 (73) 198 (72) 204 (73) 211 (76) 224 (81) 
 [199; 202] [197; 199] [203; 205] [209; 212] [223; 226] 
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Figure 6-16 Effect of socio-economic status on costs (English Tariff and SNT) 
 
Predicted costs by age group 
As a final step, cost predictions are obtained stratified by age group, TTD and also 
gender. Costs were aggregated into annual costs using quarterly costs as obtained from 
the regression model; for example costs for quarters 1, 2, 3 and 4 were added up to 
represent costs for the last year of life etc. Results are presented in Table 6.12. The 
English Tariff is used here to obtain cost predictions as an illustrative example and also 
because there were only small differences that could be found between the SNT and the 
English Tariff in both, descriptive analysis and regression analysis. 
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Results show that male individuals, aged 65-69 who are in their last year of life incurred 
£4,028 on average, whereas males aged >=90 years in their last year of life only 
incurred £2,341 on average. This confirms the earlier observation of costs for the eldest 
age group being lower towards the end of their life compared to younger ages. 
Table 6-12 Predicted costs in £ by TTD, age and gender 
Male Age Year 1 Year 2 Year 3 Year 4 Year 5 
 <65 4,183 1,354 952 787 573 
 65-69 4,028 1,259 915 694 637 
 70-74 4,298 1,370 1,051 805 640 
 75-79 4,150 1,388 1,074 800 752 
 80-84 4,026 1,402 1,081 905 785 
 85-89 2,827 1,190 1,056 990 898 
 >=90 2,341 1,289 1,309 1,256 1,169 
Female 
      
 <65 4,492 1,410 985 811 590 
 65-69 4,290 1,294 934 703 645 
 70-74 4,565 1,401 1,068 813 645 
 75-79 4,460 1,447 1,116 826 774 
 80-84 4,437 1,565 1,218 1,026 881 
 85-89 3,361 1,409 1,200 1,090 972 
 >=90 2,336 1,274 1,248 1,190 1,108 
 
Figure 6.17 shows how mean predicted costs, applying the English Tariff, that have 
been aggregated to represent years rather than quarters before death, are distributed 
over age groups. This is presented for males only, since the distribution for females is 
similar and only the scale will differ by the magnitude of the explanatory variable ‘Male’ 
that was estimated in regression analysis. Costs are estimated to be highest in the last 
year of life, with costs decreasing the further away from death an individual is. This 
pattern can be observed for all age groups. Costs in the last year of life seem to be 
highest for ages 70-84 at death and lowest for the two oldest age categories. 
Differences in costs between different times away from death are less pronounced for 
the two oldest age groups than they are for the younger ages. This figure clearly shows 
the interaction effects between age and TTD. 
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Figure 6-17 Predicted costs by age and year before death, males 
 
Figure 6.18 (males) shows the mean predicted costs on a quarterly level, for the last 
year of life only. A similar pattern can be found of how costs are distributed over age 
groups, with the two oldest age groups incurring lower costs than the remaining, 
younger ages in all four quarters before death. Costs in the last quarter of life are 
substantially higher for all age groups compared to the second, third and fourth quarter 
before death. Costs in the last quarter of life can be observed to be markedly lower for 
the two oldest age groups and lowest for the eldest (>= 90 years). The difference in 
predicted costs between quarter 1, quarter 2, quarter 3 and quarter 4 before death is 
less pronounced for the two oldest age groups than the younger ages. 
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Figure 6-18 Predicted costs by age and quarter before death, last year of life, males 
 
 
6.5 HC expenditure projections 
The following section analyses two different approaches of generating HC expenditure 
projections for Scotland and so addresses the issue of an overestimation of future HC 
expenditure if a purely demographic approach was applied, as outlined in Section 3.8.1. 
The analysis in this section tests whether similar results to those from other published 
studies can be found for a sample of the Scottish population. If results from this chapter 
should confirm previous results of an overestimation of future HC costs when employing 
a purely demographic approach, this chapter also seeks to provide an estimate of the 
magnitude of any such overestimation of future HC costs. The first approach presented 
here predicts HC expenditure only accounting for demographic changes in the 
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population and the second approach extends the first approach by controlling for 
remaining TTD. 
 In a first step population estimates are obtained for both methods. In a second step 
these estimates are multiplied by cost estimates using the purely demographic approach 
and the TTD approach.  
6.5.1 Population estimates - demographic approach 
For both approaches, HC expenditure projections are based on 2008 population 
estimates provided by National Records of Scotland, formerly GROS, which were the 
latest projections available (GROS, 2011). These estimates provide information on the 
total number of people projected to be living in Scotland up until the year 2033. 
Population estimates for the year 2011 are utilised as the base year, representing an 
index of 100. Projected costs are obtained for four future time points (2016, 2021, 2026 
and 2028). Since population estimates are only available until 2033 and since it is 
required for the TTD approach to be able to calculate the proportion of the population in 
year one to five before death, the last estimate can be obtained for the year 2028.  
Although, this results in unequal time intervals, it was judged that it adds additional 
information on future HC costs and has therefore been added to the analysis. Results 
from both modelling approaches are finally compared.  
For population estimates, all persons usually resident in Scotland are covered 
regardless of their nationality (GROS, 2011). Projecting population numbers into the 
future very likely has an increasing level of uncertainty the further away these 
projections are. However, information on the high and low variants of population 
projections were not available from NRS and the precision of population projections for 
Scotland is of minor importance here, as the aim of this study is to highlight the 
differences in projected future HC expenditure under two different approaches. 
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Population projections are available for each specific age (up to and including 
individuals aged 101) and by gender. The time horizon for these projections is also 
available for individual calendar years and up to the year 2033. Since the aim of this 
thesis is to analyse an ageing populations’ impact on HC expenditure, projections for 
that part of the population aged 65 and older are analysed.  
The simplified scenario of assuming constant age-expenditure profiles, the 
‘demographic approach’ and projecting HC expenditure is used to obtain a comparator 
for the TTD approach in order to quantify the extent to which both approaches diverge 
from each other. Using population projections from NRS as outlined above, the total 
number of the projected population is utilised and stratification is carried out for age 
group and sex.  
Observed annual HC expenditure is obtained for the entire SLS sample and not only 
those individuals in their last five years of life as described in the regression modelling 
section. Since the SLS is a representative sample of the Scottish population it can be 
assumed that any HC expenditures incurred are also representative for HC costs 
incurred on average by the Scottish population. HC expenditure is observed for three 
consecutive years (2006, 2007 and 2008) for which the average is calculated. 
Observation of HC expenditure is undertaken stratified by gender as well as by age 
groups.  
2006/2007 was also the price year that had been used throughout Chapters 4 and 5. 
The derived average annual HC expenditures are then multiplied by population 
estimates, stratified by age group and gender for the years 2011, 2016, 2021, 2026 and 
2028. Finally, costs are aggregated over all age groups and both genders and the 
resulting cost provides a projection under a simplified scenario, which only accounts for 
demographic changes in the population.  
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6.5.2 Population estimates - TTD approach 
In addition to stratifying projected population numbers by age group and gender as 
outlined above, the TTD approach also takes into account the number of people in each 
of these groups who are in their last five years of life. Again, information provided by 
NRS on the projected population in Scotland is initially utilised to obtain the necessary 
population numbers. In addition to the procedure described earlier, each single age is 
now also stratified by TTD in years, so that an estimate of the population in each 
calendar year that is in their last year of life, penultimate year of life, third year before 
death, fourth year before death and fifth year before death can be obtained. This is 
achieved by using projections of the number of deaths, which are available from NRS on 
request.  
Similar to projected population numbers, projected numbers of death are available for 
individual ages (up to and including the age of 125) and individual calendar years (up to 
and including the year 2033). The following calculations were used in order to get an 
estimate of the number of individuals projected to be in a particular year before death. 
The year 2011 is used here as an example. 
 
TTD1 = Deaths age/sex2012       Equation (6.4) 
TTD2 = Deaths age/sex2013       Equation (6.5) 
TTD3= Deaths age/sex2014       Equation (6.6) 
TTD4= Deaths age/sex2015       Equation (6.7) 
TTD5= Deaths age/sex2016       Equation (6.8) 
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Where TTD1-5 is the number of the population projected to be in particular year before 
death; Deaths age/sex is the projected number of deaths by age and sex. 
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Total population number of 
males,aged 70 in 2016
TTD=1: number of deaths, 
aged 71 in 2017
TTD=2: number of 
deaths, aged 72 in 2018
Numbers aggregated over 
agegroup (70-74 year old 
males)
TTD=4: number of 
deaths, aged 74 in 2020
TTD=3: number of 
deaths, aged 73 in 2019
TTD=5: number of 
deaths, aged 75 in 2021
Proportion of males in 
TTD=1, aged 70-74 
multiplied with cost estimates 
for quarters 4 to 1 before 
death
Proportion of males in 
TTD=4, aged 70-74 
multiplied with cost estimates 
for quarters 16 to 13 before 
death
Proportion of males in 
TTD=2, aged 70-74 
multiplied with cost estimates 
for quarters 8 to 5 before 
death
Proportion of males in 
TTD=3, aged 70-74 
multiplied with cost estimates 
for quarters 12 to 9 before 
death
Proportion of males in 
TTD=4, aged 70-74 
multiplied with cost estimates 
for quarters 20 to 17 before 
death
Proportion of males NOT in 
TTD=1-5, aged 70-74 
multiplied with cost estimates 
for quarters 20 to 17 before 
death
 
Figure 6-19 Example- obtaining population numbers by TTD 
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Figure 6.19 shows an example using the projected population number for males, aged 
70 in 2016 and the corresponding projected number of deaths. To calculate the number 
of males aged 70 in their last year of life in 2011, the number of 71 year old males, who 
are projected to die in 2017 is utilised. In order to calculate the number of 70 year old 
men who are in their penultimate year of life, the projected number of deaths for males 
aged 72 in 2018 is applied etc. These calculations are repeated for all ages (by gender 
and for individuals aged 65 and older) for the time points specified above (2011, 2016, 
2021, 2026 and 2028). This provides an estimate of the number of people expected to 
be in year 1 to 5 before death. It also provides an estimate of the number of individuals, 
who are not within their last five years of life. This is achieved through subtracting those 
in year 1, 2, 3, 4 and 5 before death from the total number of the projected population in 
each age group.  
The next step is to summarise single ages of the projected number of the population in 
their last, 2nd, 3rd, 4th and 5th year before death into age groups to align with those age 
groups used in regression analysis. As explained earlier, projections are only calculated 
for that part of the population aged 65 and older.  
Cost estimates per capita are obtained from the econometric model presented in 
Section 6.4.2. Contrary to the procedure described of obtaining cost estimates under a 
purely demographic approach, for this TTD approach, predicted costs are obtained after 
fitting the two-part model and multiplying estimates from the probability part with 
estimates from the part that estimated costs conditional on having incurred positive HC 
expenditure. These predicted costs are then obtained stratified by age group, by gender 
and also remaining TTD. Cost estimates derived from the regression model represent 
quarterly costs. These are aggregated to represent annual costs, so that:  
TTDquarter1 + TTDquarter2 +TTDquarter3 +TTDquarter4 = TTDyear1    Equation (6.9)
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For those individuals in the Scottish population, whose death is further away than five 
years as obtained from projected population and deaths numbers, cost estimates for the 
fifth year before death, are applied. This method is deemed feasible given that the 
resulting curves for observed and predicted costs are basically flat for quarters 10 to 20 
before death (see Figure 6.2). The assumption here is that annual costs beyond the fifth 
year before death are constant. Further evidence for this method is given by the 
insignificant association between TTD and incurred costs, given positive utilisation from 
about the 13th quarter before death, indicating that TTD will not have an impact on costs 
from that point in time onwards.  
Finally, costs for each stratum are multiplied by the respective population estimates for 
each age group, gender and TTD stratum and are aggregated over TTD, age group and 
gender to provide HC expenditure projections for the years 2011, 2016, 2021, 2026 and 
2028 that have been adjusted for remaining TTD.  
The year 2011 serves as the base year for HC expenditure projections and costs from 
the demographic approach and the TTD approach for that year are set to 100. All 
subsequent analyses consider any deviation from this indexed level. A comparison of 
the growth rate of costs from 2011 onwards between the demographic approach and the 
TTD approach is undertaken to show whether a simplified approach overestimates 
future HC costs and if that is the case, the magnitude of the overestimation. 
6.5.3 Results - population projections 
Figures 6.20 and Figure 6.21 show, how the projected number of the entire Scottish 
population develops over the next two decades. The presentation is done separately for 
males (Figure 6.20) and females (Figure 6.21) and represents age groups for the ages 
65 and older. A constant increase can be observed, for both males and females and for 
all age groups. 
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The slope of the graph for female age groups seems to be somewhat steeper than the 
slope for the graphs representing age groups for males. This suggests that the already 
higher proportion of females in each age group in Scotland continues to rise faster than 
the number of males in each age group. 
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Figure 6-20 Projected number of males (65+) 
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Figure 6-21 Projected number of females (65+) 
 
Figure 6.22 combines Figures 6.20 and 6.21 and shows, how the projected number of 
the entire Scottish population develops over the next two decades aggregated over all 
age groups. A constant increase can be observed, for both males and females, with the 
number of females remaining about 100,000 higher than the number of males in the 65+ 
population. 
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Figure 6-22 Aggregated number of males and females in Scotland (65+) 
 
The projected numbers of deaths for males and females from 2011 until 2033 for 
individuals aged 65 and older are presented in Figure 6.23 (males) and Figure 6.24 
(females). Both figures are based on population estimates obtained from NRS and 
represent the entire population of Scotland aged 65 and older. Comparing the number of 
deaths for males and females it can be observed that more females are dying. This is 
mainly caused by the fact that more females are alive at the age of 65 and above 
compared to males, as could be seen from Figure 6.20 and Figure 6.21 above.  
For males a slight increase in the number of deaths can be observed for the three oldest 
age groups, whereas the number of deaths for the three youngest age groups seems to 
fluctuate over the next decades, keeping relatively stable.  
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For females either a slight downward shift or a stable development of the absolute 
number of deaths can be observed for almost all age groups, apart from the eldest. For 
women aged 90 and older a steep increase in the number of deaths is observed for the 
next couple of decades.  
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Figure 6-23 Projected number of deaths in Scotland, males (65+) 
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Figure 6-24 Projected number of deaths in Scotland, females (65+) 
 
Figure 6.25 combines Figure 6.23 and Figure 6.24 and shows the aggregated number of 
deaths over all age groups and presents differences in the number of deaths for males 
and females. For females a slight downward shift in the absolute number of deaths is 
observed until 2020 after which deaths are projected to rise. For males a slight increase 
in the number of deaths can be observed up until 2017, followed by a slightly more 
pronounced increase. The difference in the absolute number of deaths between males 
and females seems to narrow over time, confirming overall, that people are projected to 
die at older ages.  
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Figure 6-25 Aggregated number of deaths, males and females (65+) 
 
 
6.5.4 Results - HC expenditure projections 
Results obtained from HC expenditure projection for both, the demographic approach 
and the TTD approach are presented in Table 6.13. These results are for that part of the 
sample aged 65 and older and for acute inpatient care expenditure, which will account 
for a substantial part of the total HC expenditure, but not for all of it. Results should 
therefore be interpreted with these limitations in mind.  
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Table 6-13 HC expenditure projections (acute inpatient care) for those aged 65+ 
Year TTD Approach Demographic 
Approach 
2011 100 100 
2016 110.2 112.7 
2021 120.2 124.8 
2026 132.3 139.9 
2028 139.6 146.5 
 
The growth rate observed for the TTD approach is projected to be lower than the growth 
rate that would be obtained when applying a simplified approach and only accounting for 
demographic changes in the population. This can be observed for all years for which a 
projection was carried out. Overall, the gap between a growth rate obtained under the 
demographic approach and a growth rate obtained under a TTD approach seems to 
widen slightly over time. Results in Table 6.13 show that in 15 to 17 years time the 
difference between projected HC expenditures will be about 7%.  
Figure 6.26 shows, how the projected HC expenditure is expected to be distributed in 
year 2011 (base year), 2016, 2021, 2026, and 2028. Both, Table 6.13 and Figure 6.26 
show an overestimation of future HC expenditure on the over 65s for acute inpatient 
care under the demographic approach. The magnitude of the overestimation is observed 
to be between 2% in 2016 and 7% in the year 2028.  
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Figure 6-26 Projection of HC expenditure for acute inpatient care (65+) 
 
 
6.6 Discussion 
Using a representative sample for the Scottish population, the SLS, the analysis in this 
chapter has shown that TTD, age at death and the interaction between these two have a 
significant effect on HC costs and so confirms findings from other previous research as 
well as findings in Chapter 5. This is very important, since other national studies might 
not have been able to utilise data that was representative of the population the study 
was undertaken in. The analysis also showed that TTD influences HC expenditure 
differently for different age groups and deprivation score quintiles.  
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The analysis of the effect that TTD in general had on costs provided similar findings to 
those obtained in Chapter 5. Using HRG costing and the English Tariff as one costing 
approach also showed TTD to be a significant predictor of costs towards the end of life. 
Comparing the magnitude of the effect between the last quarter of life in the 
Renfrew/Paisley sample and the SLS sample showed that costs for the Renfrew/Paisley 
sample were about 100% higher than in the 12th quarter before death, whereas they 
were about 85% higher for the SLS sample compared to the quarter furthest away from 
death (20th quarter). TTD in the SLS sample showed an effect that steadily increased as 
people approached death, whereas a ‘spike’ in costs for the Renfrew/Paisley sample 
could be observed for quarters seven and eight before death. Although similar, it might 
be that these results can not be compared directly since they have been obtained using 
two different samples of the Scottish population. 
The analysis in this chapter focused on three main issues, all of which are discussed in 
detail below. First of all, this study sought to test whether findings from other research 
that showed differences in HC utilisation and costs by socio-economic status (Cookson 
and Laudicella, 2011) also translates into differences in costs incurred towards the end 
of life given evidence that ‘poorer’ people seem to die prematurely (Chalmers and 
Capewell, 2001). This analysis was motivated by findings from the analysis in Chapter 5, 
where individuals from more deprived areas seemed to cost less at the end of life. A 
second issue that was investigated was the application of two different cost variables to 
provide further evidence for the importance of choosing a method to cost hospital stays 
and so to underpin the analysis undertaken in Chapter 4 in this thesis. One final and 
very important issue the analysis in this chapter concentrated on was the comparison of 
projected HC expenditure under two different modelling approaches, including and 
excluding remaining TTD, in order to obtain an estimate of the over/under-estimation of 
future costs if TTD were excluded from a projection model. 
Chapter 6  243 
 
 
6.6.1 Socio-economic status 
The impact of individuals’ socio-economic status on the probability of accessing hospital 
care seems to be influenced by TTD, as can be seen from interaction effect results 
obtained from the first part of the model (Table 6.5). As people approach death, those 
living in more deprived areas are less likely to reach hospital compared to those living in 
the most affluent deprivation score quintile. These findings confirm previous research 
undertaken in Scotland that looked at out-of-hospital cardiac deaths by socio-economic 
status and found that mortality rates out-of-hospital were much higher in deprived socio-
economic groups (Capewell et al, 2001).  
Further results for the second modelling part (costs incurred, given positive utilisation) 
revealed that the type of costing method seems to influence the effect that the socio-
economic status has on estimated hospital costs at the end of life. This could be seen in 
regression results for TTD and deprivation interactions (Table 6.8 (English Tariff) and 
Table 6.10 (SNT)). When applying the SNT to cost hospital stays a significant 
association between costs and the interactions between socio-economic status and TTD 
could be observed for the most deprived quintile. Applying the English Tariff however, 
reveals a much less pronounced (or possibly no) interaction effect between TTD and 
socio-economic status. It was already pointed out that these findings seem to be 
contrary to findings from previous research (which notably used English HRGs) that 
suggested that ‘the poor cost more’ (Cookson and Laudicella, 2011). This thesis has 
found a reverse effect, with ‘poorer’ people costing less in their last five years of life. 
One possible explanation is that the difference between costing methods mainly lies in 
the fact that the SNT does not offer a means to account for very long stays through the 
application of additional per diem costs and so places less weight on very long stays. 
People from more deprived areas are known to have longer stays at hospital, often due 
to a lack of available care in their own homes. Therefore, any deprivation category effect 
that might be present could have been modified by giving more weight to LOS in the set-
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up of the cost variable when using the English Tariff, but not when using the SNT. An 
alternative explanation could be that more is spent on individuals from more deprived 
areas during their life time, but not immediately before their death. 
6.6.2 Costing method 
In addition to the different results obtained for TTD and deprivation interaction terms, the 
costing method also influenced the remaining results of included explanatory variables. 
In terms of the size of the effect, the TTD effect is much more pronounced for the 
English Tariff than it is for the SNT (that is the coefficients are larger). However a highly 
statistically significant association of TTD with costs can be found as far back as 12 
quarters before death for the SNT, whereas statistical significance of TTD for the 
English Tariff is only found up until the fourth quarter before death.19 The smaller effect 
that can be found especially in the last quarter of life might entirely be attributable to 
missing extra per diem costs20, so that as a consequence, costs estimates will be lower 
than for the English Tariff. 
No effect of having an LTI could be found for the SNT. A possible explanation might be 
that individuals with an LTI would be expected to have longer stays at hospital and not 
accounting for extra per diem costs in the set-up of the SNT might not reflect this 
underlying reason for incurring higher costs. 
6.6.3 Population and HC expenditure projections 
As shown in Figure 6.17 and Figure 6.18, HC expenditure for acute inpatient care 
seems to be concentrated in the last year of life, and in particular the time immediately 
before death, i.e. the last quarter of life. Death is being postponed into older ages 
leading to an increased longevity as confirmed by Figure 6.23 and 6.24, where an 
                                               
19
 For quarters 7 and 12 before death only a marginally statistically significant effect is found. 
20
 Extra per diem costs are applied to those hospital stays, were the LOS exceeds a so called 
trim-point, which marks the expected LOS for each HRG and the SNT does not offer means to 
apply extra per diem costs for very long stays. 
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increase in the number of projected deaths over the next decades could be observed for 
the oldest age groups, when no such increase could be observed for the younger age 
groups. The two approaches of projecting HC expenditure demonstrated that costs do 
not rise as quickly if factors, such as TTD and increasing longevity and also the 
postponement of diseases into older ages were accounted for.  
These findings are in line, although at the lower end of the scale, with other research 
that has found future HC expenditure at risk of being overestimated if TTD is not 
accounted for and estimates of an overestimation varied between 3.4% and 18.5% 
(Breyer and Felder, 2006, Hakkinen et al., 2008, Polder et al., 2006, Serup-Hansen et 
al., 2002, Stearns and Norton, 2004).  
The analysis in this chapter showed that if deaths are postponed into older ages, and a 
compression of morbidity is present as put forward by Fries (1980), which was later 
confirmed by other researchers (Christensen et al., 2009, Payne et al., 2007), HC 
expenditure (and HC budgets) would not increase to the same extent than it would were 
these factors ignored. These factors would be ignored if, when that part of the 
population that is in their last year(s) of life would not be taken into consideration by 
obtaining separate cost estimates for the time immediately before death. The analysis in 
Chapter 6 found future HC costs in Scotland under a purely demographic approach to 
be overestimated by about 7% in 2028 thus confirming results from the wider 
international literature. 
The fact that the estimates for an overestimation of future HC expenditure are at the 
lower end of the scale compared to other, international results could be explained by the 
selection of the sample and the HC system that has been analysed. It could be 
speculated that there are national differences in terms of the extent of care that is 
delivered to people close to death. If this is the case this would have an impact on cost 
estimates obtained stratified by TTD which are subsequently used in order to project 
Chapter 6  246 
 
 
future HC expenditure under a TTD approach. When interpreting these results it should 
be noted that HC expenditure projections have been calculated for that part of the 
population aged 65 and older and for acute inpatient care only. Although this might 
constitute a large proportion of the entire expenditure, it does not provide a complete 
picture of the entire HC system and its associated costs. 
Another important factor that will contribute to differences in findings will be each 
country’s demographic structure. Differences found for HC expenditure projections using 
a demographic and a TTD approach will be larger if demographic changes occur more 
rapidly. If the number of deaths in each age group would remain constant over time then 
no differences would be found between projection approaches. 
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7 MAIN FINDINGS, POLICY IMPLICATIONS, 
LIMITATIONS AND FUTURE RESEARCH 
 
7.1 Introduction 
The empirical analyses undertaken in the three preceding chapters has, based on the 
critical assessment of the literature in Chapter 3, presented issues in the research field 
that have either not been addressed to date, or have been dealt with using a variety of 
methods resulting in different, sometimes conflicting findings. This thesis has also, for 
the first time in Scotland, employed advanced econometric methods and a 
representative sample of the Scottish population to estimate the effect that population 
ageing and remaining TTD have on HC expenditure in an acute inpatient care setting.  
This final chapter summarises the main findings of this thesis in Section 7.2. In Section 
7.3 potential policy implications are outlined, followed by a discussion of possible 
limitations of the analyses in this thesis in Section 7.4. Section 7.5 provides a 
presentation of how this work could be taken forward in the future.  
 
 
 
 
7.2 Main findings  
7.2.1 Comparison of alternative costing methods 
Chapter 4 provided an overview of alternative costing methods. The analysis in this 
chapter was motivated by the fact that researchers can, and do, apply different methods 
of costing hospital stays, i.e. there is no gold standard. The research question of ‘How 
do different methods to cost inpatient hospital stays affect cost estimates and also the 
marginal effect that explanatory variables have?’ was examined. It was vital to address 
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this issue before proceeding with the main empirical analyses in Chapters 5 and 6 since 
the availability of alternative costing methods for acute inpatient hospital stays required 
a decision on which method to use in order to inform analyses in the subsequent 
chapters. 
Ideally the costing method reflects the nature of a hospital stay, which is characterised 
by a fixed and variable cost component. It should also reflect the diagnosis and any 
procedure undertaken. Costing methods vary in the level of precision with which these 
pre-requisites are reflected in the actual unit cost that is assigned. Per diem costing, for 
instance, assumes that the first day in hospital is as expensive as each subsequent day. 
Specialty specific per episode costing is insensitive to the diagnosis and procedure. 
Costing methods that reflect case-mix (HRGs) are difficult to implement in Scotland as 
these either require the assignment of English Tariff, a fact that could be argued not to 
be appropriate for Scottish hospital episode statistics, or they require the assignment of 
the SNT, which is still being developed and currently only used for cross-boundary flows 
of payments between different health boards in Scotland. 
In order to assess differences in results, both on an absolute scale, but more importantly 
in terms of the marginal effect that a set of explanatory variables has on costs, five 
methods of assigning unit costs to acute inpatient care episodes were compared. These 
included, in addition to the methods mentioned above, a novel method that has to date 
not been used in any costing exercise and was based on research done by NRAC 
(Bishop et al., 2006). While it is recognised that the chosen costing approach should be 
mainly determined by the research question, Chapter 4 highlighted important issues that 
arise from the application of alternative methods.  
A comparison of HRG and per diem costing as the two most commonly used methods 
(Anandan et al., 2009, Lorgelly et al., 2010, Maheshwari et al., 2010, Poole et al., 2010, 
Gray et al., 2001, Stewart et al., 2002, Christensen and Munro, 2008, Harjola et al., 
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2009, Ringborg et al., 2009, Liu et al., 2002, Walker et al., 2003, Miller et al., 2009), 
revealed substantial scale differences and some difference in the size of the effects that 
explanatory variables have on costs. Chapter 4 also concluded that studies that employ 
a per diem costing approach neglect the nature of a hospital stay, which is characterised 
by fixed costs being independent of LOS and variable costs varying with LOS, and 
thereby might be in danger of overestimating costs. Although general conclusions in 
terms of sub group analysis, i.e. males are less costly than females, did not seem to be 
influenced by the type of costing, the magnitude of the effect was.  
The analysis of alternative costing methods emphasised that any inference made from 
econometric modelling of costs, where the marginal effect of explanatory variables is 
assessed, is substantially influenced by the costing method. It also revealed that the 
marginal effect of explanatory variables was influenced to a much lesser degree by the 
econometric modelling framework and it was concluded that this had a negligible impact 
on obtained estimates for HC expenditure. 
This analysis of costs took into account the special characteristics of HC expenditure 
data for which a detailed description was provided in Section 3.4 and used the 
appropriate estimators to model these expenditure data. In the discussion of findings 
from Chapter 4 the application of the HRG costing method (method 1) was 
recommended as this method facilitates the inclusion of disease specific costs, 
incorporates a fixed and variable cost component through the application of a trim point 
payment (for the English Tariff) and further allows adequate costing of hospital stays 
that involve more than one episode of care. It was therefore concluded to be the 
preferred method to cost acute inpatient stays.  
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7.2.2 Renfrew/Paisley study 
The analysis of the Renfrew/Paisley sample in Chapter 5 addressed the issue of the 
relationship between age, TTD and HC expenditure. Specifically Chapter 5 sought to 
answer three questions: 
 1. What is the independent effect of TTD and age on expenditure for acute 
 inpatient care in Scotland? 
2. How do previously unconsidered explanatory variables, such as health risks 
and health status measures impact on HC expenditure as the population ages 
and approaches death? 
3. How does sample selection, in particular the inclusion/exclusion of surviving 
sample members due to right censoring, impact on estimated costs? 
In order to answer these research questions, Chapter 5 firstly utilised findings from 
Chapter 4 in its empirical analysis of the cost of ageing and the cost of dying. The 
methods employed in Chapter 5 were novel as they compared for the first time the 
difference in estimated costs, when accounting for age and remaining TTD for different 
sample scenarios. The analysis and the development of the methods were motivated by 
findings from the literature that revealed that no consistent and robust methods were in 
place to account for right censoring of the surviving proportion of the sample population. 
The review of the literature highlighted a variety of methods that have been employed in 
the past and outlined limitations that could arise from sample selection (Zweifel et al., 
1999, Felder et al., 2000, Moorin and Holman, 2008, Seshamani and Gray, 2004c) or 
inappropriate assumptions for survivors and their TTD (Stearns and Norton, 2004, 
Breyer and Felder, 2006). 
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The empirical analysis of this present study facilitated a comparison of the impact on 
estimated costs as people approach death for different sample scenarios: the inclusion 
of decedents only (scenario A), the inclusion of decedents and survivors, using the 
censoring date as the date of death for survivors (scenario C), and the inclusion of 
decedents and survivors, using a predicted TTD for survivors (scenario D) in 
econometric modelling. As an additional guidance of how deceased or survivor status 
impact costs, scenario B was added, which included surviving sample members only.  
For the novel method, scenario D, the predicted TTD was obtained through the 
application of survival analysis and extrapolation of additional predicted years of life for 
that part of the sample population that was alive at the end of the study period, i.e. 
censored. The quarters before death and their associated observed costs for survivors 
could then be adjusted accordingly. Estimated costs showed a £491 difference on 
average in the last quarter of life between the decedent group (scenario A) and the 
group using the censoring date (scenario C) and a £12 difference between the decedent 
group (scenario A) and the group using a predicted TTD (scenario D). These results 
confirmed the initial hypothesis of an overestimation of costs, particularly in the last 
quarter of life if survivors are excluded from the analysis and provided an estimate of 
costs in order to answer research question three above.  
In addition to exploring a robust method of accounting for survivors’ right censoring the 
main findings of the analysis undertaken in Chapter 5 were that TTD, age and the 
interactions between these two factors were significant predictors for HC expenditure in 
the last 12 quarters of life. These results confirmed findings from other national research 
(Zweifel et al., 1999, Seshamani and Gray, 2004b). On average, the two youngest age 
groups (<65 and 65-69 years) were found to incur higher costs than the older age 
groups, confirming in part the ‘red herring’ argument put forward by Zweifel and 
colleagues in 1999. However, age was still found to be an important predictor for HC 
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expenditure and that TTD influenced costs differently for different age groups as shown 
through the inclusion of interactions between TTD and age. 
The strength of this analysis is also expressed through the excellent linked data with 
very low attrition rates and minimum missing data that comprise the Renfrew/Paisley 
study. Clinical measurements that were taken at baseline allowed the inclusion of 
previously unconsidered explanatory variables (Graham and Normand, 2001, Lowe, 
2005). This facilitated investigation of how important these baseline factors were in 
explaining HC expenditure as people aged and approached death.  
Some perhaps surprising results were obtained for two of the health status indicators: 
SBP and cholesterol level, where individuals with a measure within healthy limits were 
more likely to access hospital services. This result might be explained with the ‘worried 
well’ who may be seeking medical attention earlier than other people. This seems partly 
confirmed by a significant effect that a normal SBP has on costs incurred in the second 
part of the estimation, where these individuals, although more likely to access hospital 
services, were shown to incur lower costs. There might also be a lower risk for adverse 
events and subsequent related costs for individuals with a normal SBP. For the 
cholesterol level, which had a significant association with the probability of accessing 
hospital services, this significant association almost entirely disappears in the second 
part of the regression modelling. Only for the sample that includes decedents (scenario 
A) a marginally significant effect (p<0.1) could be found that suggested that individuals 
with a healthy level of cholesterol incur higher costs.  
Another explanation for these surprising results could be provided through the time of 
this study. An inverse association between the cholesterol level and the socio-economic 
status was found in previous research (Smith et al, 1998; Hawthorne et al, 1995), i.e. 
individuals from more affluent areas had a higher reading. The study took place at a 
time, when public knowledge of the harmful effects of cholesterol was limited. People 
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from more affluent areas could afford eating red meat and may have consequently had a 
higher cholesterol level. In turn, people with a healthy cholesterol level may have had 
unhealthy readings for other health status measures (Smith et al, 1998; Hawthorne et al, 
1995; Hart C, personal communication). In general, health status indicators that have 
previously not been included in the analyses were found to be significant predictors for 
costs in the future and the inclusion of such measures, where the available data allow to 
do so, is recommended here.  
Results from this present study confirm conclusions from other research such as studies 
on the issue of rationing health care by age. Williams (1997) puts forward the ‘fair 
innings’ argument, which argued that limited resources should be devoted to those that 
would benefit most, i.e. more should be done to enable younger people to survive than 
should be done to enable older people to survive (Williams, 1997). Results from the 
analysis in this thesis seem to confirm this, as costs at the end of life that were obtained 
for the eldest ages seemed to be consistently lower than those for younger age groups.  
 
7.2.3 Scottish Longitudinal Study 
Chapter 6 extended the analysis of the association between TTD, age and costs 
undertaken in Chapter 5, but using a representative sample of the Scottish population. It 
was necessary to consider a representative sample as the two remaining research 
questions this thesis set out to answer required the results to be generalisable for the 
entire Scottish population: 
1. What is the association between socio-economic status and HC expenditure 
at the end of life? 
2. How are HC expenditure projections influenced when using a model 
accounting for TTD versus a model that only accounts for the increasing 
proportion of elderly individuals? 
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The analysis was performed using a similar modelling and costing approach as 
undertaken in Chapter 5 which provided a means to validate the methods employed 
using the Renfrew/Paisley sample. The representative sample consisted of SLS sample 
members, enumerated at either the 1991 or 2001 census.  
In order to explore the impact that the socio-economic status has on costs, a measure 
representing deprivation score quintiles was included. Previous research has shown that 
people living in more deprived areas incurred higher costs in general (Cookson and 
Laudicella, 2011, Lemstra et al., 2009). Other research, undertaken in Scotland shows a 
clear association between pre-mature death and socio-economic status (Chalmers and 
Capewell, 2001). This thesis sought to ascertain whether differences between socio-
economic status and death and socio-economic status and costs also translated into 
differences between socio-economic status and the costs incurred towards the end of 
life.  
Estimated average costs in the last quarter of life seemed to differ between individuals 
from the most affluent quintile and individuals from the most deprived quintile. It was 
found that TTD influenced costs differently for different deprivation score quintiles. 
Differences were detected for the effect that the interaction terms between the socio-
economic status and TTD had on costs between the two different methods of costing 
hospital stays (the English Tariff and the SNT). When applying the English Tariff only 
marginally statistically significant associations could be observed. The model that 
employed the SNT however, revealed a significant association with costs for the most 
deprived quintile (5) and quarters 1 to 9 before death. Differences were most likely 
caused by not being able to assign extra per diem costs when using the SNT.  
Findings from this analysis contradict previous research (Cookson and Laudicella, 2011, 
Lemstra et al., 2009) as results show that there is only a very small effect that the socio-
economic status has on costs at the end of life, which suggested that poor people might 
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cost less, that is have less spent on them. It should be noted, however, that Lemstra et 
al (2009) have used income as a proxy for socio-economic status in their analysis which 
might explain some of these different findings. Cookson and Laudicella (2011) have 
used a specific disease area (hip replacement) which could also serve as an explanation 
for different results. Another explanation for these different findings is that costs are 
most likely driven by the probability of reaching hospital, which was shown to be lower 
for individuals from more deprived areas. This is in agreement with results from other 
studies undertaken in Scotland (Capewell et al, 2001). 
The second research question explored in Chapter 6, was the extent to which future HC 
expenditure (for acute inpatient care, as the most expensive sector in the NHS) might be 
overestimated if a simple approach of applying constant age-expenditure profiles to 
future population numbers was used compared to an approach that takes into account 
the changing pattern of morbidity via the inclusion of remaining TTD as a measure of 
morbidity.  
The analysis in Chapter 6 found future HC costs in Scotland in the year 2028 under a 
purely demographic approach to be overestimated by about 7%, thus confirming results 
from the wider international literature. The discussion in Chapter 6 highlighted that 
results for any overestimation of costs between the two different approaches of 
projecting HC expenditure are found to be at the lower end of the scale compared to 
other research. It was concluded that the fact that studies were carried out in a variety of 
countries, with differences in how HC was organised, paid for and delivered must 
necessarily lead to different cost estimates for the TTD approach as this mainly depends 
on the amount of money spent on individuals in their last years of life. It was also 
concluded that the speed of the demographic change will have an impact on the 
difference found between the two approaches. 
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7.3 Policy implications 
Chapter 2 provided a summary regarding how TTD had been examined by NRAC to 
decide whether it should be included in the current resource allocation formula. That 
chapter also outlined the current adjustments that are made in the resource allocation 
formula, which are for the age and sex structure of the population, remoteness and 
MLC. NRAC argue that these factors ensure that resources are allocated according to 
need, yet the formula does not currently account for TTD. 
 
Section 2.4.3 examined the reasons for the exclusion of the factor TTD in resource 
allocation in Scotland. The decision not to include TTD was partly based on the research 
that has to date been undertaken in Scotland (Lowe, 2005, Graham and Normand, 
2001). NRAC acknowledged that this was preliminary research and that further analyses 
were necessary to fully inform future reviews of the resource allocation formula. This 
thesis provides the requested extensive research, both a comprehensive cohort 
(Renfrew/Paisley study) and a representative sample (SLS) linked to Scottish acute 
inpatient care records, are employed in models which use advanced econometric 
techniques, it showed how TTD influences costs.  
One important issue for any policy maker is equity. This thesis thoroughly investigated 
how the socio-economic status impacts on costs towards the end of life and found 
poorer people to incur less costs, which might mainly be caused by the fact that they 
also seemed to be less likely to access hospital services. This finding certainly deserves 
further analysis as to the factors that cause this relationship between socio-economic 
status, access to HC and associated costs. 
In addition, a method was presented to obtain estimates of the proportion of the 
population projected to be in a particular year before death. These proportions can be 
calculated for each single year of age and separately for males and females. Projected 
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numbers of the total population and the number of deaths are available from NRS and 
can easily be implemented to calculate the proportion of the population projected to be 
in their last, second last, etc. year of life. This extension is something previous research 
in Scotland did not address and therefore was consequently unable to provide an 
estimate of future cost projections with and without TTD.  
With death as the main contributing factor to HC costs, a lower number of deaths in the 
future will lead to decreasing costs of dying and hence to lower HC projections. It is 
therefore, at least partially, counteracting the effect that an increasing proportion of 
elderly people might have on HC expenditure. However, as the diagnostic techniques 
and management of diseases are changing and a higher amount is probably spent on 
avoiding disease rather than curing it, a shift from expenditure on acute inpatient care 
towards HC sectors that are concerned with preventative care (i.e. primary care) might 
be observed in the future. 
In addition to the implications this research has for resource allocation, there are other 
factors that are important, especially for HC planning and budgeting. As shown, future 
HC expenditure is at risk of overestimation if TTD is neglected in the modelling process. 
Resources that would have been directed to finance acute inpatient care could be re-
allocated to different public sectors.  
 
7.4 Limitations 
One main and general limitation that applies to the analyses in all empirical chapters is 
that of only being able to analyse the acute inpatient care sector. It was argued that this 
might be the most important sector as it is characterised by very high costs compared to 
other HC sectors, however it is not possible to draw an overall complete picture of how 
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population ageing and TTD influence the entire HC sector or even the LTC sector. This 
is further complicated by the fact that LTC in Scotland does not fall within the remit of 
the NHS, but is the responsibility of local councils. Several studies that have also or only 
analysed how population ageing and TTD affect costs for LTC found a reversed effect to 
the one that is usually found for acute inpatient care (de Meijer et al., 2011, McGrail et 
al., 2000, Spillman and Lubitz, 2000). It is therefore important to distinguish between HC 
sectors when interpreting results and to be aware of possible differences in the effect 
that population ageing has, mainly caused by different pattern of utilisation at different 
ages. Specific limitations that concern each of the empirical chapters are presented 
below.  
7.4.1 Costing methods 
Limitations arising from the analysis of alternative costing methods can mainly be 
attributed to the fact that inpatient stays were considerably longer on average in the past 
than they are now. This raises the question of how to adequately account for this without 
over-estimating recent costs or under-estimating historic costs. Employing data from a 
cohort, which ages over time, may mean that the two effects, a) LOS decreases over 
time and b) LOS increases with age, might cancel each other out. Without access to full 
historic costs this problem is difficult to overcome. This leads to another limitation, which 
is the use of the trim point LOS in HRG based costing applying English costs. 
2006/2007 was chosen as the reference year with respective tariffs and trim point 
information. But the trim point can change over time, such that applying the same trim 
point value for all time periods observed may have also introduced bias, but full 
historical data on trim points was not available.  
Another point of criticism that could be raised is that the explanatory variables included 
in the model in Chapter 4 do not fully explain costs and this model is likely to suffer from 
omitted variable bias. However, it should be noted that the chosen explanatory variables 
are mainly to facilitate comparison of methods rather than to fully explain hospital costs. 
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Limitations that arise from the analysis of alternative costing methods ultimately affect 
the analyses in Chapters 5 and 6 as these have used the costing methods presented in 
Chapter 4. 
7.4.2 Renfrew/Paisley study 
Although the analysis in Chapter 5 using the Renfrew/Paisley sample is novel for 
Scotland and provides some important insights into the mechanism of how TTD, 
population ageing and costs interact, like many empirical analyses using longitudinal 
cohort data, it also has limitations. One limitation that has already been explained is the 
nature of inpatient stays and how these have changed over time, especially in terms of 
LOS.   
One problem that frequently characterises time series data is serial correlation, i.e. 
observations for the same observational unit (an individual) are not independent. There 
are two layers to this issue: firstly, hospital episodes are not independent. One approach 
that partly accounts for serial correlation is the use of a CIS and the aggregation of costs 
into quarterly costs. However, this leaves a second issue: the potential correlation 
between quarters before death per individual. In order to derive correct standard errors 
clustering on patient identifier was applied. One final limitation is concerned with the fact 
that clinical measurements were only taken at baseline and therefore could not be 
followed up over time. 
Results for the analysis of different sample scenarios that excluded and included the 
surviving part of the sample and recommended survival analysis in order to account for 
right censoring, will very much depend on the proportion of the sample that is alive at 
censoring and also on their age. If there is only a very small proportion that is right 
censored, it might be unlikely that results will alter substantially between various sample 
scenarios. 
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7.4.3 Scottish Longitudinal Study 
The analysis in Chapter 6 also potentially suffers from a number of limitations in addition 
to those highlighted from arising from the costing of hospital episodes over a long period 
of time. The analysis also used the method of undertaking survival analysis in order to 
account for right censoring of survivors in the SLS. Contrary to the Renfrew/Paisley 
sample the SLS sample consisted of a much larger proportion of survivors mainly 
caused by a younger average age of sample members. It could be argued that for the 
survival analysis to provide useful predictions of additional years of life, actual death 
should not be too far in the future. This is because observed costs for quarters before 
death are adjusted according to results from survival analysis. If the analysis looks at the 
last five years of life but the predicted date of death seems to be 10 or 15 years away 
from the censoring date, these observations might not be as useful as those, whose 
death is only two years away from the censoring date.  
Despite these limitations, the application of a more advanced method of including 
survivors when employing econometric modelling of costs towards the end of life has 
obvious advantages. It increases the sample size and thereby the statistical power; and 
it mitigates the problem of sample selection bias. 
 
7.5 Future research 
Evidence in this thesis and from previous research has shown that population ageing 
does not lead to an increase in future HC expenditure to the extent that might have been 
previously anticipated. This thesis is the first extensive empirical study in that research 
area in Scotland that has used linked data. However, further important research 
questions remain that can be answered utilising the excellent linked data that Scotland 
has available, such as how do geographical inequalities impact on HC costs towards the 
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end of life? Scotland is characterised by large geographical areas that are either 
accessible rural areas or very remote areas. These areas face major challenges in 
terms of access to HC services. Research has shown that for instance for acute MI the 
distance between hospital and home can predict mortality, which tends to be higher in 
these rural areas (Wei et al, 2008). Rural areas in Scotland are also characterised by a 
larger proportion of elderly people, either because younger people tend to leave these 
areas or because of a retiree emigration into these parts of Scotland. In addition, LOS in 
hospital tends to be longer in rural areas on average because of a lack of nursing homes 
or informal care at home. 
These different patterns of utilisation of HC and LTC in remote areas will have an impact 
on how TTD affects HC expenditure. On the other hand, rural areas tend to have better 
socio-economic indicators as they face lower unemployment and are generally less 
deprived than urban areas. Such an analysis might therefore be able to revisit the issue 
of the impact that socio-economic status has on costs at the end of life. 
An important aspect of future research in this area would therefore be to inform 
budgeting as to the mechanism of how the different factors described above impact on 
HC expenditure. Can results from research that did not take into account spatial 
dependencies be confirmed when including geographical location? Such an analysis 
might also be able to revisit the issue of the impact that socio-economic status has on 
costs at the end of life which may well be influenced by geographical location. 
The analyses in this thesis assumed exogeneity between TTD and HC expenditure, 
similar to many other studies that have been undertaken in this field. However, the 
possible endogeneity between these two variables is an issue that has not been solved 
entirely to date. Future methodological research could explore further avenues to purge 
TTD off its endogeneity, such as using predicted TTD instead of observed values. 
Further methodological work worthwhile undertaking could be concerned with the 
  262 
 
 
inclusion of measures of uncertainty around HC expenditure, TTD and population 
estimates as well as the application of a random effects model. This would allow us to 
ascertain whether there is any correlation between error terms (ui) that are obtained from 
the first and the second part of the model. This might also provide a better 
understanding as to whether those individuals, who are more likely to use HC services, 
also incur higher costs.  
In addition, other HC sectors would need to be analysed. As pointed out throughout this 
thesis, the sector of acute inpatient care might be very different in terms of the effect that 
TTD and age will have on future costs. It was mentioned that an analysis of the LTC 
sector might provide very different results. To gain an overall understanding of the 
financial impact of an ageing population it would be highly informative to be able to 
analyse a broader spectrum of HC services.
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Appendices 
 
Appendix I: Literature search strategy 
 
Medline 1950-2009; 24th Feb 2009  
1. (health care cost* or healthcare cost*).tw. 
2. "Cost of Illness"/ 
3. Models, Econometric/ 
4. Population Dynamics/ 
5. health care costs/ or hospital costs/ or health expenditures/ 
6. aging/ or longevity/ 
7. aged/ or "aged, 80 and over"/ or frail elderly/ 
8. (aged or elder* or ageing or aging or "over 65").ti. 
9. 8 or 6 or 7 
10. (cost* or expenditure or spend*).ti. 
11. ((healthcare or health care or hospital*) and (cost* or expenditure or spend*)).tw. 
12. 11 or 2 or 5 
13. 4 and 9 and 12 
14. limit 13 to english language 
15. proximity to death.tw. 
16. "time to death".tw. 
17. "last year* of life".tw. 
18. 16 or 17 or 15 
19. 18 and 12 
20. limit 19 to english language 
21. Long-Term Care/ 
22. social care.mp. 
23. Nursing Homes/ or Homes for the Aged/ 
24. care home*.mp. 
25. 22 or 21 or 24 or 23 
26. 25 and 10 
27. 4 and 26 and 9 
28. 25 and 4 and 9 
29. limit 28 to english language 
30. 3 and 14 
31. 3 and 29 
32. 25 and 18 and 10 
 
  264 
 
 
Appendix II: Composition of specialty groups 
 
Specialty Group Specialty Specialty Group Specialty 
Accident & Emergency Accident & Emergency Medical Other Allergy 
Acute Other Chiropody   Clinical Pharmacology & 
Therapeutics 
  Surgical Podiatry   Endocrinology  
Adolescent Psychiatry Adolescent Psychiatry   Genito-Urinary Medicine  
Cardiac Surgery Cardiac Surgery   Homoeopathy 
Cardiology Cardiology   Immunology 
Child Psychiatry Child Psychiatry   Nuclear Medicine 
Clinical Oncology Clinical Oncology   Palliative Medicine  
Communicable Diseases Communicable Diseases Medical Paediatrics Medical Paediatrics 
Coronary Care Unit Coronary Care Unit 
(Significant Facility) 
Nephrology Nephrology 
Dental Orthodontics Neurology Neurology 
  Paediatric Dentistry  Neurosurgery 
 
Neurosurgery 
  Restorative Dentistry  Obstetrics GP GP Obstetrics 
  Community Dental Practice  Obstetrics 
Specialist 
Obstetrics Ante-Natal 
  General Dental Practice    Obstetrics  
Dermatology Dermatology   Post-Natal  
Ear Nose & Throat Ear Nose & Throat   Obstetrics  
Gastroenterology Gastroenterology   Midwifery  
General Medicine General Medicine   Community Midwifery  
General Practice General Practice (excluding 
Obstetrics) 
Ophthalmology Ophthalmology 
General Psychiatry Forensic Psychiatry Oral Surgery & 
Medicine 
Oral Surgery 
  General Psychiatry    Oral Medicine 
  Psychotherapy Orthopaedics Orthopaedics 
General Surgery (excluding 
Vascular) 
General Surgery (excluding 
Vascular) 
Plastic Surgery & 
Burns 
Plastic Surgery 
Geriatric Assessment Geriatric Medicine Rehabilitation 
Medicine 
Rehabilitation Medicine 
Geriatric Long Stay Geriatric Medicine Respiratory 
Medicine 
Respiratory Medicine 
Geriatric Psychiatry Psychiatry of old age Rheumatology Rheumatology 
Gynaecology Gynaecology Special Care Baby 
Unit 
Special Care Baby Unit 
(Significant Facility) 
Haematology Haematology Spinal Paralysis Spinal Paralysis 
High Dependency Unit High Dependency Unit 
(Significant Facility) 
Surgical Paediatrics Surgical Paediatrics 
Intensive Care Unit Intensive Care Unit 
(Significant Facility) 
Thoracic Surgery Thoracic Surgery 
Learning Disabilities Learning Disabilities Urology Urology 
Medical Oncology Medical Oncology Vascular Surgery Vascular Surgery 
  Young Chronic Sick Younger Physically Disabled 
(Significant Facility) 
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Appendix III: Fixed and variable cost split21 
 
Specialty %fixed %variable 
SCBU 0.0 100.0 
ICU 0.0 100.0 
CCU 21.0 79.0 
Spinal Paralysis 0.0 100.0 
General Medicine 55.5 44.5 
Communicable Diseases 54.7 45.3 
Dermatology 7.8 92.2 
Geriatric Medicine 0.0 100.0 
Medical Paediatrics 44.2 55.8 
Nephrology 40.1 59.9 
Neurology 0.0 100.0 
Acute Other? 0.0 100.0 
Rehabilitation Medicine 0.0 100.0 
Respiratory Medicine 10.7 89.3 
Rheumatology 33.8 66.2 
General Surgery 66.7 33.3 
Accident & Emergency 0.0 100.0 
Cardiothoracic Surgery 70.4 29.6 
Ear, Nose & Throat 78.7 21.3 
Neurosurgery 68.5 31.5 
Ophthalmology 81.1 18.9 
Orthopaedics 68.2 31.8 
Plastic Surgery 68.1 31.9 
Surgical Paediatrics 55.4 44.6 
Urology 65.3 34.7 
Oral Surgery 84.6 15.4 
Community Dental Practice 93.5 6.5 
Obstetrics 60.0 40.0 
GP Obstetrics 67.2 32.8 
GP Other Than Obstetrics 38.9 61.1 
Gynaecology 71.8 28.2 
Haematology 44.5 55.5 
Clinical Oncology 0.0 100.0 
 
                                               
21
 These values were obtained through personal communication with the NHS Resource 
Programme, Health Finance Information Team at ISD Scotland. 
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Appendix IV: Interaction terms TTD*Age: Sample Scenarios 
A, B, C and D (c.f. Table 5.3) 
 
 
Scenario A Scenario B Scenario C Scenario D 
 
β SE β SE β SE β SE 
TTD1*Age2 -0.003 0.142   -0.003 0.142 -0.004 0.142 
TTD1*Age3 -0.062 0.131   -0.062 0.131 -0.060 0.131 
TTD1*Age4 -0.227* 0.125   -0.462*** 0.123 -0.222* 0.125 
TTD1*Age5 -0.354*** 0.125 -0.212 0.131 -0.915*** 0.121 -0.352*** 0.124 
TTD1*Age6 -0.521*** 0.132 -0.311** 0.141 -1.058*** 0.125 -0.459*** 0.127 
TTD1*Age7 -0.564*** 0.156 -0.399** 0.173 -1.141*** 0.139 -0.686*** 0.142 
TTD2*Age2 -0.154 0.148   -0.153 0.148 -0.154 0.148 
TTD2*Age3 -0.060 0.135   -0.059 0.135 -0.058 0.135 
TTD2*Age4 -0.195 0.130   -0.280** 0.128 -0.190 0.130 
TTD2*Age5 -0.264* 0.130 -0.013 0.130 -0.450*** 0.126 -0.262** 0.128 
TTD2*Age6 -0.402*** 0.137 -0.080 0.139 -0.572*** 0.130 -0.365*** 0.132 
TTD2*Age7 -0.505*** 0.158 -0.058 0.162 -0.637*** 0.143 -0.591*** 0.145 
TTD3*Age2 -0.105 0.150   -0.104 0.150 -0.105 0.150 
TTD3*Age3 -0.169 0.139   -0.168 0.139 -0.167 0.139 
TTD3*Age4 -0.179 0.133   -0.235* 0.131 -0.174 0.133 
TTD3*Age5 -0.347*** 0.134 -0.051 0.126 -0.434*** 0.130 -0.346*** 0.132 
TTD3*Age6 -0.486*** 0.142 -0.210 0.136 -0.585*** 0.135 -0.473*** 0.137 
TTD3*Age7 -0.521*** 0.166 -0.364** 0.164 -0.675*** 0.148 -0.607*** 0.150 
TTD4*Age2 -0.176 0.152   -0.175 0.152 -0.176 0.152 
TTD4*Age3 -0.133 0.139   -0.132 0.139 -0.131 0.139 
TTD4*Age4 -0.245* 0.133   -0.275** 0.132 -0.240* 0.133 
TTD4*Age5 -0.338** 0.134 0.105 0.129 -0.322** 0.129 -0.342*** 0.132 
TTD4*Age6 -0.331** 0.140 -0.127 0.138 -0.419*** 0.133 -0.336** 0.135 
TTD4*Age7 -0.491*** 0.165 0.016 0.160 -0.440*** 0.147 -0.453*** 0.147 
TTD5*Age2 -0.038 0.156   -0.037 0.156 -0.038 0.156 
TTD5*Age3 0.079 0.139   0.080 0.139 0.081 0.139 
TTD5*Age4 0.004 0.134   -0.009 0.132 0.009 0.134 
TTD5*Age5 -0.124 0.134 -0.157 0.128 -0.163 0.130 -0.130 0.132 
TTD5*Age6 -0.176 0.142 -0.209 0.136 -0.218 0.134 -0.147 0.136 
TTD5*Age7 -0.289* 0.164 -0.220 0.156 -0.284* 0.146 -0.205 0.146 
TTD6*Age2 -0.274* 0.160   -0.273* 0.160 -0.275* 0.160 
TTD6*Age3 -0.215 0.145   -0.213 0.145 -0.214 0.145 
TTD6*Age4 -0.222 0.139   -0.230* 0.137 -0.218 0.139 
TTD6*Age5 -0.267* 0.139 -0.094 0.128 -0.303** 0.135 -0.288** 0.137 
TTD6*Age6 -0.316** 0.146 -0.154 0.136 -0.359*** 0.139 -0.348** 0.140 
TTD6*Age7 -0.263 0.166 -0.221 0.163 -0.362** 0.151 -0.324** 0.150 
TTD7*Age2 -0.306 0.161   -0.304 0.161 -0.306* 0.161 
TTD7*Age3 -0.009 0.141   -0.007 0.141 -0.007 0.141 
TTD7*Age4 -0.121 0.136   -0.144 0.134 -0.117 0.136 
TTD7*Age5 -0.176 0.136 0.046 0.130 -0.187 0.132 -0.210 0.134 
TTD7*Age6 -0.157 0.142 0.004 0.136 -0.196 0.135 -0.177 0.136 
TTD7*Age7 -0.172 0.164 -0.135 0.163 -0.270* 0.148 -0.210 0.147 
TTD8*Age2 0.045 0.176   0.047 0.176 0.045 0.176 
TTD8*Age3 0.172 0.160   0.174 0.160 0.174 0.160 
TTD8*Age4 0.131 0.155   0.125 0.153 0.134 0.155 
TTD8*Age5 0.094 0.155 -0.056 0.130 0.072 0.151 0.052 0.153 
TTD8*Age6 0.068 0.160 -0.144 0.140 0.017 0.154 0.079 0.154 
TTD8*Age7 -0.062 0.181 -0.035 0.157 0.003 0.164 -0.028 0.164 
TTD9*Age2 -0.056 0.169   -0.055 0.170 -0.057 0.169 
TTD9*Age3 -0.049 0.156   -0.047 0.156 -0.048 0.156 
TTD9*Age4 -0.190 0.150   -0.160 0.149 -0.189 0.150 
TTD9*Age5 -0.137 0.150 -0.101 0.130 -0.143 0.146 -0.183 0.148 
TTD9*Age6 -0.160 0.156 -0.219 0.139 -0.208 0.150 -0.186 0.150 
TTD9*Age7 -0.191 0.175 -0.227 0.167 -0.230 0.162 -0.175 0.160 
TTD10*Age2 -0.016 0.164   -0.015 0.164 -0.016 0.164 
TTD10*Age3 -0.069 0.151   -0.068 0.151 -0.069 0.151 
TTD10*Age4 -0.029 0.145   -0.039 0.143 -0.029 0.145 
TTD10*Age5 -0.031 0.145 0.032 0.129 -0.039 0.141 -0.047 0.143 
TTD10*Age6 -0.112 0.151 -0.111 0.138 -0.150 0.145 -0.126 0.144 
TTD10*Age7 -0.032 0.173 -0.142 0.159 -0.122 0.156 -0.041 0.155 
TTD11*Age2 -0.044 0.156   -0.043 0.156 -0.043 0.156 
TTD11*Age3 -0.098 0.140   -0.097 0.140 -0.097 0.140 
TTD11*Age4 -0.099 0.135   -0.112 0.132 -0.098 0.135 
TTD11*Age5 -0.143 0.134 0.026 0.131 -0.142 0.129 -0.133 0.131 
TTD11*Age6 -0.117 0.142 -0.061 0.139 -0.168 0.134 -0.153 0.133 
TTD11*Age7 -0.141 0.163 -0.131 0.167 -0.215 0.147 -0.105 0.145 
*** p<0.01; **p<0.05, *p<0.1 
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Appendix V: Interaction terms TTD*Age: Sample Scenarios 
A, B, C and D (c.f. Table 5.4) 
 
 
Scenario A Scenario B Scenario C Scenario D 
 
Cost 
Ratio 
SE Cost 
Ratio 
SE Cost 
Ratio 
SE Cost 
Ratio 
SE 
TTD1*Age2 1.332 0.180   1.341 0.179 1.329 0.180 
TTD1*Age3 0.779 0.201   0.782 0.198 0.785 0.201 
TTD1*Age4 0.766 0.181   0.774 0.171 0.758 0.183 
TTD1*Age5 0.763 0.168 0.640* 0.238 0.757* 0.156 0.786 0.161 
TTD1*Age6 0.766 0.171 0.629* 0.241 0.733* 0.159 0.911 0.163 
TTD1*Age7 0.769 0.219 0.562 0.376 0.651** 0.216 0.712 0.244 
TTD2*Age2 1.164 0.220   1.158 0.219 1.155 0.221 
TTD2*Age3 0.686 0.230   0.686* 0.228 0.687 0.230 
TTD2*Age4 0.649** 0.218   0.639** 0.209 0.636** 0.221 
TTD2*Age5 0.662** 0.204 1.068 0.232 0.652** 0.193 0.678* 0.199 
TTD2*Age6 0.725 0.210 0.964 0.236 0.652** 0.198 0.843 0.205 
TTD2*Age7 0.742 0.257 1.378 0.365 0.739 0.252 0.685 0.278 
TTD3*Age2 0.903 0.254   0.909 0.252 0.906 0.253 
TTD3*Age3 0.661 0.267   0.662 0.263 0.667 0.264 
TTD3*Age4 0.730 0.263   0.724 0.249 0.725 0.262 
TTD3*Age5 0.660 0.253 1.019 0.223 0.691 0.234 0.680 0.246 
TTD3*Age6 0.708 0.247 0.789 0.226 0.647* 0.233 0.819 0.238 
TTD3*Age7 0.743 0.295 0.621 0.346 0.592* 0.281 0.642 0.307 
TTD4*Age2 0.906 0.237   0.916 0.238 0.899 0.238 
TTD4*Age3 0.686 0.259   0.679 0.258 0.680 0.258 
TTD4*Age4 0.515*** 0.217   0.541*** 0.212 0.509*** 0.220 
TTD4*Age5 0.700* 0.215 0.951 0.265 0.663** 0.199 0.720 0.210 
TTD4*Age6 0.682* 0.223 1.064 0.305 0.685* 0.213 0.782 0.215 
TTD4*Age7 0.798 0.285 0.833 0.377 0.670 0.258 0.673 0.291 
TTD5*Age2 1.135 0.293   1.113 0.299 1.132 0.296 
TTD5*Age3 0.775 0.299   0.751 0.307 0.777 0.302 
TTD5*Age4 0.621* 0.267   0.618* 0.268 0.611* 0.272 
TTD5*Age5 0.617* 0.263 1.056 0.217 0.653* 0.257 0.633* 0.260 
TTD5*Age6 0.540** 0.259 1.074 0.240 0.617* 0.264 0.618* 0.255 
TTD5*Age7 0.751 0.306 0.995 0.368 0.724 0.312 0.635 0.322 
TTD6*Age2 1.340 0.444   1.377 0.462 1.329 0.448 
TTD6*Age3 0.744 0.426   0.743 0.430 0.738 0.422 
TTD6*Age4 0.519** 0.284   0.510** 0.272 0.508** 0.286 
TTD6*Age5 0.405*** 0.259 1.046 0.234 0.460*** 0.248 0.402*** 0.255 
TTD6*Age6 0.524** 0.266 0.918 0.245 0.490*** 0.252 0.586** 0.258 
TTD6*Age7 0.619 0.315 0.806 0.353 0.506** 0.297 0.497** 0.323 
TTD7*Age2 0.419 0.602   0.421 0.605 0.420 0.602 
TTD7*Age3 0.314** 0.586   0.313** 0.589 0.318* 0.587 
TTD7*Age4 0.240** 0.580   0.255** 0.579 0.238** 0.581 
TTD7*Age5 0.355* 0.582 1.263 0.203 0.387* 0.577 0.361* 0.580 
TTD7*Age6 0.397 0.587 0.992 0.202 0.357* 0.578 0.436 0.581 
TTD7*Age7 0.350* 0.595 0.899 0.385 0.317* 0.601 0.299** 0.604 
TTD8*Age2 0.859 0.484   0.870 0.477 0.864 0.482 
TTD8*Age3 0.430* 0.464   0.436* 0.454 0.439* 0.461 
TTD8*Age4 0.432* 0.479   0.444* 0.457 0.426* 0.474 
TTD8*Age5 0.330** 0.440 0.907 0.223 0.367** 0.426 0.347** 0.434 
TTD8*Age6 0.397** 0.453 0.719 0.228 0.364** 0.431 0.421** 0.440 
TTD8*Age7 0.426* 0.477 0.609 0.341 0.334** 0.454 0.380** 0.481 
TTD9*Age2 1.908 0.529   1.991 0.545 1.938 0.541 
TTD9*Age3 0.985 0.375   1.020 0.391 0.994 0.378 
TTD9*Age4 0.678 0.256   0.733 0.247 0.673 0.258 
TTD9*Age5 0.724 0.262 1.022 0.237 0.823 0.246 0.745 0.252 
TTD9*Age6 0.696 0.257 0.890 0.225 0.739 0.240 0.787 0.256 
TTD9*Age7 0.631 0.287 0.884 0.359 0.722 0.291 0.583* 0.308 
TTD10*Age2 1.680** 0.244   1.673** 0.240 1.686** 0.241 
TTD10*Age3 1.049 0.267   1.049 0.263 1.054 0.264 
TTD10*Age4 1.504 0.294   1.605* 0.258 1.490 0.294 
TTD10*Age5 0.906 0.227 0.623** 0.226 1.030 0.203 0.926 0.211 
TTD10*Age6 1.298 0.245 0.500*** 0.236 1.094 0.212 1.283 0.221 
TTD10*Age7 0.993 0.261 0.427*** 0.350 0.890 0.253 0.913 0.281 
TTD11*Age2 1.231 0.257   1.273 0.248 1.249 0.254 
TTD11*Age3 0.836 0.281   0.855 0.271 0.852 0.277 
TTD11*Age4 0.699 0.256   0.786 0.238 0.697 0.255 
TTD11*Age5 1.174 0.334 1.144 0.213 1.201 0.251 1.057 0.287 
TTD11*Age6 0.795 0.256 0.972 0.239 0.927 0.235 0.877 0.238 
TTD11*Age7 0.864 0.290 1.377 0.422 1.248 0.341 0.767 0.300 
*** p<0.01; **p<0.05, *p<0.1 
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Appendix VI: Diagnostic Tests (c.f. Table 5.4) 
 
 
Scenario A: Decedents 
  FITTED MODEL:  Link = Log ; Family =  igaussian 
 
  Results, Modified Park Test (for Family) 
 
     Coefficient:   3.979748 
 
     Family, Chi2, and p-value in descending order of likelihood 
 
       Family                              Chi2        P-value 
 
       Inverse Gaussian or Wald:         5.6709         0.0172 
       Gamma:                           23.1549         0.0000 
       Poisson:                         52.4544         0.0000 
       Gaussian NLLS:                   93.5695         0.0000 
 
  Results of tests of GLM Log  link 
 
       Pearson Correlation Test:                        0.7958 
       Pregibon Link Test:                              0.6395 
       Modified Hosmer and Lemeshow:                    0.3882 
 
 
 
Scenario B: Survivors only, using censoring date as date of death 
 
  FITTED MODEL:  Link = Log ; Family =  igaussian 
 
  Results, Modified Park Test (for Family) 
 
     Coefficient:   2.894239 
 
     Family, Chi2, and p-value in descending order of likelihood 
 
       Family                              Chi2        P-value 
 
       Inverse Gaussian or Wald:         0.0632         0.8016 
       Gamma:                            4.5157         0.0336 
       Poisson:                         20.2621         0.0000 
       Gaussian NLLS:                   47.3025         0.0000 
 
  Results of tests of GLM Log  link 
 
       Pearson Correlation Test:                        0.5163 
       Pregibon Link Test:                              0.9081 
       Modified Hosmer and Lemeshow:                    0.0750 
 
 
 
  269 
 
 
Scenario C: Decedents and survivors, using survivors’ censoring date 
 
FITTED MODEL:  Link = Log ; Family =  igaussian 
 
  Results, Modified Park Test (for Family) 
 
     Coefficient:   3.747877 
 
     Family, Chi2, and p-value in descending order of likelihood 
 
       Family                              Chi2        P-value 
 
       Inverse Gaussian or Wald:         4.2959         0.0382 
       Gamma:                           23.4648         0.0000 
       Poisson:                         57.9948         0.0000 
       Gaussian NLLS:                  107.8860         0.0000 
 
  Results of tests of GLM Log  link 
 
       Pearson Correlation Test:                        0.4558 
       Pregibon Link Test:                              0.0240 
       Modified Hosmer and Lemeshow:                    0.0062 
 
 
 
 
 
 
 
 
Scenario D: Decedents and survivors, using predicted date of death for survivors 
 
FITTED MODEL:  Link = Log ; Family =  igaussian 
 
  Results, Modified Park Test (for Family) 
 
     Coefficient:   3.928224 
 
     Family, Chi2, and p-value in descending order of likelihood 
 
       Family                              Chi2        P-value 
 
       Inverse Gaussian or Wald:         5.2997         0.0213 
       Gamma:                           22.8699         0.0000 
       Poisson:                         52.7422         0.0000 
       Gaussian NLLS:                   94.9165         0.0000 
 
  Results of tests of GLM Log  link 
 
       Pearson Correlation Test:                        0.7229 
       Pregibon Link Test:                              0.6884 
       Modified Hosmer and Lemeshow:                    0.6150 
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Appendix VII: Ethics Approval Form 
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Appendix VIII: SLS Project Clearance Form 
 
 
 
 
 
 
SLS PROJECT CLEARANCE FORM 
 
 
 
SLS Unit, Room 1G1, 
        Ladywell House, 
        Ladywell Road, 
        Edinburgh,  
        EH12 7TF. 
 
        2 February 2010 
Dear Claudia 
 
Your project proposal “Population Ageing: What are the implications for healthcare 
expenditure in Scotland?” has now been assessed by the SLS Research Board. I am 
pleased to inform you that the board decided that your proposal has been: 
 
 Cleared as it stands 
 Cleared as it stands, with some suggestions for change/improvement 
 Cleared under condition there are minor changes 
 Cleared under condition there are major changes 
 Rejected 
 
You may be aware that there is another current SLS project being carried out by David 
Bell of Stirling University.  The Research Board feels that it would be useful for you to 
contact David (if you haven’t already done so) in order to avoid any duplication of effort, 
and to discuss whether there is scope for collaborating on aspects of your research.    
 
Your SLS Support Officer, Peteke Feijten, can put you in touch with David, and will be 
able to advise on the next steps. 
 
With kind regards, 
 
Claire Boag, SLS project manager 
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Appendix IX: Diagnostic Tests (c.f. Table 6.6) 
 
 
 
English Tariff 
FITTED MODEL:  Link = Log ; Family =  Gamma 
 
  Results, Modified Park Test (for Family) 
 
     Coefficient:   2.860117 
 
     Family, Chi2, and p-value in descending order of likelihood 
 
       Family                              Chi2        P-value 
 
       Inverse Gaussian or Wald:         0.0298         0.8630 
       Gamma:                            1.1265         0.2885 
       Poisson:                          5.2686         0.0217 
       Gaussian NLLS:                   12.4560         0.0004 
 
  Results of tests of GLM Log  link 
 
       Pearson Correlation Test:                        0.6586 
       Pregibon Link Test:                              0.6282 
       Modified Hosmer and Lemeshow:                    0.0022 
 
 
 
SNT 
  FITTED MODEL:  Link = Log ; Family =  Gamma 
 
  Results, Modified Park Test (for Family) 
 
     Coefficient:   .222258 
 
     Family, Chi2, and p-value in descending order of likelihood 
 
       Family                              Chi2        P-value 
 
       Gaussian NLLS:                    8.2521         0.0041 
       Poisson:                        101.0475         0.0000 
       Gamma:                          527.9486         0.0000 
       Inverse Gaussian or Wald:      1288.9554         0.0000 
 
  Results of tests of GLM Log  link 
 
       Pearson Correlation Test:                        0.7250 
       Pregibon Link Test:                              0.5266 
       Modified Hosmer and Lemeshow:                    0.3117 
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Appendix X: SLS Output Clearance Form 
 
 
 
 
 
SLS OUTPUT CLEARANCE FORM 
 
 
 
SLS Unit, Room 1G1, 
        Ladywell House, 
        Ladywell Road, 
        Edinburgh,  
        EH12 7TF. 
 
        20 December 2011 
Dear Claudia 
 
Thank you for sending the SLS chapter of your thesis, the introduction and conclusion.  
I have suggested a few changes (tracked in your original document), to emphasise that 
the SLS is an anonymised dataset , and a couple of other minor points.  Once you have 
made these changes then these three chapters can be considered cleared.   
 
Regards 
 
Claire Boag,  
SLS project manager 
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